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Diabetes mellitus is a group of metabolic diseases characterized by high blood sugar 
(glucose) levels that result from defects in insulin secretion or action, or both. Normally, 
blood glucose level is tightly controlled by insulin, a hormone produced by the endocrine 
pancreas. When the blood glucose level rises, insulin is released from the pancreas to 
normalize the glucose level. There are several types of diabetes, of which type 1 and type 2 
diabetes are the most common. Type 1 diabetes (T1DM, insulin-dependent diabetes or 
juvenile-onset diabetes) is characterized by loss of the insulin-producing beta cells of the 
islets of Langerhans in the pancreas leading to insulin deficiency. Type 2 diabetes (T2DM, 
non-insulin-dependent diabetes or adult-onset diabetes) results from insulin resistance,        
a condition in which cells fail to use insulin properly, sometimes combined with an absolute 
insulin deficiency. 
 
Diabetes effects an estimated 6% of the adult population in Western society and over 2% 
worldwide1. T2DM accounts for more than 90% of all diabetics2 and its worldwide 
prevalence is increasing and expected to grow by 3% per year due to population growth, 
aging, urbanization, and increasing prevalence of obesity and physical inactivity. 
Worldwide, the total number of people with diabetes is projected to rise from 171 million in 
2000 to 366 million in 2030, with the largest relative increase to occur in the Middle 
Eastern Crescent, sub-Saharan Africa and India3.  
 
The worldwide prevalence of T1DM is much lower and remains the predominant type of 
diabetes during childhood in many countries with relatively high incidence in Scandinavia4. 
Nevertheless, the incidence of T1DM is also increasing and the number of T1DM patients 
younger that 15 years in Europe is predicted to rise from 94.000 in 2005 to 160.000 in 
20205. 
 
Pharmacological treatment of T1DM focuses mainly on the administration of recombinant 
human insulin to compensate for the deficiency of insulin. In T2DM, several classes of 
drugs are used. Sulfonylurea derivatives such as glibenclamide act by increasing insulin 
release from the beta cells in the pancreas. Biguanides such as metformin act through 
reducing gluconeogenesis in the liver and enhancing cellular glucose uptake, both resulting 
in lower blood glucose levels. Glitazones act through several pathways, including a 
decrease in insulin resistance6. 
 




Proper pharmacological treatment and improved lifestyle can greatly reduce the severity of 
the chronic complications of diabetes. Nevertheless, diabetic complications such as 
nephropathy, cardiomyopathy, neuropathy and retinopathy remain common in patients. 
These complications are believed to result from hyperglycemic damage to small vessels, 
referred to as microvascular disease. Diabetes is also an important factor in accelerating 
atherosclerosis, thus leading to stroke, coronary heart disease, and microvascular diseases7. 
 
Diabetic nephropathy 
Diabetic nephropathy is a common cause of chronic kidney failure (20-30%), resulting in 
an increased number of patients requiring end-stage renal failure management, particularly 
dialysis8. Diabetic nephropathy is characterized by specific renal morphological and 
functional alterations. Features of early diabetic renal changes are glomerular 
hyperfiltration, glomerular and renal hypertrophy, increased urinary albumin excretion, 
increased basement membrane thickness and mesangial cells expansion with accumulation 
of extracellular matrix (ECM) proteins. Advanced diabetic nephropathy is characterized by 
albuminuria, a decline in renal function, decreased creatinine clearance, glomerulosclerosis 
and interstitial fibrosis9;10.   
Renal fibrosis in diabetic nephropathy develops, in part, through activation of renal 
fibroblasts leading to secretion and remodeling of the ECM. Although activated resident 
renal fibroblasts (myofibroblast) are critical effectors of renal fibrosis some studies suggest 
that fibroblasts originating from epithelial–mesenchymal transition (EMT) may play an 
important additional role. Regardless of their origin, the development of renal fibrosis is 
dependent on the secretion of profibrotic mediators such as cytokines, protease inhibitors, 
growth factors and inflammatory mediators11. These include transforming growth factor β 
(TGF-β), connective tissue growth factor, angiotensin II, endothelin-1 and fibroblast 
growth factor10;12;13.  
 
Transforming growth factor family (TGF-β) 
TGF-β is one of the most studied cytokines involved in diabetic nephropathy and is a 
member of a large family of structurally related cytokines (Figure 1). The family consists of 
more than 30 growth factors, including bone morphogenetic protein (BMP), inhibins and 
activins14. Members of the TGF-β family regulate a wide variety of biological processes, 
such as proliferation15, differentiation, cytokine production and immune cell modulation16. 
A key role for TGF-β1 in the pathogenesis of renal fibrosis has been established in both 






rabbits rapidly causes glomerulosclerosis17. Overexpression of TGF-β in normal, uninjured 
glomeruli by gene transfection produces glomerulosclerosis within days18. Moreover, 
transgenic mice with the TGF-β gene under control of the albumin promoter die of renal 
failure caused by a lesion that resembles rapidly progressive glomerulonephritis with 
tubulointerstitial fibrosis19. 
Also in diabetes, the functional role of TGF-β1 in renal fibrosis was demonstrated by 
studies in which the inhibition of TGF-β1 using neutralizing antibodies, decorin or 
antisense oligonucleotides, result in the prevention or amelioration of renal fibrosis20-22.  
Although, TGF-β appears to be the most prominent cytokine in renal fibrosis, other       
TGF family members may play an important modulatory role. An example of this is Bone 
Morphogenetic Protein-7 (BMP-7), which is expressed in the healthy kidney. Loss of renal 
BMP-7 expression is associated with the early development of diabetic nephropathy23, 
possibly because the decrease of renal BMP-7 expression favors TGF-β driven renal 
fibrogenesis. In accord, treatment of streptozotocin induced diabetic mice with exogenous 
human recombinant BMP-7 effectively prevented and reversed renal fibrosis24;25. The 
interaction of TGF-β and BMP-7 has been studied at the molecular level and in vitro 
experiments demonstrate that the interaction of downstream signaling molecules are 
responsible for the antagonistic effects of BMP-7 on TGF-β mediated renal fibrogenesis26.  
 
TGF-β superfamily member signaling pathways 
Members of the TGF-β superfamily signal through TGF-β type I and II receptors (Figure 2). 
Binding of the ligand to the type II receptor causes recruitment of the type I receptor into a 
heterodimeric receptor complex. Activation by phosphorylation of the type I receptor 
serine/threonine kinase induces serine phosphorylation of receptor Smads. In most tissues, 
TGF-β causes Smad2/3 activation, whereas BMP activates Smad1, 5, and 8. Subsequently, 
phosphorylated receptor Smads bind to the common Smad4 to form the Smad complex, 
which translocates into the nucleus to regulate target gene transcription. Two inhibitory 
Smads (Smad6 and Smad7) are amongst the target genes, providing the possibility of 
negative feedback control. It should be pointed out that within the TGF-β superfamily, both 
pathways cross-regulate each other to maintain homeostasis during normal physiology. This 
interaction can occur at different levels, including competition for receptors and Smads27. 
 





Figure 1: The TGF-ß superfamily. Dendrogram of all human TGF-ß superfamily members (colour 










Figure 2: General mechanism of the (A) TGF-β and activin/nodal and (B) BMP pathways, with their 
corresponding Smad proteins. The ligand binds a complex of transmembrane receptor 
serine/threonine kinases (type I and II). The activated type I receptors phosphorylate selected Smads, 
and these receptor-activated Smads (R-Smads) then form a trimer of two R-Smads and a single 
Smad4, which is subsequently translocated into the nucleus. Nuclear Smad complexes then regulate 
transcription of target genes, through physical interaction and functional cooperation with           
DNA-binding transcription factors (X) and coactivators or repressors. Activation of R-Smads by type 
I receptor kinases is inhibited by Smad6 or Smad7. 
 




This classical view of the TGF-β superfamily member signaling pathways is complicated 
by the fact that TGF-β family members can also signal through Smad independent signaling 
routes, involving several members of the mitogen-activated protein kinase (MAPK), Akt 
and RhoA signaling cascades (Figure 3). As these pathways are also capable of cross-talk, 
the signaling cascade of TGF-β superfamily members becomes a complex network. 
Although TGF-β1 is an important player in this network, increased levels of TGF-β1 do not 
always condemn the kidney to fibrosis, as illustrated by BMP-7 treatment preventing renal 
fibrosis despite elevated levels of TGF-β116;24. Therefore, research addressing the 
involvement of other TGF-β family members in renal fibrosis may provide new therapeutic 




Figure 3: TGF-β receptor signaling through Smad-independent pathways. Non-Smad signaling 








Growth Differentiation Factor 15 (GDF15) 
In a microarray study described in chapter 2, we identified the TGF-β family member, 
Growth Differentiation Factor 15 (GDF15), to be highly upregulated in kidney after 
induction of experimental diabetes. The upregulation of GDF15 preceded changes in   
TGF-β1 expression, despite early activation of renal fibroblasts. In addition, 
epidemiological data became available suggesting a link between circulating GDF15 levels 
and the incidence of cardiovascular disease and diabetes28. We therefore hypothesized that 
GDF15 is a factor involved in the development of diabetic nephropathy. 
GDF15 is also known as macrophage inhibitory cytokine-1 (MIC-1), placental transforming 
growth factor-β (PTGF-β) or β-N-acetylglucosaminidase-1 (NAG-1). Previous studies 
demonstrated that GDF15 is involved in the regulation of several cellular processes, 
including the cell cycle29, proliferation30, differentiation31 and apoptosis32;33. GDF15 is 
generated as a 40-kDa propeptide and after cleavage of the N-terminus, a 30-kDa   
disulfide-linked dimeric protein is secreted as the active form34. Unlike other TGF-β family 
members, the propeptide of GDF15 is not required for proper folding and secretion35. 
In healthy animals, GDF15 is expressed in the placenta and the prostate with low 
expression in other organs. However, GDF15 is highly expressed as an immediate-early 
gene in multiple organs after a wide variety of injuries. Cardiomyocytes express and secrete 
GDF15 during periods of ischemia and reperfusion36. As GDF15 knockout mice develop 
more cardial damage, GDF15 was suggested to be a protective factor37. Further, GDF15 
was upregulated after injury in the lung, liver and kidney38;39, suggesting that GDF15 
induction is a widespread cellular injury response.  
The receptor for GDF15 is still unknown. Several reports document activation of TGF-β 
responsive promoters and the inhibition of cellular growth by GDF15 being dependent on 
expression of TGF-β receptors type I and II, or Smad439;40. However, based on the 
similarity in the primary structure, GDF15 may be closer to the BMP subfamily than to the 
TGF-β subfamily41 and may therefore activate BMP receptors. In cardiomyocytes GDF15 
elicited a TGF-β/ activin-like response through Smad2,3, but also activated ERK and Akt42, 
suggesting that GDF15 is involved in the activation of Smad-independent pathways. Thus, 
GDF15 may provoke both signaling pathways that correspond or deviate from canonical 
TGF-β signaling, possibly depending on the cell type investigated.  
 




Scope of this thesis 
The overall aim of the studies described in this thesis is to establish the role of GDF15 and 
its signaling pathways in the development of diabetic nephropathy. 
 
In chapter 2 we explored the early changes in renal gene expression after the induction of 
experimental type 1 diabetes in rats. GDF15 was found to be upregulated immediately after 
induction of diabetes. Smad2 activation and smooth muscle actin expression were both 
detectable in the absence of increased TGF-β expression, suggesting that other factors than 
TGF-β (such as GDF15) may be involved in the development of early fibrosis.  
 
In chapter 3 of this thesis, the signaling cascades activated by GDF15 and the involvement 
of GDF15 on proliferation, apoptosis, profibrosis in the development of diabetic 
nephropathy were studied in vitro in human mesangial cells. 
 
In chapter 4 we investigated the effect of the genetic deletion of GDF15 on the 
development of diabetic nephropathy in experimental models of type I and type II diabetes 
in mice. 
  
As vasomotor control has been shown imperative in the development of kidney damage, the 
effects of GDF15 on vasomotor responses of mice aorta were evaluated in chapter 5.  
 
In chapter 6 we explored whether blood levels of GDF15 predict the progression of 
nephropathy in type 2 diabetic patients and in patients with hypertension. 
 
Finally, in chapter 7 the main findings of the studies are summarized and discussed into a 
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Experimental diabetic nephropathy is a chronic kidney disease characterized by the 
development of tubulointerstitial and glomerular fibrosis several weeks after the onset of 
diabetes. The pathways leading to fibrosis are apparently initiated early after induction of 
diabetes, as pre-fibrotic markers are detectable within one week of diabetes. In the current 
study, we aimed at identifying genes associated with renal pre-fibrosis in the first week 
after induction of diabetes in the rat streptozotocin (STZ) model. 
 
Methods 
Male Wistar rats were made diabetic by a single injection of STZ. mRNA was isolated 
from kidneys at days 1, 2, 4 and 7 after STZ induction. An expression array including dye 
swap was performed at all time points and expression of individual genes within the first 
week of diabetes were compared to non-diabetic controls. The area under the curve was 
calculated to quantify the overall level of changes in expression of individual genes.  
 
Results 
Blood glucose levels were elevated at day one and remained similarly elevated at all 
subsequent time points. Induction of renal pre-fibrosis was confirmed by increased α-SMA 
expression and increased phosphorylated-Smad2/3 levels after one day 1 of diabetes and at 
all later time points. A total of 290 genes were found to be significantly changed in the first 
week of diabetes. Initiation of renal pre-fibrosis was not associated with increased renal 
expression of TGF-ß mRNA expression but changes in the expression of several 
modulators of TGF-ß signaling including GDF15, one of the most prominent genes         
up-regulated early in the diabetic injury. Moreover, P311, follistatin and two proprotein 
activating proteases showed prominent expression changes, suggesting the involvement of 
these factors in the induction of pre-fibrosis in early diabetes.  
 
Conclusion 
We identified fibrosis related genes in rat kidney that are upregulated shortly after the 
induction of diabetes. Previously, some of the identified genes have been associated with    
a more advanced stage of renal fibrosis. Our study suggests that these genes may be 
involved in the initiation of pre-fibrosis in early diabetes. These genes and their signaling 
pathways may represent targets to interfere in early diabetic nephropathy. 





In the near future, a dramatic increase in the prevalence of diabetes mellitus is expected1;2. 
Despite glycemic control, long lasting diabetes can lead to complications including diabetic 
retinopathy, diabetic neuropathy, and diabetic nephropathy in both type I and type II 
diabetes. Control of blood glucose levels through various drugs, including                   
alpha-glucosidase inhibitors, amylin analogues, DPP-4 inhibitors, glinides, GLP-1 
derivatives and and insulins3 has proven to attenuate these complications4;5. Furthermore, 
reduction of blood-pressure through the use of inhibitors of the Renin-Angiotensin System 
(RAS) has proven beneficial in the prevention of diabetic nephropathy6, and evidence 
suggests this effect to be in part mediated by inhibited renal expression of the fibrogenic 
cytokine TGF-β7 . 
 
Diabetic nephropathy is a progressive chronic kidney disease and on average, patients 
develop diabetic nephropathy after 15 – 20 years of diabetes. Both types of diabetes are 
associated with the development of diabetic nephropathy, a condition that ultimately 
progresses into end-stage renal disease. Despite the benefits of blood sugar and blood 
pressure control, current therapies do not halt the progression of diabetic nephropathy8.  
Several animal models of diabetes have been developed9;10 and although the underlying 
cause of diabetes differs between models, diabetic nephropathy usually develops much 
faster in experimental models than in humans. In rodents, renal fibrosis can be detected 
after several weeks of diabetes11. Nevertheless, similar histological changes are present in 
kidneys of both diabetic humans and animals, including glomerular and tubular basement 
membrane thickening, glomerulotubular hypertrophy/ hyperplasia, mesangial and 
tubulointerstitial expansion (extracellular matrix [ECM] accumulation), glomerulosclerosis 
and tubulointestinal fibrosis12, indicating that animal models may be used to investigate the 
molecular pathways leading to diabetic nephropathy. 
 
Experimental models of diabetes show that differentiation of interstitial fibroblasts into 
myofibroblasts is one of the initiating mechanisms leading to diabetic nephropathy13. Once 
activated, myofibroblasts produce extracellular matrix molecules including collagens, 
proteoglycans and fibronectin as well as proteases capable of degrading the ECM14. These 








The differentiation of renal fibroblasts into myofibroblasts seems to represent a very early 
event in diabetes and is already present after 7 days in the streptozotocin (STZ) induced 
diabetic rat15. As activation of myofibroblasts is a common feature in several models of 
kidney disease, unraveling the mechanisms of early myofibroblast activation in diabetes, 
may therefore contribute to a better understanding of the development of kidney fibrosis in 
general.  
 
In this study, we aimed at identifying factors that are associated with the activation of 
fibrosis within the first week of diabetes in the rat single dose STZ model. To this end, we 
performed an expression microarray analysis on rat kidneys obtained on 0, 1, 2, 4 and 7 
days after the induction of diabetes. Gene expression timecurves were constructed relative 
to non-diabetic controls. The area under the curve was calculated to quantify the expression 
of genes that were selectively up- or down-regulated in the first week of diabetes. Although 
expression microarrays have been performed previously in the rat STZ model16;17, this is 
the first time that renal gene expression was characterized at these early timepoints after the 
induction of diabetes. 
 
Materials and methods  
Animals 
Male Wistar rats (weight 250 – 270 g, 7-8 weeks old, Harlan) were used in the study. The 
animals were acclimatized to the environment for at least 3 weeks prior to experimentation. 
All experimental procedures were conducted according to the guidelines for the use of 
experimental animals approved by the Animal Experiments Ethical Committee of the 
University of Groningen, the Netherlands. Animals were housed under standard conditions 
with free access to food (standard rat chow) and drinking water throughout the study. 
Diabetes was induced in rats by i.v. injection of streptozotocin (STZ) in citrate buffer      
(60 mg/kg). Blood samples were taken before induction for measurement of glucose levels. 
A sham group injected with citrate buffer only (n=10) was included. STZ treated rats were 
sacrificed at day 1 (n=6), 2 (n=7), 4 (n=5) and 7 (n=6) after induction of diabetes. At 
sacrification, rats were anesthetized with isoflurane (2%) and an aortic blood sample was 
collected. Plasma was isolated and stored at -80˚C. The kidneys were perfused with saline 
and removed. Midcoronal slices were fixed in 4 % paraformaldehyde, processed for 
paraffin embedding and further used for immunohistochemistry. A second slice was frozen 
in liquid nitrogen, stored at -80˚C and used for RNA isolation. 
 





Total RNA was isolated with a Qiagen RNA isolation kit (Qiagen, Venlo, The Netherlands) 
from rat frozen kidney samples containing both cortex and medulla. The RNA 
concentration and purity were determined spectrophotometrically by measuring the 
absorbance at 260 nm. RNA integrity was checked on 1% agarose gels. 
 
Messenger-RNA amplification and Cy-dye coupling 
Linear amplification of mRNA was performed according to a protocol of the Dutch Cancer 
Institute (www.nki.l.nl/nkidep/pa/microarray/protocols.htm). Briefly, amplification started 
with first strand cDNA synthesis from 2 µg of total RNA, using Superscript II                 
RT-polymerase (GIBCO - Invitrogen Inc, Carlsbad, Ca, USA) and a specific oligo(dT) 
primer containing a 17bp T7 polymerase recognition site (5'-
GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG[T]24-3') (Eurogentec, 
Seraing, Belgium). After second strand synthesis, double-stranded cDNA was purified with 
the Qiaquick PCR purification kit (Qiagen) and the yield was determined 
spectrophotometrically. In vitro transcription was performed with the T7 Megascript kit 
(Ambion, Huntingdon-Cambridgeshire, UK) as described by the manufacturer and 
aminoallyl-UTP (Ambion) was incorporated as described by Hoen et al (2003). Amplified 
RNA (aRNA) was purified with the RNA clean up protocol (Qiagen). Five µg of aRNA 
was labeled by coupling monoreactive Cyanine-3 or Cyanine-5 fluorophores (Amersham 
Biosciences, Little Chalfont, Buckinghamshire, UK) to the aminoallyl-modified 
nucleotides. Labeled aRNA was separated from unincorporated Cyanine-3 or Cyanine-5 
molecules over Microspin G50 columns (Amersham Biosciences) as described by the 
manufacturer. 
For the identification of genes differentially expressed between diabetic animals and non-
diabetic control, a common reference design was applied. In this design, day 0              
(non-diabetic, Cy3 labeled) was compared to each consecutive time point (days 1, 2, 4 and 
7, Cy5 labeled), resulting in 4 arrays. In addition, a dye swap was performed, resulting in a 
total of 8 array hybridizations. For each time point, equal amounts of total RNA of at least 
five animals were pooled.  
 
Micro-array slides and hybridization 
Operon OpArray rat slides V3 printed with 26962 oligos were purchased from Operon 
Biotechnologies, Germany. Blocking, prehybridization and hybridization were performed 






with ethanolamine at 42°C during 1 h. Prehybridization was performed with prewarmed 
prehybridization buffer containing 0.5% bovine serum albumin (Sigma-Aldrich, St. Louis, 
MO, USA) at 42°C during 45 min. Subsequently, the slides were washed three times with 
preheated water (52°C), dried by centrifugation at 620 rpm during 5 min and immediately 
used for hybridization. The hybridization sample consisted of the fluorescently labeled 
probe mixture and 30 µg poly-A (Sigma Aldrich) mixed with an equal volume of preheated 
(52°C) two times concentrated hybridization buffer. This hybridization sample was heated 
at 95°C for 3 min before it was applied to the preheated slides. Hybridization was 
performed in hybridization chambers (Telechem International Inc, Sunnyvale, CA, USA) in 
a water bath at 42°C in the dark for approximately 48 h. Subsequently, slides were washed 
with 5 wash solutions under agitation: 1xSSC/0.2% SDS at 42ºC; 0.1xSSC/0.2% SDS at 
42ºC; 0.1xSSC at 42º; 0.1xSSC at room temperature and 0.01xSSC at room temperature. 
Each wash step lasted 5 minutes. Finally, slides were dried by centrifugation at 600 rpm 
during 5 min and scanned with an Affymetrix GMS428TM array scanner. 
 
Micro-array data analysis 
Fluorescent signal intensities from scanned images were processed and analyzed using 
Agilent Feature Extraction software version 9.1.3.1 (Agilent Technologies). A quality 
control report was generated for each array. Data was imported into GeneSpring GX 
version 7.3.1 (Agilent, Santa Clara, CA, USA). This software package allows multi-filter 
comparisons using data from different experiments to perform the normalization, 
generation of restriction (filtered) lists and functional classifications of the differentially 
expressed genes18. Normalization was applied in dye swap in three steps: 'per spot 
normalization' divided by control channel; 'per chip normalization', where each 
measurement was divided by the 50th percentile of all measurements in its array; and 'per 
gene normalization', by which all the samples were normalized against the median of the 
control samples. After normalization, the expression of each gene was reported as the ratio 
of the value obtained for each condition differential to the control condition. As each slide 
was also performed with a dye swap, the gene expression values from both arrays were 
averaged. 
Plots were constructed to evaluate the relative expression of individual genes in time. To 
identify genes that are specifically regulated within the first week after induction of 
diabetes, we calculated the area under the curve (AUC) for individual genes on the array 
using the trapezoid method. Differences in time ranges between different experimental days 




were accounted for in the AUC calculation. Genes were considered significantly regulated 
if their AUC was outside the 3 standard deviation limit.  
This method does not recognize significant up- or downregulation of a gene at specific time 
points, but rather provides a measure to determine the extent of change in relative gene 
expression of a particular gene within the first week of diabetes. Typically, spots with low 
intensities provide noise and therefore these spots are usually filtered out by setting             
a threshold for signal intensity. In our area under the curve calculation, negative areas  
(down-regulation) compensated for positive areas (up-regulation), further eliminates noise. 
Therefore all spots that passed the quality control check were included in the analysis. 
 
RT PCR 
PCR analysis was employed to verify the results of selected array data with real-time PCR. 
For this, 1µg of kidney RNA of individual rats was reversely transcribed into cDNA.   
Real-Time PCR samples were prepared with 2× ABsolute™ QPCR SYBR® Green ROX 
Mix (Westburg, Leusden, Netherlands), 10 uM of primer and 2.5 µl template DNA in         
a total volume of 25 µl. The PCR profile consisted of 15 min at 94 °C, followed by 40 
cycles with heating to 94 °C for 15 s and cooling to 60 °C for 1 min. PCR product 
specificity and purity was evaluated by generating a dissociation curve following the 
manufacturer’s recommendations. The sequences of the primers used are listed in Table 1.  
Table 1: Primer sequences 
gene Forward primer (5’→3’) Reverse primer (5’→3’) 
TGF-ß1 AACAATTCCTGGCGTTACCT TATTCCGTCTCCTTGGTTCA 
vimentin CTCTGGCACGTCTTGACCTT CTGCACCTGTCTCCGGTATT 
collagen 3A1 AAGGACACGCTGGTGCTCAA TTCGCCTGAAGGACCTCGTT 
GDF15 ACCTGCTGAGCCGACTGCAT CCAATCGCACCTCTGGACTG 
P311 CCTGTGCCTAAGGAAGTGA GGTGGAGGTAACCGATAGC 
follistatin CAGTGCCTGCCACCTGAGAA CAGCGACCTCTGCCAACCTT 
KIM-1 GTCTGTATTGTTGCCGAGTG GGTCTTGTTGGAGGACTTGT 
PACE4 CACCGCAGGCAGAGACTCCA CACGGCGACAAGACAGGCAC 
aminopeptidase O GCCATCAGGATATGGTATAA TGCTCAGTCAGATCATCTAA 










Frozen kidney fragments were crushed and lysed in 300 µl of ice-cold RIPA buffer        
(1% Igepal ca-630, 1% SDS, 5 mg/ml sodium deoxycholate, 1 mM sodium orthovanadate, 
10 mM ß-mercapto-ethanol, 40 µg/ml PMSF, 100 µg/ml benzamidine, 500 ng/ml pepstatin 
A, 500 ng/ml leupeptine and 500 ng/ml aprotinin in PBS). Protein concentrations were 
determined using a Bio-Rad protein assay (Bio-Rad, The Netherlands). On a 5-20%     
SDS-PAGE gel, 20 µg of total protein was run and transferred to nitrocellulose. 
Phosphorylation of Smad2/3 was detected with the p-Smad2/3 (Ser 423/425) antibody    
(sc-11769, Santa Cruz) in combination with a polyclonal HRP conjugated anti-goat IgG 
secondary antibody (sc-2768, Santa Cruz). GDF-15 expression was detected with the 
primary antibody Mic-1 (Y60) (Cell Signaling Technology, #3249S) in combination with 
polyclonal HRP conjugated goat anti-rabbit IgG secondary antibody (P0448, Dako) and      
a housekeeping monoclonal GAPDH antibody (10R-6109a) with a polyclonal HRP 
conjugated anti-mouse IgG secondary antibody (P0260, Dako) was used. Signals were 
detected by the ECL-detection method (Amersham, The Netherlands). 
 
Immunohistochemistry  
To evaluate renal prefibrosis after induction of diabetes, sections were stained for α-smooth 
muscle actin (mouse monoclonal anti-α- smooth muscle actin, α-SMA, Sigma Chemical 
Co, St Louis, MO, USA). Before the immunostaining procedure, paraffin sections (3 µm) 
were dewaxed and subjected to antigen retrieval by an overnight incubation in 0.1M 
Tris/HCl buffer, pH 9.0, at 80º. For immunohistochemistry, a two-step immunoperoxidase 
technique was used, according to standard methods, as previously described19. Peroxidase 
activity was developed using 3’,3’-diaminobenzidine tetrachloride and H2O2. The 
expression of α-SMA by immunohistochemistry was measured using computer-assisted 
morphometry. Totals of 30 fields were evaluated at a magnification of 200×. The total area 
of staining (excluding blood vessels and glomeruli) was divided by the total area measured 
and expressed as a percentage.  
 
TGF-β bioassay 
Active and latent TGF-β levels were determined as described previously20. In short, Mv1Lu 
cells stably transformed with a SBE-luciferase reporter construct21, were plated in 96 wells 
plates. Single wells were incubated overnight with 50 ul DMEM and 50 ul heparinized 
plasma. Latent TGF-β was activated by adding HCl (80 mmol/L) to the plasma and 
incubation for 1 hour at 4°C. Thereafter, the solution was neutralized by the addition of 




NaOH (80 mmol/L) to the plasma. Luciferase activity was determined using Promega’s 
luciferase assay system according to the manufacture's protocol. 
 
Statistical analysis 
Data are expressed as mean value ± S.E.M. Differences between groups were tested by 
Student’s t-test and analysis of variance (ANOVA) by Microsoft Excel (2003 SP3 version). 
The normal distribution of the AUC was tested with a Kolmogorov-Smirnov test with 
Lilliefors Significance Correction using SPSS 16. A p value less than 0.05 was considered 




Induction of diabetes 
In STZ injected rats, blood glucose levels were elevated as of day 1 and remained at similar 
levels at all subsequent time points (Table 2). Furthermore, diabetic animals showed 
decreased body weights at all time points. 
 
Table 2:  Main animal characteristics 
 control diabetic 
  day 1 day 2 day 4 day 7 
Body weight (g) 378 ± 12.4   340 ± 17.2* 322 ± 13*  269 ± 9.6*   329 ± 11.5* 
Glucose (mM) 8.5 ± 0.5   23 ± 2.5* 23.6 ± 1.7* 19.3 ± 1.9* 24.8 ± 1.9* 
L kidney (g) 1.8 ± 0.1 1.6 ± 0.1 1.9 ± 0.1 1.7 ± 0.1 1.9 ± 0.1 
R kidney (g)   1.4 ± 0.04   1.4 ± 0.05 1.8 ± 0.1 1.7 ± 0.1 1.8 ± 0.2 
Values are mean ± SEM (* p<0.05 versus control) 
 
Markers of renal pre-fibrosis 
Renal pre-fibrosis was quantified by measuring α-SMA staining in the cortical interstitium. 
α-SMA was significantly increased on day 2 (Figure 1A) and remained elevated at all 
subsequent time points. Further, activation of the profibrotic Smad2/3 pathway was 
determined by measuring the levels of phosphorylated Smad2/3 in kidney homogenates by 
western-blot. Phosphorylated-Smad2/3 levels were elevated after the induction of diabetes 
as of day 1 onwards (Figure 1B). Real-time PCR for TGF-ß1, vimentin, collagen 3A1 and 
KIM-1 did not show increased expression at any of the time points (Figure 1, panels C,D,E 






























































































































































































Figure 1: Expression of pre-fibrotic markers after STZ mediated induction of diabetes  
A) Quantification of interstitial alpha-SMA expression on stained immunohistochemical sections. B) 
Quantification of Smad 2/3 phosphorylation by western blot using a phospho-specific Smad2/3 
antibody. C,D,E and F) Real-time PCR quantification of renal TGF-ß1, vimentin, collagen 3A1, 
KIM-1 mRNA expression. * indicates significantly different (P<0.05) from day 0. 
 




Latent and active TGF-ß levels in plasma 
Mink lung cells stably transfected with a TGF-β sensitive SBE-luciferase reporter construct 
were incubated with untreated or acid activated plasma of diabetic animals for 24 hours. At 
day 1, active TGF-ß was moderately decreased (Figure 2A) while latent TGF-ß was 
increased more than 20-fold (Figure 2B). Levels of active and latent TGF-ß returned to 
control values by day 2 and subsequent time points. 
Days of diabetes





























































Figure 2: Levels of active and latent TGF-β1 in the plasma of diabetic animals  
A) Active TGF-β1 levels were decreased at day 1 and normalized by day 2. B) Latent TGF-β1 levels 
were increased by day 1 and normalized by day 2 (* indicates p<0.05 vs day 0). 
 
Gene expression analysis 
The Operon OpArray rat slides contained 26.989 oligonucleotide spots. After hybridization, 
spots were scanned and typically more than 99.9% of the spots on each slide passed the 
quality control tests for spot shape and low spot background outside of the spot. After 
quantification of the arrays, plots were constructed to evaluate the relative expression of 
individual genes in time. To identify genes that were specifically regulated within the first 
week after induction of diabetes, we calculated the area under the curve (AUC) for 
individual genes on the array using the trapezoid method (Figure 3A). A histogram plot of 
the AUC’s of gene expression in time (Figure 3B) demonstrated a normal distribution 
(p<0.001). We considered genes with AUC’s outside 3 times the standard deviation from 
the mean as being significantly changed during the first week of diabetes. The mean in 






range of -1.176 to 1.194 fold change were considered significantly changed. In this way, 
290 genes were identified to be specifically regulated within the first week of diabetes    
(see Table 3 for the top 25 up- and down regulated genes). 
 
Figure 3: Normal distribution of the area under the curve (AUC) for gene expression in time 
A) Examples for calculation of the AUC. Relative expression of individual genes (log(ratio)) 
compared to non-diabetic controls (day 0) were plotted in time. Example plots a and c demonstrate up 
regulated and down regulated genes, respectively. Plot b: Positive and negative areas were not 
converted to absolute numbers, resulting in a sum of the positive and negative areas that is close to 
zero, eliminating genes that show erratic expression in time. B) The AUC was calculated for all 
individual genes and a histogram plot was constructed to visualize the distribution of the AUC of 
gene expression in time. The AUC’s demonstrated a normal distribution (p<0.001) with a mean of 
0.009. Genes with AUC’s outside 3 standard deviations of the mean were considered significantly 
different from non diabetic controls. 
 
Gene ontology 
As we aimed at identifying factors which are associated with the activation of 
myofibroblasts within the first week of diabetes, we identified all factors associated with 
TGF-ß signaling, cell growth, differentiation and proliferation, apoptosis, response to stress 
and protease activity in the list of 290 genes (Table 4). 
 
Renal upregulation of Growth Differentiation Factor 15 (GDF15) 
GDF15, a member of the TGF-ß family was the second most strongly up-regulated gene in 
our array analysis. The upregulation of GDF15 in the first week of diabetes was confirmed 
with RT-PCR on individual animals (Figure 4A), demonstrating a more than 20-fold 




induction of GDF15 mRNA expression on days 1 and 2 after induction of diabetes. GDF15 
expression showed a trend towards normalization to control levels at subsequent time 
points, although GDF15 levels were still significantly increased at day 7. In addition, 
protein levels of renal GDF15 expression approved RT-PCR confirmation (Figure 4B). 
Days of diabetes




































































Figure 4: Up-regulation of renal GDF15 expression 
A) Real-time PCR on kidneys of individual rats confirms the up-regulation of renal GDF15 mRNA 
expression after induction of diabetes. B) GDF15 protein levels by western blot. C) Representative 
picture shows GDF15 protein expression from 2-3 samples per group. The blot was re-probed for 
GapdH to show equal loading Final data from 2 blots are means ± SEM (* indicates P< 0,05 vs day 0) 
 
Confirmation of array data by real-time PCR 
To confirm the results obtained with the microarray, real-time PCR was performed for a 
subset of genes related to renal prefibrosis (Figure 5). Real-time PCR on individual kidneys 
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Table 3: Gene list showing the top 25 up and down regulated renal genes in the first week after 
induction of diabetes  
AUC Gene acc. # Description 
Top 25 up regulated genes 
2.76 NM_173323 UDP-glucuronosyltransferase 
2.28 NM_019216 growth differentiation factor 15 
2.26 NM_173094 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 
2.23 XM_216142 retinoic acid receptor responder (tazarotene induced) 2 
2.19 NM_053587 S100 calcium binding protein A9 (calgranulin B) 
2.09 XM_343171 Rattus norvegicus lymphoctye Met-ase 1 (Gzmm), mRNA 
2.01 NM_201418 Ns5atp9 protein 
1.95 NM_183403 Rattus norvegicus glutathione peroxidase 2 (Gpx2), mRNA. 
1.92 XM_241671 similar to DNA2 DNA replication helicase 2-like 
1.87 NM_144755 tribbles homolog 3 
1.87 NM_012716 solute carrier family 16 (monocarboxylic acid transporters) 
1.86 XM_346212;XM_228626 similar to Discs large homolog 
1.81 NM_031834 sulfotransferase family 1A, phenol-preferring, member 1 
1.80 XM_228669;XM_229139 high-mobility group box 4 
1.77 NM_012559 fibrinogen, gamma polypeptide 
1.75 XM_238283 similar to Glycerol-3-phosphate acyltransferase 
1.74 NM_053822 Rattus norvegicus S100 calcium binding protein A8 (S100a8) 
1.73 NM_175763 immunoglobulin superfamily, member 1 
1.71 NM_023980 G protein-coupled receptor 74 
1.70 XM_215293 vanin 1 
1.70 M84148 Rat IgK chain VJ1 region mRNA 
1.69 NM_019296 cell division cycle 2 homolog A 
1.69 XM_224970 similar to cytoskeleton associated protein 2 
1.66 NM_199115 angiopoietin-like protein 4 
1.65 NM_201635;XM_230882 cytochrome P450, subfamily 24 
   
Top 25 down regulated genes 
-4.200 NM_019347 UREA TRANSPORTER, KIDNEY.  
-2.678 NM_052802 KIDNEY ANDROGEN-REGULATED PROTEIN.  
-2.445 XM_342237 PDZ domain containing 6 (predicted) 
-2.214 NM_012784 Rattus norvegicus cannabinoid receptor 1 (brain) (Cnr1), mRNA 
-2.073 NM_001011948 Rattus norvegicus solute carrier family 7 (cationic amino acid      
-2.014 NM_001017465 Rattus norvegicus similar to solute carrier family 7  
-1.994 NM_001000851 olfactory receptor 807 (predicted) 
-1.970 NM_031044 HISTAMINE N-METHYLTRANSFERASE (EC 2.1.1.8) (HMT) 
-1.866 NM_030837 SOLUTE CARRIER FAMILY 21 MEMBER 4  
-1.848 XM_001070678 PREDICTED: Rattus norvegicus similar to taste receptor, type 2  
-1.830 XM_345911 Similar to BMP-binding endothelial regulator 
-1.806  unknown EST 
-1.801 NM_001077650 Rattus norvegicus endothelin 3 (Edn3), mRNA 
-1.791  unknown EST 
-1.770 XM_234288 sine oculis-related homeobox 6 homolog (Drosophila) (predicted) 
-1.746 NM_001008944 vomeronasal 1 receptor, j4 
-1.745 XM_001078113 PREDICTED: Rattus norvegicus AHNAK nucleoprotein  
-1.722 NM_019169 ALPHA-SYNUCLEIN.  
-1.696 NM_001106778 Rattus norvegicus anoctamin 4 (Ano4), mRNA   
-1.674 XM_216331 similar to hypothetical protein (predicted) 
-1.673 XM_229020 similar to dystrophin 
-1.650 NM_012566 ZINC FINGER PROTEIN GFI-1  
-1.641 NM_001000548 olfactory receptor 158 (predicted) 
-1.640 XM_218181 NACHT, leucine rich repeat and PYD containing 12 (predicted) 






Table 4: List of genes involved in TGF-ß signaling, cell growth, differentiation and proliferation, 
apoptosis, response to stress and protease activity which were up or down regulated within the first 
week of diabetes. Genes were grouped based on gene ontology classification numbers provided with 
the operon microarray slides. 
AUC Gene acc. # Description 
7179 (transforming growth factor beta receptor signaling pathways), 17015 (regulation of transforming growth factor beta receptor signaling pathway) 
2.28 NM_019216 growth differentiation factor 15 
-1.20 NM_178096 neuronal regeneration related protein P311 
 
0008151:cell growth and/or maintenance 
1.57 NM_012930 carnitine palmitoyltransferase 2 
1.42 NM_012879 solute carrier family 2 (facilitated glucose transporter), member 2 
1.38 NM_130741 lipocalin 2 
1.37 NM_031821 polo-like kinase 2 
1.32 XM_220119;NM_001009470 cyclin B2 
1.32 XM_219276 similar to ATP-binding cassette transporter sub-family A member 15 
1.32 NM_017100 polo-like kinase 1 
1.26 NM_080782 cyclin-dependent kinase inhibitor 1A 
1.25 XM_220540 similar to solute carrier family 5 (sodium/glucose cotransporter), member 10 
-1.32 NM_031584 solute carrier family 22 (organic cation transporter), member 2 
-1.40 NM_012488 alpha-2-macroglobulin 
-1.44 XM_223975 similar to Zinc transporter ZIP2 (Eti-1) (6A1) (hZIP2) (Solute carrier family 39 member 2) 
-4.20 NM_019347 solute carrier family 14 (urea transporter), member 2 isoform 1 
   
5172 (vascular endothelial growth factor receptor binding), 8283 (cell proliferation), 8284 (positive regulation of cell proliferation), 8285 (negative 
regulation of cell proliferation), 30154 (cell differentiation), 42127 (regulation of cell proliferation), 45596 (negative regulation of cell differentiation),  
1.66 NM_199115 angiopoietin-like protein 4 
1.49 XM_215849 similar to budding uninhibited by benzimidazoles 1 homolog 
1.29 XM_215924 similar to ubiquitin-conjugating enzyme E2C 
1.22 XM_225460 similar to Antigen KI-67 
-1.21 XM_215890 similar to Angiopoietin-4 precursor (ANG-4) (ANG-3) 
-1.35 NM_030827 low density lipoprotein receptor-related protein 2 
-1.52 NM_017082 Uromodulin 
-1.54 XM_343923 similar to retinoic acid, EGF, and NGF upregulated 
-1.56 NM_012561 Follistatin 
   
6915 (apoptosis), 6916 (anti-apoptosis), 6919 (caspase activation), 42981(regulation of apoptosis), 43066 (negative regulation of apoptosis), 43065 
(positive regulation of apoptosis)   
1.26 NM_022622 BRCA1 associated RING domain 1 
-1.30 XM_214418 FAST kinase domains 3 
-1.32 NM_139258 Bcl2 modifying factor 
-1.64 XM_218181 similar to PYRIN-containing APAF1-like protein 7 isoform 2 
-1.72 NM_019169 synuclein, alpha 
   
0006950:response to stress 
1.44 NM_012861 O-6-methylguanine-DNA methyltransferase 
1.39 NM_183403 glutathione peroxidase 2 
   
0019538:protein metabolism, protease activity, peptidase activity 
1.33 NM_001012346 Rattus norvegicus aminopeptidase O 
-1.26 NM_012999 PAIRED BASIC AMINO ACID CLEAVING ENZYME 4 PRECURSOR (PACE4) 
-1.37 XM_235070 ubiquitin specific protease 44 (predicted) 
-1.22 XM_218997 similar to ubiquitin specific protease 47 
 





This study is the first expression array study describing renal gene expression changes in 
the first week of diabetes in a rat model of STZ induced diabetes. The study aimed at 
identifying genes associated with the induction of prefibrosis and activation of the TGF-ß 
signaling pathway. Rats were diabetic as of the first day after STZ administration and blood 
glucose levels remained similarly elevated at all subsequent time points. The elevation of 
blood glucose levels was associated with increased phosphorylation of renal Smad2/3, the 
classical signaling route of the profibrotic factor transforming growth factor beta (TGF-ß). 
Furthermore, tubulointerstitial α-SMA staining was significantly increased after two days 
of diabetes and remained elevated at subsequent time points. These results demonstrate that 
induction of tubulointerstitial prefibrosis in our model of uncontrolled type 1 diabetes is 
already evident after just two days of diabetes. Early induction of tubulointerstitial 
prefibrosis in the STZ induced diabetic rats was demonstrated before, although the earliest 
studied time point in this study was one week after STZ injection15. Nevertheless, this and 
our study demonstrates that induction of pre-fibrosis in uncontroled STZ induced diabetes 
is present within the first week of diabetes. 
 
Despite increased phosphorylation of Smad2/3 and increased α-SMA staining, we did not 
find evidence for increased renal TGF-β expression in the first week of diabetes using 
either the microarray or real-time PCR technique. It is commonly accepted that local 
expression of TGF-ß participates in renal Smad2/3 activation and subsequent myofibroblast 
activation. However, there is only limited data on renal TGF-ß expression in early STZ 
induced diabetes. Staining for renal TGF-ß expression demonstrated increased glomerular 
TGF-ß expression in the glomerulus as early as ten days after STZ injection in mice22. 
Furthermore, increased TGF-ß mRNA expression was reported in both glomerular and 
interstitial tissues as early as three days after STZ injection in rats with severe diabetes23. 
These differences between these studies and our data may be explained by differences in rat 
strain and slightly lower blood glucose levels in our study. Nevertheless, our data 
demonstrates a marked increase in tubulointerstitial α-SMA expression and activation of 
the Smad2/3 route in the absence of a strong increase in TGF-ß mRNA expression, 
suggesting that the TGF-ß signaling cascade is modulated through other mechanisms than 
upregulation of renal TGF-ß1 mRNA expression in early diabetes.  
 
Several studies demonstrated a correlation between circulating TGF-ß levels and the 






In our model, analysis of circulating latent and active TGF-ß levels demonstrated a 
dramatic increase in latent TGF-ß levels after one day of diabetes with subsequent 
normalization at all later time points. The strong transient upregulation of latent-TGF-ß 
plasma levels immediately upon induction of diabetes has not been documented before and 
the source of the latent TGF-ß is unknown. Although the increase of latent TGF-ß plasma 
levels normalizes by day two, local conversion and activation of circulating latent TGF-ß 
within the diabetic kidney may have contributed to the activation of Smad2/3 at day one 
after STZ injection. However, the Smad2/3 pathway remained activated at all subsequent 
time points, suggesting that other members of the TGF-ß family may be involved in the 
sustained Smad2/3 activation. 
In our array analysis, we therefore focused on genes that could potentially modulate the 
TGF-ß signaling cascade in diabetes. In our gene ontology analysis, only one gene involved 
in TGF-β signaling (GDF15) was found upregulated after induction of diabetes. 
 
 Growth Differentiation Factor 15 (GDF15) is one of the most prominently upregulated 
genes in our array analysis and is an immediate early gene and member of the TGF-ß 
signaling family. The kinetics of renal GDF15 expression followed a specific pattern with a 
20 fold upregulation on days one and two after induction of diabetes with a trend towards 
normalization at subsequent time points. Previously, renal upregulation of GDF15 mRNA 
expression has been demonstrated in models of renal ischemia and reperfusion injury and in 
the 5/6 nephrectomy model with similar kinetic profiles25. Furthermore, GDF15 
upregulation has been demonstrated after chemical and hyperoxic injury of the lung, by 
surgical, chemical and heat induced injury of the liver26 and after ischemia/ reperfusion 
injury of the heart27, indicating that GDF15 is a general mediator of the organ injury 
response. Nevertheless, our study is the first to show that GDF15 is upregulated in the 
kidney immediately after induction of experimental diabetes. Furthermore, the clinical 
importance of GDF15 in diabetes has recently been demonstrated in a study showing that 
higher plasma levels of GDF15 are a predictor of all-cause and cardiovascular mortality and 
morbidity in patients with diabetic nephropathy28. Even so, the function of GDF15 in the 
kidney remains unknown, but studies performed in the heart and in cultured 
cardiomyocytes demonstrate that GDF15 has anti-apoptotic effects29. In addition, these 
studies report conflicting data on the hypertrophic effects of GDF15. Xu et al30, 
demonstrated an anti-hypertrophic effect of GDF15 associated with Smad2/3 activation in 
the mouse myocardium and in cultured cardiomyocytes. In contrast, a recent study by 




Heger et al29 demonstrated prohypertrophic effect of GDF15 associated with Erk and 
subsequent Smad1 activation in cultured adult cardiomyocytes.  
 
Furthermore, we observed down-regulation of an inhibitor of the TGF-β signaling cascades 
after induction of diabetes. Neuronal regeneration related peptide P311 was significantly 
down-regulated in the first week of diabetes. Recently, a role for P311 has been suggested 
in the regulation of the phenotype of myofibroblasts in immunoglobulin-A nephropathy31. 
Furthermore, a study performed in NIH 3T3 cells demonstrated that P311 stimulated 
smooth muscle specific protein overexpression resulted in reduced Smad3 activity, down 
regulated the expression of TGF-ß1 and TGF-ß2 and induced a nonfibrogenic 
myofibroblast phenotype32. Therefore, down regulation of P311 may enhance TGF-ß 
signaling and contribute to the development of a more pro-fibrotic myofibroblast phenotype 
in early diabetes.  
 
As we found only two genes related to TGF-β signaling, we extended our analysis to 
factors, that may be indirectly influencing TGF-β signaling. Myofibroblast activation may 
be stimulated by the observed renal down-regulation of follistatin. Follistatin is an 
antagonist of activin A, a TGF-β family member and a potent activator of renal interstitial 
fibroblasts in diabetic nephropathy33. Local activation of latent-TGF-ß through increased 
protease and peptidase activity could contribute to the activation of the TGF-ß signaling 
cascade. We found upregulation of aminopeptidase O, an aminopeptidase related to 
aminopeptidase B and Leukotriene A4 hydrolase34. Although the involvement of 
aminopeptidase O is fibroblast activation are unclear, inhibition of aminopeptidase B 
reduced the fibrotic properties of cardiac fibroblasts, indicating a role of these 
aminopeptidases in fibroblast activation35. Furthermore, we found down-regulation of 
PACE4, a subtilisin-like proprotein convertase involved in the activation of bone 
morphogenic proteins (BMPs) and matrix metalloproteinases (MMPs)36;37. As BMPs have 
opposing effects on TGF-ß38-41 and MMPs are involved in extracellular matrix degradation 
in STZ induced diabetes42-45, the down-regulation of PACE4 may contribute to renal 
fibroblast activation in early diabetes. 
 
Our list of renal genes regulated in the first week after induction of diabetes shares only a 
limited number of genes with genes obtained in microarray studies in more established 
diabetes. Down regulation of Kidney Androgen regulated protein (KAP) has been 






murine diabetes46. A study performed on transgenic mice over-expressing KAP 
demonstrates a role for KAP in hypertension and renal alterations mediated by oxidative 
stress47, although its function in diabetes remains unclear. Nevertheless, our study 
demonstrates that downregulation of KAP is evident in the first week after induction of 
diabetes. Furthermore, changes in the expression of heme-oxygenase-1, solute carrier 
family 7, tubulin, trefoil factor 3 and components of cytochrome P450 have been described 
at later time points of experimental diabetes in mice46. Nonetheless, less than two percent of 
the genes identified by us in the first week of diabetes are also identified at later time 
points, indicating the initiation of specific and transient gene expression profiles after 
induction of diabetes. 
A limitation of the current study is that the employed method for analysis of the array data 
has limited capability to detect genes that are specifically regulated at single time points. 
However, as renal pre-fibrosis takes several days to develop, this limitation is not likely to 
affect the analysis of the genes involved in the induction of renal pre-fibrosis. 
 
In summary, we have identified several genes associated with the induction of prefibrosis in 
the first week of streptozotocin induced diabetes in rats. The products of these genes were 
previously identified as modulators of TGF-ß signaling and included GDF15, P311, 
follistatin and two proprotein activating proteases. Initiation of renal prefibrosis was not 
associated with increased renal expression of TGF-ß mRNA expression but a transient 
increase in circulating latent TGF-ß may participate in the induction of renal prefibrosis. 
The identification of these TGF-ß modulating renal genes in early diabetes may lead to       
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Transforming growth factor (TGF-β) is generally regarded as the key mediator in the 
development of renal fibrosis due to the induction of extracellular matrix (ECM) 
production. Growth Differentiation Factor 15 (GDF15), a secreted member of the TGF-β 
superfamily, is primarily expressed in the glomerulus early after induction of diabetes. In 
the current study, we aimed at establishing the functional implications and the signaling 
pathways of GDF15 on glomerular mesangial cells. Furthermore, we evaluated whether 
GDF15 responses resembled TGF-ß1 responses. 
 
Methods 
To investigate the signaling pathways of GDF15, human mesangial cells (THMC) were 
stimulated with GDF15 or TGF-β and activation of Smad pathways and MAP kinase 
pathway were analyzed by western blotting. The effects of preincubation with GDF15 and 
TGF-β on proliferation, apoptosis and α-SMA gene expression were investigated. SiRNA 
silencing of type 2 receptors was used to identify the receptor for GDF15 in THMC. 
 
Results 
Unlike TGF-β, GDF15 did not signal through the classical Smad 2, 3 or Smad 1, 5, 8 
pathways in THMC, but signaled through the MAP kinase pathway, including p38, JNK 
and MEK. GDF15 had no effects on apoptosis or initiation of fibrosis in THMC but 
induced proliferation of THMC through activation of p38 and JNK. Silencing of type 2 
receptors demonstrated that GDF15 signals through the BMPR2 receptor in THMC. 
 
Conclusion 
In conclusion, GDF15 stimulated proliferation of human mesangial cells (THMC) through 
activation of the MAPK members JNK and p38 and involved the BMPR2 receptor. GDF15 










Growth Differentiation Factor 15 (GDF15), a distant member of the Transforming growth   
factor-β family and an early response gene, is emerging as an independent predictor of 
cardiovascular disease (CVD) and diabetic kidney disease. In insulin-dependent diabetes 
mellitus and nephropathy, GDF15 was recently identified as a predictor of all-cause and 
cardiovascular mortality and morbidity1. Furthermore, this study demonstrated that higher 
levels of circulating GDF15 were associated with faster deterioration of kidney function. In 
obese type 2 diabetic (T2DM) patients, GDF15 levels were increased compared to         
non-diabetic obese patients2;3. Furthermore, GDF15 levels correlated with insulin resistance 
in obese T2DM patients4. Interestingly, elevated levels of GDF15 have been reported 
before the onset of T2DM, suggesting that GDF15 may be a part of an anti-inflammatory 
response preceding the onset of T2DM5. Finally, increased GDF15 levels have been 
reported in diabetic pregnancies6. 
 
Despite the role as biomarker for progression of CVD and kidney disease, relatively little is 
known on the functional role of GDF15. Mice that are genetically deleted for GDF15 
demonstrated no major abnormalities, except for decreased body weight, possibly through 
an interaction of GDF15 with adiponectin expression in fat cells7. Under physiological 
conditions, GDF15 is weakly expressed in most tissues. However, GDF15 expression is 
markedly increased in response to injury in various tissues8-11, including heart and kidney10. 
As GDF15 knockout mice show increased tissue damage after cardiac injury, GDF15 is 
believed to be a protective factor by reducing apoptosis and influencing cellular 
proliferation12-14. Furthermore, a recent study demonstrated that GDF15 inhibits leukocyte 
recruitment and inflammation by inhibiting endothelial integrin activation in an 
experimental model of myocardial infarction15.  
 
In a recent experiment, renal GDF15 expression was found to be strongly upregulated in the 
glomeruli of diabetic rats and was associated with the induction of renal fibrosis16. As 
glomerular mesangial cells play an important role in production of glomerular extra cellular 
matrix (ECM) production in diabetic kidney disease, we aimed at identifying the functional 
effects of GDF15 in cultured human mesangial cells (THMC). Furthermore, we aimed at 








Materials and methods 
Cell Culture 
Transformed human mesangial cells (THMC) and podocytes (gift from K. Sharma, UCSD, 
San Diego, USA) were cultured in Dulbecco’s modified Eagle’s medium: Nutrient mixture 
F-12 (DMEM/F12, 1g/L glucose; Gibco BRL) supplemented with 1.0 mg/l L-glutamine, 
2% or 10% of fetal calf serum (FCS; PAA Laboratories), 100 µg/ml streptomycin (Gibco 
BRL) in a humidified incubator at 37 °C and 5% CO2. When cells reached confluence, they 
were passaged in a 1: 20 ratio with 0.05% trypsin-EDTA (Gibco BRL); passages 6-30 were 
used. For incubation in high glucose and mannitol, THMC were cultured in DMEM/F12 
supplemented with glucose or mannitol to 30 mM for 24 hours.  
Mouse mesangial cells (MMC) cultured from transgenic mice expressing GFP under the 
control of a Collagen 1A promoter were grown on a collagen І (8.4 µg/cm2) coated plates in 
low glucose (1 g/l) DMEM supplemented with 10% FCS and 100 µg/ml streptomycin in a 
humidified incubator at 37 °C and 5% CO2. MMC were seeded in 10% FCS medium in  
96-well plates (Nunc) coated with collagen I. After overnight incubation, cells were treated 




THMC were grown in 96-well plates until 80% confluence. 24 hours prior to stimulation, 
the cells were placed in CO2-independent medium, supplemented with 2% FCS. Hypoxia 
was induced by incubating the cells in a humidified hypoxia chamber (100% N2) for 16 
hours. Control cells were incubated at 37˚C with 5% CO2. Subsequent to the hypoxia, cells 
were returned to normal growth conditions (37˚C with 5% CO2) for 4 hours. 
 
SiRNA transfection 
SiRNA transfection was performed using Lipofectamine 2000 (Invitrogen). For this, 
THMC were grown in a 12 wells plate for 24 hours.  SiRNA transfection was performed in 
duplicate, using 2 µl Lipofectamine 2000 and 80 pmol/ml siRNA in 100 µl Optimem. 
SiRNA’s sequences used were: negative control scrambled siRNA (Ambion; AM4611), 
ActRIIA (Sigma), ActRIIB (Sigma), BMPRII (Sigma). After 4 hours of transfection the 
medium was changed for culture medium with 2% FCS for 24 hours. GDF15 (50 ng/ml) 
was added to the cells for 5 minutes. Cells were washed with cold phosphate-buffered 
saline (PBS) and subsequently lysed for protein isolation (RIPA buffer) to investigate 
MEK1/2 activation.  





RNA from THMC was isolated using a RNA isolation kit (NucleoSpin® RNA II, 
Macherey-Nagel GmbH & Co. KG). The integrity of RNA was determined using agarose 
gel electrophoresis, and the RNA concentration was measured spectrophotometrically at 
260 nm. RNA (1 µg) was reversely transcribed into cDNA. Real-Time PCR for GDF15 was 
performed using AbsoluteTM QPCR SYBR® Green ROX Mix (Westburg, Leusden, 
Netherlands), 400 nM of primer and 2,5 µl template DNA in a total volume of 25 µl. 
Quantitative real-time PCR was performed at 95˚C for 15 minutes followed by 40 cycles of 
denaturing at 95˚C for 15 seconds and annealing/ extending at 60˚C for 1 minute.         
Real-Time PCR for GDF15 was performed using AbsoluteTM QPCR SYBR® Green ROX 
Mix (Westburg, Leusden, Netherlands), 400 nM of each primer (GDF15 F: 5’-
CAGAGTTGCACTCCGAAGAC-3’, GDF15 R: 5’-CACTTCTGGCGTGAGTATCC-3’) 
and 2 µl template DNA in a total volume of 10 µl. PCR product specificity and purity were 




Cells were seeded in 6-well plates (Nunc) at a concentration of 10.000 cells in 2 ml culture 
medium with 2% FCS. GDF15 (10 ng/ml, Pepro Tech, 120-28), and GDF15 (50 ng/ml) and 
TGF-β (10 ng/ml, Pepro Tech, 100-21) were added to the cells for 5 minutes, 30 minutes or 
1 hour. Cells were washed with cold phosphate-buffered saline (PBS) and subsequently 
lysed in 125 µl of ice-cold RIPA buffer (1% Igepal ca-630, 1% SDS, 5 mg/ml sodium 
deoxycholate, 1 mM sodium orthovanadate, 10 mM β-mercapto-ethanol, 40 µg/ml PMSF, 
100 µg/ml benzamidine, 500 ng/ml pepstatin A, 500 ng/ml leupeptine and 500 ng/ml 
aprotinin in PBS). Protein concentrations were determined using Bio-Rad protein assay.  
 
Western blotting 
Proteins were separated by gel electrophoresis. For electrophoresis, 10 µg of total protein 
was combined with a 5x protein loading buffer (10% SDS, 50% glycerol, 10% β-mercapto-
ethanol, 0.05% bromophenol blue in 0.33 M Tris HCL, pH 6.8) and subjected to a 4-20% 
Precise Protein Gel (Pierce). The separated proteins were transferred to a nitrocellulose 
membrane. Non-specific binding sites were blocked by incubation with 5% Skim Milk in 
TBS/T-20 (0.05 M Tris, 150 mM NaCl, 0.04% Tween-20) for 30 minutes. The membrane 
was immunoblotted with phospho-MEK antibody (sc-7383 Santa-Cruz; 1:500), anti-active 






1:500), phospho-Smad2 (Cell Signaling Ser 465/467; 1:500) and phospho-SAPK/JNK 
(Thr183/Tyr 185; Cell Signaling; 1:250). Primary antibodies were detected with 
horseradish-peroxidase-conjugated rabbit anti-mouse IgG (Dako; 1:1000) and with goat 
anti-rabbit IgG (Dako; 1:2000). As a housekeeping protein, GAPDH (Fitzgerald: 1:10.000) 
was used. After incubation, the membrane was washed with TBS/T-20 and 
immunoreactivity was visualized with SuperSignal West Pico Chemiluminescent kit and 
exposed by Gene-Gnome (Westburg B.V., Leusden, The Netherlands). 
 
Proliferation Assay 
Cells in 96-well plates (Nunc) at a concentration of 1000 cells in 100 µl culture medium 
were incubated with 2% FCS or 10% FCS as a control. Incubation with 50 µM MEK1 
inhibitor PD98059 (Cell Signaling Technology; #9900) was performed for 1.5 hour, 50 µM 
p38 inhibitor SB202190 (Sigma; S7067) for 1 hour, 20 µM JNK inhibitor SP600125 
(Sigma; S5567) for 1 hour. Cells were treated with GDF15 (50 ng/ml) or TGF- β (10ng/ml) 
for 48 hours. Proliferation was measured with the Cy-QUANT NF cell proliferation kit 
(Invitrogen) according to the manufacturer’s instructions. 
 
Apoptotic assay 
The Apo-ONE® Homogeneous Caspase-3/7 Assay, Promega, was used to measure 
apoptosis following the manufacturer’s description. In short, 50 µl of Apo-ONE      
Caspase-3/7 Reagent was added to 50 µl medium of each well of the 96-wells plate. 
Contents were mixed for 30 seconds and incubated for 1 hour, after which fluorescence was 
measured with an fluorescent plate reader.  
 
Statistical analysis 
Data are expressed as mean value ± S.E.M. Differences between groups were tested by 
Student’s t-test and analysis of variance (ANOVA) by Microsoft Excel (2003 SP3 version). 
A p value less than 0.05 was considered statistically significant. 
 






GDF15 expression is upregulated by high glucose. 
To investigate whether glomerular GDF15 expression may be upregulated by high glucose 
in diabetes, cultured human mesangial cells (THMC) and podocytes were incubated in 
normal tissue culture medium and in medium containing 30 mM glucose or 30 mM 
mannitol as an osmotic control (Figure 1). Quantitative real-time PCR demonstrated that 
GDF15 expression was increased almost four-fold in THMC after pretreatment with high 
glucose (372±150%) compared to controls (100±48%). In podocytes, the induction of 
GDF15 expression was less pronounced after pretreatment with high glucose (155±51%) 















































































Figure 1: GDF15 mRNA expression is upregulated in cultured THMC and podocytes by high 
glucose. A) GDF15 expression in THMC, B) GDF15 expression in podocytes. Cell were exposed to 







Effects of GDF15 on cellular proliferation, apoptosis and initiation of fibrosis in cultured 
THMC. 
To test the functional effects of GDF15 on THMC, we investigated the role of GDF15 in 
cellular proliferation, apoptosis and initiation of fibrosis in cultured THMC (Figure 2). 
Cells were also treated with TGF-β to determine whether the effects of GDF15 were 
distinct from those of TGF-β.  
GDF15 profoundly stimulated THMC proliferation under culture conditions with 2% FCS 
(185±10.9%) compared to controls (Figure 2A). The GDF15 induced proliferation of 
THMC was comparable to the effect of 10% FCS (189±8%). TGF-β did not significantly 
induce THMC proliferation (139±8.8%).  
To investigate the effects of GDF15 on apoptosis of THMC, caspase activity was measured 
(Figure 2B). Under normal culturing conditions, pretreatment with GDF15 did not induce 
caspase activity while pretreatment with TGF-β caused a significant increase in caspase 
activity (135±5%) over controls (100±5%). As hypoxia was known to increase caspase 
activity in THMC (unpublished data), THMC were cultured in hypoxic conditions. 
Overnight exposure of THMC to hypoxia increased caspase activity (187±35%). 
Pretreatment with GDF15 did not affect caspase activity while TGF-β caused a further 
increase in caspase activity (350±16%). 
To investigate the effects of GDF15 on initiation of fibrosis in THMC, the gene expression 
of α-smooth muscle actin (α-SMA) was determined (Figure 2C). Pretreatment with GDF15 
did not affect α-SMA expression, while pretreatment with TGF-β caused increased α-SMA 
expression (260±33%). Furthermore, GDF15 treatment did not increase GFP expression in 
mesangial cells isolated from transgenic mice carrying a GFP gene under control of a 
collagen-I promoter (Figure 2D). In contrast, TGF-β caused increased collagen-GFP 
expression after 48 hours.  
Together, these data demonstrate that GDF15 and TGF-β induce markedly distinct 
functional effects in THMC.  
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Figure 2: Effects of GDF15 and TGF-β on cellular proliferation, apoptosis and initiation of 
fibrosis in cultured THMC. A) GDF15 stimulates proliferation of THMC. B) GDF15 did not affect 
caspase activity in THMC in control and in hypoxic conditions. TGF-β increased caspase activity in 
both normal and hypoxic conditions. C) GDF15 did not affect α-SMA expression while TGF-β 
increased α-SMA expression. D) GDF15 did not alter collagen-GFP expression in mesangial cells 
obtained from transgenic mice with GFP under control of a collagen-I promoter. TGF-β increased 














Effects of GDF15 and TGF-β on Smad and MAPK signaling in THMC 
To investigate the signaling cascades activated by GDF15 and TGF-β in THMC, Western-
blot was performed on cells stimulated with GDF15 and TGF-β (Figure 3).  
As members of the TGF-β superfamily generally signal through Smad2/3 or Smad1/5/8 
signaling, the effect of GDF15 on phosphorylation of these proteins was assessed. Using 
phospho-specific antibodies to Smad2/3 and Smad1/5/8, we found that GDF15 did not 
stimulate Smad2/3 or Smad1/5/8 in THMC at the indicated time-points (Figure 3A,B). In 
contrast, TGF-β activated both Smad2/3 and Smad1/5/8 after 30 minutes of stimulation.  
As members of the TGF-β superfamily of signaling molecules can also signal through the 
noncanonical MAPK pathway, we investigated whether GDF15 activated members of the 
MAPK signaling cascades in THMC using phosphospecific antibodies. GDF15 transiently 
increased p-MEK1/2 levels after 5 minutes of stimulation (Figure 3C), Furthermore, p-JNK 
levels were increased after 60 minutes of GDF15 stimulation (Figure 3D) and p38 levels 
were increased after 30 minutes of GDF15 stimulation (Figure 3E). Stimulation with    
TGF-β for 30 minutes only increased p-JNK levels (Figure 3D). 
















































































































































































































































Figure 3: Effects of GDF15 and TGF-β on activation of Smad and MAPK signaling cascades.  
A) Exposure of THMC for 5, 30 and 60 minutes to GDF15 (50 ng/ml) did not increase p-Smad2/3. 
TGF-β for 30 minutes resulted in a 20 fold increase in p-Smad2/3. B) GDF15 did not increase          
p-Smad1,5,8 levels, while TGF-β caused a 5 fold increase in p-Smad1/5/8. C) MEK1/2 was 
transiently activated by GDF15 after 5 minutes. p-MEK1/2 levels were at control levels at all other 
time-points and after stimulation with TGF-β for 30 minutes. D) p-JNK levels were significantly 
increased after 60 minutes of GDF15 and 30 minutes of TGF-β stimulation. E) p-38 was significantly 






Effects of MAPK inhibitors on GDF15 induced proliferation 
To investigate whether GDF15 stimulates proliferation of THMC through MAPK 
signaling, we tested the effects of specific MAPK inhibitors on GDF15 induced THMC 
proliferation (Figure 5). In the absence of inhibitors (light grey bars), GDF15 increased 
THMC proliferation by 147±3% of controls (100±7%), confirming the effects of GDF15 on 
THMC proliferation. Again, a similar stimulation was achieved by incubation with 10% 
FCS (148±2%). 
Incubation with MEK inhibitor increased basal proliferation to 130±3% (Figure 5, black 
bars). In the presence of MEK inhibitor, stimulation with 10%FCS and GDF15 further 
increased THMC proliferation to 150±2% and 143±2%, respectively. Therefore, these 
results demonstrate that the MEK pathway has an anti-proliferative effect on THMC. 
Furthermore, MEK inhibition did not inhibit GDF15 induced THMC proliferation. 
Incubation with JNK inhibitor decreased basal THMC proliferation to 39±4% of control 
(Figure 5, white bars). Although stimulation with 10% FCS still resulted in increased 
THMC proliferation (74±9%), the proliferation by GDF15 was not significantly increased 
(50±9%).  
Similarly, p38 inhibition also decreased basal THMC proliferation to 17±2% of control 
(Figure 5, dark grey bars). Stimulation with GDF15 still significantly increased THMC 
proliferation (41±5%) but this response was inhibited compared to stimulation with 10% 
FCS (85±16%.). 
Taken together, these results demonstrate that THMC proliferation is dependent on the JNK 
and p38 pathway. Furthermore, JNK and p38 inhibition inhibited the effects of GDF15 on 
THMC proliferation. 
 
Identification of receptors involved in GDF15 signaling in THMC 
To identify the receptor(s) through which GDF15 signals in THMC, the effect of receptor 
silencing on MEK1/2 activation was investigated. Members of the TGF-β superfamily of 
signaling molecules first bind to a type 2 receptor with subsequent activation of type 1 
receptors. As the type 2 receptors are the primary receptors for TGF-β superfamily ligands, 
we aimed at silencing the type 2A and type 2B activin receptors (ActR2A and ActR2B, 
respectively) and the type 2 BMP receptor (Figure 4). Transfection of THMC with SiRNA 
directed to ActR2A and ActR2B did not affect the response to GDF15. In contrast, 
transfection using a SiRNA directed to BMPR2 resulted in a complete abrogation of the 
effects of GDF15 on MEK1/2 activation. 



































Figure 4: Effect of silencing of type 2 receptors on GDF15 mediated activation of MEK1/2. THMC 
were transfected with SiRNA directed to activin receptors 2A and 2B and BMP receptor 2                 
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Figure 5: Effects of MAPK inhibitors on GDF15 induced proliferation of THMC. THMC were 
cultured in medium containing 2%FCS and treated with inhibitors for MEK, JNK and p38. 
Proliferation was stimulated with 10% FCS (positive control) or GDF15. (*p<0.05 vs control, 







This is the first study to describe the signaling pathways of Growth Differentiation Factor 
15 (GDF15) in cultured human mesangial cells (THMC) and identify the JNK and p38 to 
be prominently involved in absence of activation of the canonical Smad signaling routes. 
Furthermore, we are the first to identify GDF15 to signal through stimulation of the type 2 
BMP receptor.  
 
Members of the TGF-β superfamily of signaling molecules which include TGF-β, BMP, 
activins and GDFs generally signal through the classical (Smad) and noncanonical (MAPK) 
signaling pathways. Surprisingly, GDF15 did not activate the classical signaling cascade 
involving Smad2/3 or Smad1/5/8. This is in contrast to a previous study in which GDF15 
activated the Smad2/3 signaling cascade in cultured cardiomyocytes17;18. Furthermore, a 
recent paper demonstrated that GDF15 activated the Smad1/5/8 signaling cascade in 
cultured cardiomyocytes but not Smad2/319;20. It is unclear why GDF15 does not employ 
Smad signaling in THMC. However, the absence of Smad activation by GDF15 in THMC 
can not be explained by defects in Smad signaling in THMC, as TGF-β stimulated both 
Smad2/3 and Smad1/5/8 in THMC. Although the classical (Smad) and noncanonical 
(MAPK) signaling pathways of TGF-β, BMP and other family members have been 
described extensively in literature, it remains unclear whether both pathways act 
independently or coordinately. Some studies showed that the classical and noncanonical 
pathways were codependent and provided redundancy21;22. However, our current study in 
THMC demonstrates that GDF15 can activate the MAPK system without activating the 
Smad signaling cascades. 
 
GDF15 did not affect fibrosis in THMC, although mesangial cells play an important role in 
glomerular ECM production in diabetic kidney disease (for review, see23). In contrast, 
TGF-β caused increased alpha-smooth muscle actin expression in THMC and induced 
collagen promoter activity in transgenic mouse mesangial cells. As Smad2/3 activation is 
widely recognized as a requirement for increased ECM production24, the absence of an 
effect of GDF15 on Smad2/3 signaling is in line with the observation that GDF15 does not 
affect fibrosis in THMC. 
 
GDF15 induced proliferation of THMC through the noncanonical MAPK signaling 
cascade, which was dependent on JNK and p38 signaling. This observation is in line with 
proliferative effects of GDF15 in several other cells types including various cancer lines, 




pulmonary endothelial cells and bile duct cells25-28. Furthermore, several studies have 
reported the involvement of the MEK, JNK and p38 pathways in proliferation of cultured 
mesangial cells29-31, although the relative contribution of each component varied. In our 
studies, inhibition of JNK and p38 led to a decrease in basal proliferation of THMC to 39% 
and 17% of control values, respectively. The large effect of each individual component on 
THMC proliferation suggests a considerable level of interaction or redundancy between 
JNK and p38 signaling in THMC.  
 
Our study is the first to identify BMPR2 as the putative receptor through which GDF15 
activates MAPK, as siRNA treatment downregulating the receptor abrogated GDF15 
effects on MEK1/2. It has been demonstrated that BMP receptors can associate with TGF-β 
activated kinase TAK1 in a complex with other partners including XIAP and TAB, 
resulting in phosphorylation of p38 and JNK32-34. Furthermore, TAK1 has been shown to 
activate MEK1/235. Together, these data suggest that GDF15 activates p38, JNK and MEK 
through activation of TAK1 by the BMPR2. 
 
GDF15 did not affect basal caspase levels in THMC nor did it affect the induction of 
caspase activity after a noxious stimulus, indicating that GDF15 does not affect apoptosis in 
THMC. This is in contrast to studies performed in cardiomyocytes where GDF15 prevented 
cardiomyocyte apoptosis14. However in contrast to THMC, GDF15 increased Smad1/5/8 
signaling in cardiomyocytes36;37, a pathway known to inhibit cardiomyocyte apoptosis38. 
Therefore, the effects of GDF15 on apoptosis may only be present in cells in which GDF15 
signaling is coupled to activation of Smad1/5/8. 
 
GDF15 was found to be upregulated in the glomerulus of diabetic animals early after 
induction of diabetes. Nevertheless, the mechanism for GDF15 upregulation remained 
unclear. The incubation of cultured THMC and podocytes in conditions of high glucose 
increased GDF15 expression in both cell types, although induction of GDF15 expression 
was stronger in THMC. As osmotic controls did not change GDF15 expression, our data 
demonstrates that the induction of GDF15 expression in diabetes may be caused by high 
glucose. Nevertheless, the four-fold induction of GDF15 expression observed in THMC is 
less than the twenty-fold induction of renal GDF15 expression observed in whole kidney 
lysates of diabetic rats (Chapter 1, Figure 4). Although the results obtained in cultured 






GDF15 expression in vivo in diabetic rats may indicate that other factors than high glucose 
may contribute to the induction of renal GDF15 expression in diabetes.  
In conclusion, GDF15 stimulated proliferation of human mesangial cells (THMC) through 
activation of the MAPK members JNK and p38 and involved the BMPR2 receptor. GDF15 
signaling in THMC did not employ the classical Smad pathway and was distinct from  
TGF-β. Consequently, GDF15 did not affect fibrosis and apoptosis in THMC. Future 
experiments in GDF15 knockout mice will be aimed at establishing the functional 
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GDF15 is emerging as valuable biomarker in cardiovascular disease and diabetic kidney 
disease. Also, GDF15 represents an early response gene induced after tissue injury and 
studies performed in GDF15 knockout mice suggest that GDF15 plays a protective role 
after injury. In the current study, we investigated the role of GDF15 in the development of 
diabetic kidney damage in type 1 and type 2 models of diabetes. 
 
Methods and results 
Renal damage was assessed in GDF15 knockout (ko) mice and wild type (wt) mice in the 
streptozotocin type 1 and the db/db type 2 diabetic model. Genetic deletion of GDF15 
resulted in augmented tubular and interstitial damage in both models of diabetes, despite 
similar diabetic states in ko and wt mice. Increased tubular damage in ko animals was 
associated with increased glucosuria and polyuria in both models. In both type 1 and type 2 
diabetes, ko mice showed increased interstitial damage as indicated by increased α-SMA 
staining and collagen type 1 expression. In contrast, glomerular damage was similarly 
elevated in diabetic ko and wt mice. In the type 1 model, GDF15 ko mice demonstrated 
increased expression of inflammatory markers.  In the type 2 model, elevated levels of 
plasma creatinine indicated impaired kidney function in ko mice. 
 
Conclusion 
These data indicate that GDF15 both protects the kidney from diabetic damage and 
maintains renal tubular function in both type 1 and type 2 models of diabetes. 
 
  




Growth Differentiation Factor 15 (GDF15), a distant member of the Transforming growth   
factor-β family and an early response gene, is emerging as an independent predictor of 
cardiovascular disease (CVD) in the elderly and a predictor of prognosis in patients with 
established CVD1-3.  
Diabetes is a common cause of CVD and a number of recent studies demonstrated an 
association between elevated GDF15 levels and CVD. In insulin-dependent diabetes 
mellitus and nephropathy, GDF15 was recently identified as a predictor of all-cause and 
cardiovascular mortality and morbidity4. The study demonstrated that higher levels of 
circulating GDF15 were associated with a faster deterioration of kidney function. In obese 
type 2 diabetic (T2DM) patients, GDF15 levels were increased compared to non-diabetic 
obese patients5;6. Furthermore, GDF15 levels correlated with insulin resistance in obese 
T2DM patients5. Interestingly, elevated levels of GDF15 have been reported before the 
onset of T2DM, suggesting that GDF15 may be a part of an anti-inflammatory response 
preceding the onset of T2DM7. Finally, increased GDF15 levels have been reported in 
diabetic pregnancies8.  
Despite the growing body of literature demonstrating that GDF15 is a valuable biomarker 
for (diabetic) CVD, relatively little is known on the functional role of GDF15. Mice that are 
genetically deleted for GDF15 demonstrate no major abnormalities, except for decreased 
body weight, possibly through an interaction of GDF15 with adiponectin expression in fat 
cells9. Under physiological conditions, GDF15 is weakly expressed most tissues. However, 
GDF15 expression is markedly increased in response to injury in various tissues10-12, 
including heart and kidney10. As GDF15 knockout mice show increased tissue damage after 
cardiac injury, GDF15 is believed to be a protective factor by reducing apoptosis and 
influencing cellular proliferation13-15. Furthermore, a recent study demonstrated that GDF15 
inhibits leukocyte recruitment and inflammation by inhibiting endothelial integrin 
activation in an experimental model of myocardial infarction16.  
In a recently performed microarray experiment, we identified GDF15 as a prominent renal 
factor up-regulated immediately after the induction of diabetes in rats. This and the 
previously reported association of GDF15 with diabetic kidney damage in patients, led us 
to hypothesize that GDF15 may play a role in the development of diabetic kidney damage 
in early diabetes. Thus, we investigated the relationship between GDF15 expression and 
renal damage in type 1 diabetic rats. In addition, the role of GDF15 in the development of 
renal diabetic damage was assessed in wild type and GDF15 knockout mice models with 






Materials and methods 
Animal models 
The experimental protocols were approved by the Institutional Animal Care and Use 
Committee of the University of Groningen (Groningen, the Netherlands).  
 
Streptozotocin induction of type 1 diabetes in rats 
Male Wistar rats (weight 250 – 270 g, 7-8 weeks old, Harlan) were housed under standard 
conditions with free access to food (standard rat chow) and drinking water throughout the 
study. Diabetes was induced in rats by a single injection of streptozotocin (STZ) in citrate 
buffer (60mg/kg i.v). A sham group injected with citrate buffer only (n=10) was included. 
STZ treated rats were sacrificed at day 1 (n=6), 2 (n=7), 4 (n=5) and 7 (n=6) after induction 
of diabetes. At sacrification, rats were anesthetized with isoflurane (2%) and an aortic blood 
sample was collected. Plasma was isolated and stored at -80˚C. The kidneys were perfused 
with saline and removed. Kidney sections were frozen in liquid nitrogen, stored at -80˚C 
and used for RNA isolation. For GDF15 immunohistochemistry, kidney sections were 
embedded in tissue-tek OCT and frozen in liquid nitrogen. 
 
Streptozotocin induction of type 1 diabetes in mice 
For measurement of renal GDF15 expression in the first week of diabetes, male mice (8-10 
weeks old; C57BL/6) were made diabetic by repeated i.p. injections of a low dose 
streptozotocin (35mg/kg STZ) during five consecutive days. STZ was prepared fresh daily 
and dissolved in 0.1 M citrate buffer (pH 4.38). Mice were sacrificed on day 0 (n=5),          
1 (n=5), 2 (n=5), 4 (n=5), 7 (n=4) after the last STZ injection. A control non-diabetic group 
received saline i.p. and was sacrificed on day 0 (n=2). Blood samples and both kidneys 
were collected at the end of the experiment for analysis of glucose levels (blood) and 
GDF15 expression (kidneys). 
 
Streptozotocin induction of type 1 diabetes in GDF15 wild type and knockout mice 
Male wild-type mice and GDF15 knockout mice (8-10 weeks old) were bred from 5 
breeding pairs generously provided from the Johns Hopkins University Baltimore, 
Maryland, USA. All mice were housed under standard conditions with free access to food 
and drinking water throughout the study. Wild-type and knockout mice were made diabetic 
by low dose STZ injections as described above (50mg/kg i.p, 5-6 mice per group). Healthy 
wild-type and knockout groups consisted of 7 mice. Urine samples were collected to 
measure basal proteinuria, albuminuria and urine creatinine. Mice were placed in metabolic 
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cages for 24 hours after last day of injection (day 0), week 1 and week 2. Mice were 
anesthetized with isoflurane (2%) and a blood sample was collected. Glucose measurement 
was performed from fresh blood immediately after sacrification with an Accu-chek® 
glucose meter (Roche Diagnostics, Netherlands). Plasma was collected and stored at -80˚C. 
Kidneys were perfused with saline and removed. Midcoronal slices from kidney were fixed 
in 4 % paraformaldehyde, processed for embedding and further used for 
immunohistochemistry. For protein and RNA isolation, tissues were snap frozen in liquid 
nitrogen, and stored at -80˚C until further processing. 
 
Type 2 diabetes in mice 
Five female heterozygous db/+ mice B6.Cg-Dock7m +/+ Lepr db/J mice (7 weeks of age) 
were purchased from The Jackson Laboratories. To evaluate the effect of genetic deletion 
of GDF15 in the db/db type 2 diabetic mouse model, homozygous GDF15 knockout mice 
were interbred with heterozygous db/+ mice. The desired male genotypes db/db GDF15+/+ 
(n=10) and db/db GDF15-/- (n=8) were subsequently obtained by successive rounds of 
inbreeding. Non-diabetic db/+ GDF15-/- mice (n=6) were used a controls. Genotyping for 
mouse leptin receptor mutation was performed as described previously17. Mice were housed 
under standard conditions with free access to food and drinking water throughout the study.  
Body weight and blood pressure were measured weekly. Mice were placed in metabolic 
cages for 24 hours when aged 6, 8, 10, 12, 14, 16 and 18 weeks, and food and water intake 
were measured. Urine samples were collected to measure basal proteinuria, creatinine, 
glucose, and concentration of sodium and potassium. Blood samples were obtained from 
the tail vein or eye socket. Plasma glucose concentrations were determined by the       
Accu-chek® glucose meter (Roche Diagnostics, Netherlands), HbA1c levels were analyzed 
by hematology analyzer (ADVIA120, SIEMENS). At an age of 18 weeks mice were 
anesthetized with isoflurane (2%) and blood samples were collected. Fresh blood was used 
for HbA1c, LDL, HDL, cholesterol and creatinine measurements (Demecal Set, 
LabAnywhere, Haarlem, Netherland). Plasma was isolated and stored at -80˚C. The kidneys 
were frozen in liquid nitrogen, stored at -80˚C and used for RNA isolation. 
 
Real-Time PCR 
RNA from kidneys was isolated using a RNA isolation kit (NucleoSpin® RNA II, 
Macherey-Nagel GmbH & Co. KG). The integrity of RNA was determined using agarose 
gel electrophoresis, and the RNA concentration was measured spectrophotometrically at 






performed using AbsoluteTM QPCR SYBR® Green ROX Mix (Westburg, Leusden, 
Netherlands), 400 nM of primer and 2,5 µl template DNA in a total volume of 25 µl. 
Quantitative real-time PCR was performed at 95˚C for 15 minutes followed by 40 cycles of 
denaturing at 95˚C for 15 seconds and annealing/ extending at 60˚C for 1 minute. Real-
Time PCR for KIM-1, Collagen1, Nephrin, Podocin, GapdH18, MIP-2, KC, ICAM19, and 
glucose transporters20 was performed using AbsoluteTM QPCR SYBR® Green ROX Mix 
(Westburg, Leusden, Netherlands), 400 nM of each primer (table 1) and 2 µl template DNA 
in a total volume of 10 µl. Quantitative real-time PCR was performed at 95˚C for 15 
minutes followed by 40 cycles of denaturing at 95˚C for 15 seconds and                
annealing/ extending at 60˚C for 30 seconds, 75˚C for 30 seconds. PCR product specificity 
and purity were evaluated by generating a dissociation curve following the manufacturer’s 
recommendations. 
Table 1: Sequences of PCR primers 
gene Forward primer (5’→3’) Reverse primer (5’→3’) 
GDF15 ACCTGCTGAGCCGACTGCAT CCAATCGCACCTCTGGACTG 
KIM-1 AAATCCAGAGATTCCCACACG GTCGTGGGTCTTCCTGTAGC 
Collagen 1 GGCCATTGGTGGTGCTGAC TAAAGGAGGAAACGGCAAAG 
Nephrin TCTTCAAATGCACAGCCACCA CAAAGCCAGGTTTCCACTCCA 
Podocin AAGGACAGATATGGGCACTGTCA CCAGGAGCACCTAAGCTATGGAA 
GapdH AAATGGTGAAGGTCGGTGTG TGAAGGGGTCGTTGATGG 
MIP-2 CCAAGGGTTGACTTCAAGAAC AGCGAGGCACATCAGGTACG 
KC CAATGAGCTGCGCTGTCAGTG CTTGGGGACACCTTTTAGCATC 
ICAM TGTTTCCTGCCTCTGAAGC CTTCGTTTGTGATCCTCCG 
GLUT1 GGTGTTTGGCTTAGACTCCATC GCTCTACAACAAACAGCGACAC 
GLUT2 GAAGAGGAGACTGAAGGATCTGC GTAGCAGACACTGCAGAAGAGC 
SGLT1 GGAAGCATATGACCTGTTCTG GACAGAGTGACATCAGACAACAC 
SGLT2 CTTCTGTCGGGTACACTACCTC CCTGGTTGTAGCTCATGACATC 
 
Albumin levels in urine 
Albumin urine levels from 24h urine collections were measured using an ELISA kit for 
mouse Albumin (Bethyl Laboratories, Montgomery, TX), according to the manufacturer’s 
instructions. 
 
Glucose, creatinine levels and proteinuria  in urine 
Urine from 24h collections were stored at -20 °C until analyses were performed. Urinary 
glucose, creatinine and protein were measured by multi-test analyser system (Roche 
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Modular, Mannheim, Germany). Urinary glucose, UAE, Albumin/Creatinine and 
proteinuria were calculated from 24h urinary volume.  
 
Immunohistochemistry 
To evaluate GDF15 localization in the diabetic rat and mouse kidney, a staining for GDF15 
was performed on kidneys collected at day 1 after the STZ mediated induction of diabetes. 
Frozen sections (4 µm) were cold-dried and fixed in acetone. Sections were incubated with 
the primary antibody GDF15 (C-12): sc-46248 (dilution 1:20), followed by incubation with 
FITZ-labelled secondary antibody (Southern Biotechnology Associates, Birmingham, 
Alabama, USA). 
Kidneys fixed in paraformaldehyde were used for α-SMA staining. Four µm sections were 
cut, deparaffinized, hydrated, processed with 1mmol/EDTA (pH 9.0) for antigen retrieval. 
All steps were according to the Vector MOM kit protocol. To evaluate pre-fibrosis after 
diabetic injury, sections were stained for α-smooth muscle actin (α-SMA, mouse 
monoclonal anti-α-smooth muscle actin, Sigma Chemical Co, St Louis, MO, USA) in 1:100 
dilution, with MOM diluent certifying negative staining. Peroxidase activity was developed 
by incubation with AEC (Dako) The expression of α-SMA was measured using    
computer-assisted morphometry. Total staining was evaluated at a magnification of 20x. 
Glomeruli and arteries were excluded from measurements. α-SMA staining was divided by 
the area measured and expressed as a percentage. An average score was calculated per 
section. 
To evaluate the renal damage after diabetic injury, sections were stained for kidney injury 
molecule (KIM-1), a marker of tubular damage (rabbit polyclonal, generously provided by 
Dr. H. van Goor, UMCG). Paraffin sections were dewaxed and subjected to antigen 
retrieval in 0.1M Tris/HCl buffer, pH9, by overnight incubation at 800C. A 2-step 
immunoperoxidase technique was used, as previously described21. Control slides, in which 
the primary antibody was replaced with PBS were consistently negative. The expression of 
KIM-1 was measured using computer-assisted morphometry. Total staining was evaluated 
at a magnification of 20x and expressed as a percentage. Evaluation of the stainings and 
morphometric analysis were performed in a blinded manner. 
 
Morphological analysis  
Four µm thick formalin fixed sections were deparaffinized and stained for periodic acid 
Schiff (PAS) for quantification of focal glomerulosclerosis (FGS) and tubular injury. FGS 






expansion and focal adhesion in each quadrant in a glomerulus and expressed on a scale 
from 0 to 4. If 25% of the glomerulus was affected, it was scored as 1, 50% as 2, 75% as    
3 and 100% as 4. In total, 50 glomeruli per kidney were analyzed, and the total FGS score 
was calculated by multiplying the score by the percentage of glomeruli with the same   
FGS-score. Thus, the total FGS score ranged from 0 to 200. Histological changes of tubular 
morphology were evaluated by assessment of four markers of damage: tubular necrosis, 
loss of brush border, denudation of basement membrane and intraluminal casts. Each 
parameter was graded on a scale from 0 to 3, according to the extent of the injury (0: <5%; 
1: 5-25%; 2: 25-75%; 3: >75%). In total, 30 tubules per kidney were analyzed, and the 
histological score was calculated. Thus total histological score ranged from 0 to 90. 
 
Cell culture  
Transformed human mesangial cells (THMC) were cultured in Dulbecco’s modified 
Eagle’s medium: Nutrient mixture F-12 (DMEM/F12; Gibco BRL) supplemented with 1,0 
mg/l  L-glutamine, 2% or 10% of fetal calf serum (FCS; PAA Laboratories), 100 µg/ml 
streptomycin (Gibco BRL) in a humidified incubator at 37 °C and 5% CO2. For 
proliferation experiments, cells were plated in a 96-well plate at a concentration of 1000 
cells in 100 µl culture medium with 2% FCS. As a positive control for cell growth, cells 
were seeded in culture medium with 10% FCS. To investigate the effect of GDF15 on 
proliferation, cells were treated with 50 ng/ml GDF15 for 48 hours. In addition, cells were 
treated with TGF-β (10 ng/ml) or a combined treatment of TGF-β and GDF-15. The 
CyQUANT® NF Cell Proliferation Assay Kit (Invitrogen) was used to measure cell 
proliferation. Medium was removed and 100 µl of 1x dye binding solution was added to 
each well. Cells were incubated for 30 minutes at 37˚C with 5% CO2. Fluorescence was 
measured using a fluorescent plate reader with excitation at 485 nm and emission detection 
at 530 nm.  
Mink lung epithelial cells (MLEC) were cultured in low glucose (1 g/l) DMEM 
supplemented with 10% FCS and 100 µg/ml streptomycin in a humidified incubator. Cells 
were seeded in 6-well plates (Nunc) at a concentration of 10.000 cells in 2 ml culture 
medium with 2% FCS (THMC), 10% FCS (MLEC). After overnight incubation, cells were 
treated with 50 ng/ml GDF15 and 3 ng/ml TGF-β ) for 5 minutes. Unstimulated cells in 2% 
FCS or 10% FCS were taken as a control. 
Mouse mesangial cells (MMC) cultured from transgenic mice expressing GFP under the 
control of a Collagen 1A promoter were grown on a collagen І (8.4 µg/cm2) coated plates in 
low glucose (1 g/l) DMEM supplemented with 10% FCS and 100 µg/ml streptomycin in a 
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humidified incubator at 37 °C and 5% CO2. MMC were seeded in 10% FCS medium in  
96-well plates (Nunc) coated with collagen I. After overnight incubation, cells were treated 
with 50 ng/ml GDF15 and 10 ng/ml TGF-β for 48 hours. Fluorescence was measured at 
509 nm. 
 
Protein isolation and Western blotting 
Cells (6-well dish format) were washed with cold phosphate-buffered saline (PBS) and 
subsequently lysed in 125 µl of ice-cold RIPA buffer (1% Igepal ca-630, 1% SDS, 5 mg/ml 
sodium deoxycholate, 1 mM sodium orthovanadate, 10 mM β-mercapto-ethanol, 40 µg/ml 
PMSF, 100 µg/ml benzamidine, 500 ng/ml pepstatin A, 500 ng/ml leupeptine and           
500 ng/ml aprotin in PBS). Protein concentrations were determined using Bio-Rad protein 
assay. Proteins were separated by gel electrophoresis. For electrophoresis, 10 µg of total 
protein was combined with a 5x protein loading buffer (10% SDS, 50% glycerol, 10%      
β-mercapto-ethanol, 0.05% bromophenol blue in 0.33 M Tris HCL, pH 6.8) and subjected 
to a 4-20% Precise Protein Gel (Pierce). The separated proteins were transferred to a 
nitrocellulose membrane. Non-specific binding sites were blocked by incubation with 5% 
Skim Milk in TBS/T-20 (0.05 M Tris, 150 mM NaCl, 0.04% Tween-20) for 30 minutes. 
The membrane was immunoblotted with phospho-Smad2 (Cell Signaling Ser 465/467; 
1:500), phospho-Smad 1/5/8 (Chemicon Lot LV1467481; 1:500), or GAPDH antibody 
(Fitzgerald industries 10R-6109a, 1:10.000). Primary antibodies were detected with 
horseradish-peroxidase-conjugated goat anti-rabbit IgG (Dako; 1:2000) or with rabbit anti-
mouse IgG (Dako; 1:1000). After incubation, the membrane was washed with TBS/T-20 
and immunoreactivity was visualized with SuperSignal West Pico Chemiluminescent kit 
and exposed by Gene-Gnome (Westburg B.V., The Netherlands). 
 
Statistical analysis 
Data are expressed as mean value ± S.E.M. Differences between groups were tested by 
Student’s t-test and analysis of variance (ANOVA) by Microsoft Excel (2003 SP3 version). 







Renal GDF15 expression is up-regulated early after STZ induced diabetes in both rats and 
mice.  
In a microarray experiment aimed at identifying renal factors associated with the induction 
of renal damage in early diabetes in rats, we identified GDF15 as one of the most prominent 
factors up-regulated within the first week of diabetes (Mazagova et al., submitted). To 
substantiate the up-regulation of GDF15, type 1 diabetes was induced by standard protocols 
and renal expression of GDF15 was investigated using RT-PCR and immunostaining.  
Real-time PCR demonstrated a very strong up-regulation of GDF15 in the first week of 
STZ induced diabetes in rats (Figure 1A). In addition, real-time PCR on kidneys obtained 
from diabetic mice showed that GDF15 was also substantially up-regulated in the low-dose 
STZ model in mice (Figure 1B). Immunohistochemistry demonstrated that GDF15 staining 
was primarily present in the glomeruli in both rats and mice (Figure 1C and 1D, 
respectively). Thus, these data demonstrate an increased glomerular expression of GDF15 
early after induction of type 1 diabetes in both rat and mouse. 
 
Metabolic parameters of type 1 diabetic wt and GDF15 ko mice. 
To investigate the functional implications of GDF15 in type 1 diabetic kidney disease, we 
compared the induction of renal diabetic damage in wild-type and GDF15 knockout mice in 
the first two weeks after induction of diabetes by STZ. The principal animal characteristics 
are shown in Table 2. In non-diabetic mice, body weight of GDF15 ko mice was 
significantly lower than in wt mice. Further, non-diabetic GDF15 ko mice displayed 
increased kidney weight and kidney to body weight ratio compared to non-diabetic wt mice. 
Food and water intake, urine output and urine glucose levels were similar in non-diabetic 
GDF15 ko and wt mice. 
Induction of diabetes resulted in elevated blood glucose levels at day 7 and day 14, which 
did not differ between GDF15 ko and wt mice (Table 2). Body weights decreased after 
induction of diabetes in wt and GDF15 ko mice at both time points. Food intake was 
similar for diabetic wt mice compared to nondiabetic controls. In contrast, food intake was 
increased in diabetic GDF15 ko at both time points compared to nondiabetic ko mice. 
Water intake and urine output in diabetic wt animals were increased by day 7, but returned 
to normal levels at day 14. In contrast, water intake and urine output in diabetic GDF15 ko 
mice were significantly increased at day 7 and 14 compared to nondiabetic wt and ko mice. 
Urinary glucose excretion was increased in all diabetic mice but was significantly higher 
for diabetic GDF15 ko mice compared to diabetic wt mice. 
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Induction of diabetes resulted in a similar increase in urinary albumin excretion (UAE) and 
albumin/creatinine ratio in both wt and GDF15 ko mice. Despite increased UAE, animals 
did not show proteinuria. 
These data demonstrated that genetic deletion of GDF15 did not change the diabetic state, 
but resulted in  more severe symptoms of diabetes.  
 
Days of diabetes





































































                 Single dose STZ diabetic rats                                                                            Low dose STZ diabetic mice
 
 
Figure 1: Renal GDF15 expression and immunostaining in diabetic rats and mice. A) Real-time 
PCR for renal GDF15 expression in diabetic rats after a single dose of STZ. * p < 0.05 control vs 
diabetic animals. B) Renal GDF15 expression in the low dose STZ model in mice. C,D) GDF15 
immunohistochemistry at day 1 of diabetes demonstrating GDF15 staining in the glomeruli of rats (C) 






Table 2: Animal characteristics of type 1 diabetic mice. 




















BW beginning (g)  26.7±0.7  23.7±0.3*  26.7±0.8     25.1±0.9 24.3±1.3 22.9±0.5 
BW end (g)  26.6±0.4  24.6±0.2*  24.6±0.6     22.5±1 20.6±1.1#    21.7±0.9 
Blood glucose 
(mmol/l)  10.8±1.4 12.7±0.6   19.4±2.5#    21.4±2.7# 19.9±1.3#  20.5±3.2# 
L kidney (mg) 178±5    196±8     179±6   203±7* 148±11     173±13 
R kidney (mg)     189±6    207±8     190±8 202±7 162±11 202±8* 
Liver (mg) 1415±50 1209±52*   1466±41   1326±105 1096±70 1327±137 
Heart (mg) 150±7    145±6     136±7      133±3   120±6      138±8 
L kidney/BW (mg/g)     6.7±0.1     8.0±0.3*    7.3±0.1#      9.1±0.3*#   7.3±0.5   8.1±0.7 
R kidney/BW (mg/g)     7.1±0.2    8.4±0.3   7.7±0.2     9.0±0.3*   7.9±0.4      9.3±0.2*# 
liver/BW (mg/g)   53.3±1.9     49±2.0    59.7±1.1#    58.8±2.5*# 53.3±1.9    60.5±4.6*# 
heart/BW (mg/g)     5.7±0.2    5.9±0.2    5.5±0.1  6.0±0.2  5.9±0.3      6.4±0.4 
Food intake (g/day)     2.9±0.1    2.4±0.4    3.2±0.4   4.0±0.5#  1.8±0.5    4.2±1.1# 
Water intake (ml/day)     4.1±0.2    4.3±0.2    5.6±0.6 11.2±1.9* 3.8±0.6   11.9±3.6* 
Urine output (ml/day)     2.1±0.3    1.6±0.1    3.3±0.6     8.1±1.7*# 1.9±0.8     8.1±3.2*# 
Urine glucose 
(mg/day)     1.9±0.4    0.7±0.2    100±38#    278±107*# 97.7±93.1    606±297*# 
UAE (ug/day)   102±17   98.3±31.0     653±140#    461±59# 658±360#   484±146# 
Alb/Creat ratio 
(ug/mg)   111±17    82±21   1128±247# 1161±287# 863±36#     779±126# 
Proteinuria (mg/day)     3.3±0.6    2.7±0.4    3.0±0.5 3.0±0.7 1.1±0.3 3.9±1 
HbA1c (%)     4.0±0.1    4.1±0.5    4.0±0.1 3.9±0.2 4.8±0.3   4.0±0.2 
Data are given as mean ± SEM, n= number of animals; BW: body weight, L: left, R: right, UAE: 
urine albumine excretion, Alb/Creat ratio: urine albumin to creatinine ratio; HbA1c: glycated 
hemoglobin (* P < 0.05 GDF15 ko versus wt, # P < 0.05 diabetic versus control mice) 
 
Interstitial and tubular damage in type 1 diabetic wt and GDF15 ko mice. 
The expression of interstitial α-smooth muscle actin (α-SMA), a marker of renal             
pre-fibrosis, was determined using immunohistochemistry and morphometric analysis. In 
non-diabetic wt and ko mice, α-SMA expression was predominately expressed in arteries 
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with marginal expression in the tubular interstitium (Figure 2A and 2D, respectively). 
Interstitial α-SMA was more apparent after one and two weeks of diabetes both in wt and 
GDF15 ko mice (panel 2B,C,E,F, respectively). Quantification of α-SMA staining 
demonstrated an approximately doubling of interstitial α-SMA expression after one week of 
diabetes in wt mice which remained at a similar level in week 2 (Figure 3A). GDF15 ko 
mice showed a similar increase in α-SMA staining at week 1, followed by a substantial 
further increase at week 2.  
Tubular damage was assessed by immunonhistochemical staining for Kidney Injury Marker 
1 (KIM-1). KIM-1 staining was confined to tubules and was detected in kidneys of diabetic 
GDF15 ko and diabetic wt mice at both time points investigated (Figure 2H,I,K,L). 
Morphometric quantification demonstrated increased KIM-1 expression after one and two 
weeks of diabetes in both GDF15 ko and wt mice (Figure 3B) with no apparent differences 
between groups. 
 
Renal damage markers in type 1 diabetic wt and GDF15 ko mice. 
To further assess renal damage, we quantified the mRNA expression of renal damage 
markers by real-time PCR on RNA isolated from kidney sections containing medulla and 
cortex. Induction of diabetes was associated with a more pronounced increase in KIM-1 
mRNA expression in the GDF15 ko group over wt at week 1 (Figure 4A). At week 2, KIM-
1 expression in wt mice returned to control levels but KIM-1 expression in GDF15 was still 
significantly elevated in GDF15 ko mice, although significantly lower than at week 1. 
Renal expression of type 1 collagen mRNA expression (Figure 4B) showed a similar 
pattern as KIM-1. Type 1 collagen mRNA expression was increased in wt mice at week 1 
and normalized by week 2. In GDF15 ko, type 1 collagen mRNA expression at week 1 was 
significantly higher than in wt mice and remained elevated over controls by week 2, 
although at a lower level.  
To assess injury to podocytes, we measured the renal expression of nephrin and podocin. 
There was no significant difference in the expression of these podocyte markers between 
diabetic GDF15 ko and wt mice, neither between diabetic groups and control groups 






















Figure 2: Representative pictures from immunohistology, showing (A-F) interstitial α-SMA 
expression, (G-L) KIM-1 expression in tubular epithelial cells. Pictures from control mice are shown 
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Figure 3: Interstitial pre-fibrosis (α-SMA) and tubular damage (KIM-1). (A) Morphometrical 
analysis of α-SMA staining in diabetic kidneys showed significantly more α-SMA expression in the 
GDF15 knockout mice compared to wildtype mice. (B) Increased KIM-1 expression was found in the 
diabetic mice (*p < 0.05 GDF15 ko vs wt, # p< 0.05 diabetic vs control mice) 
 
Expression of inflammatory markers in type 1 diabetic wt and GDF15 ko mice. 
To assess early renal inflammation after induction of diabetes, we measured the expression 
of chemokine KC, intracellular adhesion molecule ICAM-1 and macrophage inflammatory 
protein MIP-2 (Figure 4E, F, G).  At day 7 of diabetes, the expression of KC, ICAM-1 and 
MIP-2 were all significantly increased in GDF15 ko mice compared to non-diabetic GDF15 
ko mice. The expression of these inflammatory markers at day 7 of diabetes was less 
pronounced in wt mice and did not reach significant levels for KC and MIP-2. At day 14 of 
diabetes, the expression of KC, ICAM-1 and MIP-2 did not differ between GDF15 ko and 
wt mice. 
 
Expression of renal glucose transporters in type 1 diabetic wt and GDF15 ko mice. 
As diabetic GDF15 ko mice demonstrated increased urinary glucose excretion and 
increased urinary volume, we examined the renal expression of glucose transporters  
(Figure 4H, I, J, K). We observed considerable variation in renal glucose transporter 
expression, especially at day 7 of diabetes. However, the expression of Glut1, Glut2, 
SGLT1 and SGLT2 did not significantly differ between GDF15 ko and wt mice at any of 







In summary, our results in a model of type 1 diabetes indicated more renal damage in 
diabetic GDF15 ko mice over diabetic wt mice, despite similar blood glucose levels. 
Diabetic GDF15 ko mice showed increased urinary glucose loss, increased urine production, 
increased α-SMA staining, increased type 1 collagen mRNA expression, increased KIM-1 
mRNA expression and increased expression of inflammatory markers KC, ICAM1 and 
MIP-2 over diabetic wt controls.  
 
 







































































































































































Figure 4: Expression of renal markers in wild type and GDF15 knockout mice after STZ mediated 







Genetic deletion of GDF15 in the type 2 diabetic db/db model. 
To substantiate the effect of genetic deletion of GDF15 in accelerating renal damage in a 
type 2 model of diabetes, we interbred GDF15 ko mice with db/+ mice. The progression of 
diabetic nephropathy was monitored in male db/db GDF15-/- (diabetic GDF15 ko), db/db 
GDF15+/+ (diabetic wt) and in db/+ GDF15-/- control mice (non-diabetic GDF15 ko) from 
an age of 6 weeks onwards. 
Body weights (Figure 5A) were similar in both diabetic GDF15 ko and diabetic wt mice 
and were significantly increased over non-diabetic GDF15 ko controls. Food intake   
(Figure 5B) in diabetic wt and diabetic GDF15 ko mice was increased over non-diabetic 
GDF15 ko controls throughout the experiment. Significant levels of proteinuria did not 
develop in any of the diabetic groups (Figure 5F). Blood pressure was similar in all groups 
(Figure 5I). 
Water intake (Figure 5C) and urine output (Figure 5D) were significantly increased for 
diabetic wt mice and diabetic GDF15 ko mice compared to diabetic GDF15 ko controls. As 
of week 9, diabetic GDF15 ko mice showed a further increase in both water intake and 
urine production compared to diabetic wt mice. 
Throughout the experiment, urinary glucose loss (Figure 5E) was elevated for diabetic wt 
and diabetic GDF15 ko mice compared to non-diabetic controls. As of week 14, diabetic 
GDF15 ko mice progressed to a higher level or urinary glucose loss compared to diabetic 
wt mice. Blood glucose (non-fasting) and HbA1C were similarly increased for both diabetic 
wt and diabetic GDF15 ko mice except for the final time point (week 18) in which blood 
glucose and HbA1c were both higher in the diabetic GDF15 ko mice (Figure 5G,H).  
Additional parameters were measured at the end of the experiment at an age of 18 weeks 
(Table 3). Weights of both kidneys and the liver were increased in both diabetic wt and 
diabetic GDF15 ko over non-diabetic GDF15 ko controls. Heart weight was significantly 
increased over controls only in diabetic GDF15 ko mice. Cholesterol, LDL, HDL and 
triglyceride levels were similar for diabetic wt and diabetic GDF15 ko mice. In contrast, 
serum creatinine levels were significantly increased only in diabetic GDF15 ko mice. 
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Table 3: Animal characteristics of type 2 diabetic mice at week 18 
Parameter Non-diabetic 
 GDF15 ko (n=6) 
Diabetic wt 
(n=10) 
Diabetic GDF15 ko 
(n=8) 
L kidney (mg) 194.0±7.1   250.0±11.6#    268.1±19.7# 
R kidney (mg) 190.5±7.7   272.0±13.5#    261.2±14.3# 
Liver (mg) 1175±65   4106±498# 4439.8±576# 
Heart (mg) 140.7±5.7 157.7±8.3  163.0±4.8# 
MABP (mmHG)    106±5.8   89.9±5.6 100.3±4.9 
UAE (ug/day)     23.9±11.1  280.1±72#  298.6±55# 
Alb/Creat ratio (ug/mg)  58.8±17   226.3±81.5     203.4±33.6# 
Cholesterol (mmol/l)     2.6±0.3       5.8±0.6#       5.5±0.8# 
LDL (mmol/l)     0.2±0.0     0.3±0.1     0.3±0.1 
HDL (mmol/l)       1±0.2       1.8±0.3#       1.7±0.3# 
Triglycerides (mmol/l)    0.5±0.1     0.7±0.2     1.4±0.7 
Serum Creatinine (µmol/l)   18.5±2.4   16.0±4.0       29.6±7.0*# 
Data are given as mean ± SEM, n=number of animals; L: left, R: right, MABP: mean arterial blood 
pressure, UAE: urine albumine excretion; Alb/Creat ratio: urine albumin to creatinine ratio; LDL: 
Low-density lipoprotein; HDL: High-density lipoprotein (* p<0.05 diabetic wt vs diabetic GDF15 ko 
mice, # p<0.05 vs non-diabetic control GDF15 ko mice) 
 
Interstitial and tubular damage in type 2 diabetic mice. 
To assess diabetic interstitial damage in the kidney, we measured interstitial α-SMA 
expression by immunohistology. Interstitial α-SMA was expressed in both diabetic wt and 
diabetic GDF15 ko mice at 18 weeks of age (Figure 6B,C, respectively). Quantification of 
α-SMA staining by morphometric analysis demonstrated increased interstitial α-SMA 
expression in diabetic GDF15 ko and diabetic wt over non-diabetic GDF15 ko controls 
(Figure 7A). Diabetic GDF15 ko showed a further increase in α-SMA staining. 
KIM-1 staining (Figure 6D,E,F) was confined to tubules and was most pronounced in 
kidneys of diabetic GDF15 ko mice (Figure 6F). Morphometric quantification demonstrated 
significantly increased KIM-1 expression in diabetic GDF15 ko over diabetic wt mice and 
non-diabetic GDF15 ko controls (Figure 7B). 
PAS staining (Figure 6G-I) and subsequent morphometric analysis demonstrated increased 
glomerulosclerosis in both diabetic GDF15 ko and diabetic wt mice over non-diabetic 






The tubular damage score assessed on PAS stained sections was significantly increased 
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Figure 5: Effect of genomic deletion of GDF15 on parameters of type 2 diabetes (* p<0.05 diabetic 
wt vs diabetic GDF15 ko, # p<0.05 diabetic mice vs non-diabetic GDF15 ko mice; in panels A,B,C,D 
significant throughout the experiment, panel E as of week 7, panel G throughout the experiment for 
diabetic wt and as of week 8 for diabetic GDF15 ko, panel H as of week 8 for diabetic wt and as of 
week 9 for diabetic GDF15 ko). I) Blood pressure was significantly different between groups. 
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Figure 6: Representative pictures from immunohistology, showing (A-C) interstitial α-SMA 
expression, (D-F) KIM-1 expression in tubular epithelial cells, (G-I) PAS staining. Pictures from 




Taken together, these results demonstrate that diabetic GDF15 ko mice have substantially 
more tubular damage than diabetic wt mice at week 18 of age. In contrast, diabetic 
glomerular damage is not affected by genetic deletion of GDF15. 
non-diabetic GDF15 ko    diabetic wt   diabetic GDF15 ko 
 
A         B              C 
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Figure 7: Interstitial pre-fibrosis (α-SMA), tubular damage (KIM-1) and kidney damage (PAS 
staining). (A) Morphometrical analysis of α-SMA staining in diabetic kidneys showed significantly 
more α-SMA expression in the diabetic GDF15 ko mice compared to non-diabetic GDF15 control 
and diabetic wt mice. (B) Increased KIM-1 expression was found in the diabetic GDF15 ko mice. 
(C,D) Renal morphology showed significant increase of FGS and tubular damage in the diabetic 
GDF15 ko mice compared to non-diabetic GDF15 control mice. (* P < 0.05 diabetic GDF15 ko 
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Renal damage markers in type 2 diabetic mice. 
In addition to immunohistochemistry of KIM-1, we quantified KIM-1 mRNA expression 
by real-time PCR (Figure 8A). KIM-1 expression was significantly increased over controls 
only in diabetic GDF15 ko mice. Type 1 collagen expression was increased in diabetic wt 
mice with a further increase in diabetic GDF15 ko mice, although this did not reach 
statistical difference (Figure 8B). In diabetic wt mice, expression of podocyte markers 
nephrin and podocin were increased over non-diabetic GDF15 ko controls (Figure 8C,D). 
In diabetic GDF15 ko mice, only podocin expression was increased over non-diabetic 
GDF15 ko controls. 
To assess renal inflammation, we measured the expression of chemokine KC, intracellular 
adhesion molecule ICAM-1 and macrophage inflammatory protein MIP-2 (Figure 8E, F, 
G). The expression of KC did not differ between groups. ICAM1 expression was 
significantly decreased in both diabetic wt and diabetic GDF15 ko mice. MIP-2 expression 
was highest in diabetic GDF15 ko mice, but did not reach significant levels over non-
diabetic GDF15 ko controls. 
 
Expression of renal glucose transporters in type 2 diabetic mice. 
As diabetic GDF15 ko mice demonstrated increased urinary glucose excretion and 
increased urinary volume, we examined the renal expression of glucose transporters (Figure 
8H, I, J, K). We observed decreased expression of Glut1, Glut2, SGLT1 and SGLT2 only in 
diabetic GDF15 ko mice.  
 
Taken together, genetic deletion of GDF15 in a model of type 2 diabetes resulted in more 
renal damage in GDF15 ko mice over wt mice, as demonstrated by increased urinary 
glucose loss and increased urine production. These changes were accompanied by increased 
levels of renal damage markers in the GDF15 ko mice. Kidneys from type 2 diabetic 
GDF15 ko mice showed increased KIM-1 mRNA and KIM-1 protein expression over 
diabetic wt control, indicating more tubular damage in the diabetic GDF15 ko mice. 
Furthermore, plasma creatinine levels were increased only in the diabetic GDF15 ko mice, 

























































































































































































































































































































































Figure 8: mRNA expression of renal markers in type 2 diabetic mice. (* p<0.05 diabetic GDF15 ko 
vs diabetic wt,  # p<0.05 diabetic mice vs non-diabetic GDF15 ko control mice) 
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In-vitro effects of GDF15 on TGF-β signaling 
TGF-β is central to the development of diabetes induced renal injury. As genetic deletion of 
GDF15 resulted in significantly increased pre-fibrosis and collagen-I expression we 
determined the effects of GDF15 on TGF-β signaling in cells of renal and non-renal origin. 
In cultured human mesangial cells, GDF15 did not stimulate the pro-fibrotic p-Smad2/3 
pathway nor did it affect the anti-fibrotic p-Smad1/5/8 signaling cascade (Figure 9A,B). 
Cultured human mesangial cells were responsive to GDF15, as GDF15 stimulated cellular 
proliferation (Figure 9C). In cultured mesangial cells obtained from transgenic mice 
expressing GFP under the control of a Collagen 1A promoter, GDF15 did not induce 
Collagen 1A promoter activity nor did it reduce TGF-β induced promoter activity      
(Figure 9D). GDF15 did not affect p-Smad2/3 and p-Smad1/5/8 levels in mink lung 
epithelial cells, a cell line commonly used for its high sensitivity to TGF-β (Figure 9E,F). In 
addition, GDF15 did not prevent TGF-β mediated p-Smad2/3 and p-Smad1/5/8 activation         
(Figure 9E,F). In similar experiments performed in cultured tubular epithelial cells and 
NIH-3T3 fibroblast, GDF15 was also found to have no effects on Smad2/3 or Smad1/5/8 










































































































































































































































Figure 9: Effects of GDF15 on profibrotic signaling pathways in cell types responsive to TGF-β. 
A,B) GDF15 did not activate p-Smad2/3 nor p-Smad1/5/8 in cultured human mesangial cells 
(THMC). C) Despite no effects on Smad2/3 and Smad1/5/8 signaling, GDF15 stimulated proliferation 
of human mesangial cells D) Mesangial cells cultured from transgenic mice expressing GFP under the 
control of a Collagen 1A promoter showed increased Collagen 1A promoter activity after 48 hours of 
stimulation with TGF-β. GDF15 did not affect Collagen 1A promoter activity E,F) GDF15 did not 
activate p-Smad2/3 nor p-Smad1/5/8 in mink lung epithelial cells (MLEC). GDF15 did not inhibit 
TGF-β stimulated Smad2/3 and Smad1/5/8 activation. (*p<0.05 relative to controls, GDF15 50ng/ml, 
TGF-β 10 ng/ml). 




The most striking observations in the present study investigating the role of GDF15 in 
diabetes is that genetic deletion of GDF15 augments renal tubular and interstitial damage in 
both type 1 and type 2 diabetes models. Increased interstitial and tubular damage was 
accompanied by excessive loss of glucose in the urine (glucosuria) and increased urine 
production (polyuria). Furthermore, impaired kidney function as measured by increased 
plasma creatinine levels was found in type 2 diabetic GDF15 knockout mice.  
 
Despite the increased tubular damage in the GDF15 knockout mice, the glomerular 
sclerosis scores were similarly increased in the type 2 diabetic GDF15 knockout and wild 
type mice. In addition, urinary albumin excretion and albumin/ creatinine ratios were 
similarly increased in diabetic GDF15 knockout and diabetic wild type mice. As tubular 
albumin reabsorption is inhibited in diabetes22, these changes reflect similarly increased 
levels of albumin leakage in the glomerulus of diabetic GDF15 knockout and diabetic wild 
type mice. We therefore conclude that in contrast to tubular damage, genetic deletion of 
GDF15 did not affect diabetic glomerular damage.  
 
In both models, genetic deletion of GDF15 had no major effect on the severity of diabetes 
as blood glucose levels and HbA1C levels were similar between diabetic groups. The type 2 
diabetic db/db model displayed increased blood glucose and HbA1C levels in the diabetic 
GDF15 knockout mice over wild type controls at the latest time-point investigated (week 
18). However, as increased glucosuria in the diabetic GDF15 knockout mice was already 
evident as of week 14, we conclude that the augmented renal damage in GDF15 knockout 
mice is not caused by more severe diabetes. 
 
Genetic deletion of GDF15 caused increased renal expression of α-SMA and collagen type 
1 indicating that GDF15 may play an anti-fibrotic role in the diabetic kidney. As GDF15 is 
a member of the TGF-β family of signaling molecules, several studies have investigated the 
effects of GDF15 on Smad signaling, the signaling molecules down-stream of TGF-β. 
Conflicting reports on the effects of GDF15 on Smad signaling have been reported in 
experimental models of cardiac disease. In cultured cardiomyocytes, GDF15 activated the 
Smad2/3 signaling cascade, a profibrotic pathway commonly activated by TGF-β13;15. In 
contrast, a more recent paper demonstrated that GDF15 activated the Smad1/5/8 signaling 
cascade in cultured cardiomyocytes but not Smad2/313;23. As cardiomyocytes are not the 






associated with cardiac hypertrophy and not with organ fibrosis. In a set of in vitro 
experiments we were unable to observe a direct effect of GDF15 on either Smad2/3 or 
Smad1/5/8 signaling in cell types sensitive to TGF-β. These experiments included cells of 
renal origin (human and mouse mesangial cells and tubular epithelial cells) and non-renal 
cells (NIH-3T3 fibroblasts and mink lung epithelial cells). Furthermore, GDF15 was unable 
to inhibit TGF-β induced p-Smad2/3 signaling in these cells. Therefore, our results suggest 
that GDF15 modulates the renal expression of α-SMA and collagen type 1 through an 
indirect route and not by interfering with Smad signaling directly. 
 
Evidence for such an indirect pathway has recently been reported in a study demonstrating 
that GDF15 may inhibit organ damage through controlling inflammatory cell recruitment. 
In this study, it was demonstrated that GDF15 inhibited leukocyte-integrin activation in 
experimental myocardial infarction in mice. Furthermore, GDF15 knockout mice 
demonstrated excessive leukocyte adhesion to the cardiac endothelium16. Similarly, our 
experiments show potentiation of the renal inflammatory response in diabetic GDF15 
knockout mice over diabetic wt mice, demonstrated by increased expression of chemokine 
KC, adhesion molecule ICAM1 and macrophage inflammatory protein MIP-2 after STZ 
induced diabetes. These differences were most profound at week 1 rather than week 2 of 
the STZ diabetic model, suggesting that GDF15 may play an important role in preventing 
inflammatory cells recruitment in early diabetic inflammation of the kidney. Indeed, in the 
type 2 diabetic model we did not observe a similar up-regulation of these inflammatory 
markers at the end of the experiment. 
 
The phenotype of the diabetic GDF15 knockout mice resembles in part those of patients 
with familiar renal glucosuria (FRG). These patients have impaired tubular resorption of 
glucose, resulting in polyuria and glucosuria. The main cause of FRG are mutations in the 
gene encoding for SGLT2, a critical transporter for tubular glucose resorption from the 
urine. The loss of excessive glucose in the urine in FRG patients has a lowering effect on 
blood glucose levels, resulting in a reduction of diabetic complications24. This condition has 
led to the development of drugs that specifically inhibit SGLT2.  
 
In our experiment in type 2 diabetic mice we found a selective down-regulation in the renal 
expression of SGLT2 and other glucose transporters in the diabetic GDF15 knockout mice 
over diabetic wild type control and non-diabetic GDF15 knockout mice. As SGLT2 is the 
main glucose transporter to resorb glucose from the urine into the tubular cell25, our data in 
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type 2 diabetic mice suggest that the observed glucosuria is caused by tubular SGLT2 
down-regulation. In the type 1 diabetic model, the association between the expression of 
glucose transporters and the presence of glucosuria was less clear and may have been 
obscured by the large variation in the expression of glucose transporters within some 
groups.  
 
In contrast to the FRG patients and subjects on SGLT2 inhibitors, genetic deletion of 
GDF15 and the associated glucosuria did not result in lower blood glucose levels and 
protection from diabetic complications to the kidney. Despite the increased glucosuria in 
GDF15 knockout mice, blood glucose levels were similarly elevated in diabetic GDF15 
knockout and wild type mice in both models of diabetes. In the type 1 model, food intake 
was significantly increased in the diabetic GDF15 knockout over diabetic wild type and 
non-diabetic controls, allowing the maintenance of high blood glucose levels. In the type 2 
diabetic model, food intake in the GDF15 knockout mice was not significantly higher over 
diabetic wild type controls. However, food consumption in the obese db/db mice is 
dramatically increased over non-diabetic db/+ controls throughout the experiment, 
providing sufficient spare capacity to maintain high blood sugar levels. Therefore, the 
maintenance of high blood glucose levels in the diabetic GDF15 knockout mice most likely 
prevents the protective effects of increased glucosuria in the GDF15 knockout mice. 
 
Although the streptozotocin (STZ)-induced diabetic mouse model is commonly used26, we 
cannot exclude that some of the effects observed in the STZ model are caused or 
augmented by direct toxicity of STZ to the kidney or to other organs. However similar renal 
changes were found in the type 2 diabetic db/db mice model. Therefore, it is unlikely that 
changes in direct effects of STZ on ko animals played a prominent role in the excess renal 
damage found in this study. 
 
In both rats and mice, increased GDF15 expression was localized in the glomerulus. 
However, the tubuli and renal interstitium appear to be important targets for GDF15 as 
genetic deletion of GDF15 had profound effects on interstitial pre-fibrosis and tubular 
function and integrity. It is conceivable that the diabetic damage is detected in the 
glomerulus resulting in increased glomerular GDF15 production. Subsequently, glomerular 
GDF15 may be transported by the efferent arteriole to exert its protective effects in the 
renal interstitium and on the tubuli. Development of selective glomerular GDF15 knockout 






GDF15 production in diabetes. Furthermore, the receptor for GDF15 has still not been 
identified, hampering the identification of (renal) target tissues for GDF15. 
 
Finally, GDF15 has recently emerged as a promising clinical biomarker for cardiovascular 
disease and type 2 diabetes4;27. In these studies, higher GDF15 plasma levels were 
associated with increased cardiovascular morbidity and increased kidney damage. This 
appears to be in contrast to the protective role for GDF15 in myocardial infarction28 and 
diabetic kidney disease (this study).  
In the present study we showed that the diabetic glomerulus is a source of GDF15 with its 
targets in the tubular and interstitial compartment. Therefore plasma GDF15 levels may 
reflect the extent of diabetic damage in the glomerulus. Nevertheless, GDF15 provides 
protection to the interstitium and tubuli. Therefore the development of GDF15 agonists may 
provide new possibilities for the treatment of diabetic complications to the kidney in both 
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Growth Differentiation Factor 15 (GDF15) is emerging as an independent predictor of 
cardiovascular disease (CVD) although the functional relationship between GDF15 and 
CVD is not clear. Increased GDF15 levels have been associated with endothelial 
dysfunction in a selected patient population. We therefore investigated whether GDF15 
modulates endothelial function in aortas of wild type (wt) and GDF15 knockout (ko) mice. 
 
Methods 
Vascular contractions to phenylephrine (PE) and relaxation to acetylcholine (ACh) were 
assessed in aortic rings obtained from healthy wt and GDF15 ko mice. In these animals, 
also the effects of GDF15 pretreatment on vascular function were determined. The 
involvement of reactive oxygen species (ROS) and caveolae was determined using   
tempol/ catalase and MCD, respectively. 
 
Results 
PE induced contractions and ACh mediated relaxations were similar in wt and GDF15 ko 
mice. Pretreatment with GDF15 inhibited contraction and relaxation in both wt and ko 
groups. Inhibition of contraction by GDF15 was absent in denuded vessels and after 
blocking NO-synthase. Relaxation in wt was mediated mainly through NO and EDHF, 
while GDF15 ko mice mainly employed PGs and EDHF. Pretreatment with GDF15 
impaired ACh mediated relaxation in wt mice by decreasing NO, while in GDF15 ko mice 
this was mediated by decreased action of PGs. Disruption of caveolae resulted in a similar 
inhibition of vascular responses as GDF15 and administration of GDF15 did not result in a 
further inhibition of vascular responses. ROS inhibition did not affect vascular function.  
 
Conclusion  









Endothelial dysfunction is widely recognized as a key event leading to cardiovascular 
disease and is defined as an imbalance between vasodilating and vasoconstricting 
substances produced by the endothelium1;2. In addition, endothelial dysfunction is 
associated with increased adhesion molecule expression and reduced anticoagulant 
properties3. 
 
Growth differentiation factor 15 (GDF15), a distant member of the Transforming Growth   
Factor-β family and an early response gene, is emerging as an independent predictor of 
cardiovascular disease in the elderly and a predictor of prognosis in patients with 
established cardiovascular disease4-8. In an elderly population an association between 
GDF15 levels and endothelial dysfunction was found8. Furthermore, a recent study 
demonstrated an effect of GDF15 on endothelial adhesion molecule expression, as GDF15 
inhibited leukocyte recruitment and inflammation by inhibiting endothelial integrin 
activation in an experimental model of myocardial infarction9. 
 
These data suggest a possible role for GDF15 in the development of endothelial 
dysfunction in cardiovascular disease. Therefore, we investigated the effects of genetic 
deletion of GDF15 and the effects of acute treatment with recombinant GDF15 on vascular 
responsiveness of mouse aorta. For this, vascular contractility and endothelium mediated 











Materials and methods 
Animal model 
The experimental protocol was approved by the Institutional Animal Care and Use 
Committee of the University of Groningen (Groningen, the Netherlands). The basic study 
was performed in 7 male mice (12-14 weeks old, 25.1- 29.4 grams; C57BL/6, Harlan, The 
Netherlands) and 7 male GDF15 ko mice (12-14 weeks old, 22.6- 25.3 grams, from internal 
breeding, 5 breeding pairs of GDF15 ko mice on a C57BL/6 background were obtained 
from Johns Hopkins University Baltimore, Maryland, USA) housed under standard 
conditions with free access to food and drinking water throughout the study. Supplement 
vascular data were obtained from additional 19 male mice (10-14 weeks old, 24- 31 grams; 
C57BL/6, Harlan, The Netherlands). WT and ko mice were anesthetized with isoflurane 




Freshly isolated thoracic aortic rings (1.5 - 2 mm in length) were mounted on 200µm 
stainless wires in individual myograph baths (Danish Myo Technology A/S, Aarhus, 
Denmark) as described previously 10. Briefly, baths containing 6ml of Kreb’s solution were 
warmed to 37°C and pre-equilibrated continuously with 95%O2/5%CO2 to maintain pH at 
7.4. Length of aortic strips was assessed by microscopy. Aortic rings were equilibrated for 
40 min until they were at a steady baseline. Then, rings were subjected twice to stimulation 
with potassium chloride KCl (60 mM) in order to obtain reproducible contractile responses. 
After stabilization, each ring was treated for 20 minutes with different compounds: control, 
TGF-β treatment (3 ng/ml) or GDF15 treatment (50 ng/ml). Contraction responses were 
measured as cumulative concentration response curves to KCl (10 mM-90 mM) and PE  
(10 nM-100 µM). Indomethacin (10 µM) or L-NMMA (1 µM) was used to identify the 
contribution of specific endothelium derived relaxing factors. Endothelium-dependent 
relaxation was measured by obtaining concentration-response curves to                          
ACh (10 nM-300 µM) in rings precontracted with PE (1 µM). The influence of vasoactive 
prostanoids on the response to ACh was examined by incubating rings with the non-specific 
cyclooxygenase inhibitor indomethacine (10 µM) administered 20 min before application 
of PE. The influence of nitric oxygen (NO) was examined by incubating rings with 
indomethacine (10 µM) and a NO synthesis inhibitor L-NG-monomethyl arginine             
(L-NMMA) (1 µM) administered 20 min before application of PE. At the end of each 
experimental protocol, endothelium-independent relaxation was measured by applying the 
Vascular responsiveness of  GDF15 
107 
 
nitric oxide-donor sodium nitroprusside (0.1 mM). In some experiments, the endothelial 
cell layer was removed by rubbing the luminal side of the vessel with a moistened wire. 
Non-denuded or denuded aortas were treated for 20 minutes with control or GDF15 
pretreatment.  
 
Involvement of ROS or caveolae in endothelium-dependent relaxation of the aorta   
To investigate the involvement of ROS and caveolae on endothelium-dependent relaxation 
of the aorta, aortic rings were preincubated for 40 minutes with the membrane-permeable 
radical scavengers tempol (100 µmol/l) and catalase (500 U/ml) or with the caveolae 
disrupting agent methyl-β-cyclodextrin (MCD, 1mM). ACh dose response curves were 
obtained as described above.  
 
Drugs 
Krebs solution was prepared freshly and of the following composition (mM): 120.4 NaCl,         
5.9 KCl, 2.5 CaCl2, 1.2 MgSO4, 25.0 NaHCO3, 1.2 NaH2PO4, 11.5 glucose; all components 
obtained from Merck (Darmstadt, Germany). Stock solution (10 mM) for indomethacine, 
was prepared in 96% ethanol. Tempol, freshly prepared catalase, and MCD were dissolved 
in saline solution. All other drugs were dissolved in deionized water. NG-Monomethyl-L-
arginine acetate salt was purchased from MP Biomedicals (Illkirch, France). Recombinant 
human TGF-β1 and GDF15/MIC-1 were obtained from Peprotech and dissolved in PBS. 
All other compounds were purchased from Sigma. The concentrations presented in the 
concentration-curve responses are expressed as final molar concentrations in the organ 
baths. 
 
Calculations and statistical analysis 
Concentration-response curves to ACh and SNP were expressed as percentage relaxation of 
preconstriction obtained with PE. Concentration-response curves to ACh were 
characterized by calculation of the Area Under the Curve (AUC). The AUC was used to 
present total ACh relaxation, first in the absence of indomethacin for total ACh responses, 
later in the presence of indomethacin for prostaglandin contribution. Data are present as 
mean ± S.E.M. and n refers to the number of animals in each group. Concentration-
response curves of individual rings were plotted with SigmaPlot version 10.0 (Systat 
Software Inc, San Jose, CA). Statistical analysis was done with SPSS 16.0.2 for Windows 






with repetitive ANOVA, differences between points with one-way ANOVA. A probability 




Effects of genetic deletion of GDF15 on vascular function. 
To investigate the potential effects of GDF15 on vascular function, we first compared the 
vascular function of healthy wt and GDF15 ko mice. Animal characteristics are listed in 
Table 1. GDF15 ko mice had lower body weights, increased left and right kidney weights 
and decreased liver weight compared to wt controls. 
 
Table 1: Animal characteristics 
 Wt (n=7) GDF15 ko (n=7) 
Age (weeks) 14±0,4 14±0,8 
Body weight (g) 26,6±0,4 24,6±0,2# 
L kidney (mg) 178±5 196±8# 
R kidney (mg) 189±6 207±8# 
Liver (mg) 1415±50 1209±52# 
Heart (mg) 150±7 145±6 
liver/BW (mg/g) 53.3±1.9 49±2.0 
heart/BW (mg/g) 5.7±0.2 5.9±0.2 
All data are presented as mean ± SEM 
#p<0.06 GDF15 ko vs. wt control mice 
 
Pretreatment with GDF15 impairs contractile reactivity. 
Contractile responses of aortic rings were obtained by constructing cumulative 
concentration response curves to PE (PE, figure 1A,B). PE induced contraction of wt and 
GDF15 ko mice did not differ with respect to EC50 and maximum response (Emax). 
Pretreatment with GDF15 (50 ng/ml, for 30 minutes) induced a significant reduction in the 
response to PE both in wt and GDF15 ko animals. To investigate whether the vascular 
effects of GDF15 were distinct from those of TGF-β, additional rings were pretreated with 
a high dose of TGF-β (3ng/ml). TGF-β did not affect the PE response (Figure 1A,B). As 
GDF15 pretreatment also inhibited the response to 100µM KCl following the PE 
concentration response curve in both wt and ko mice (Figure 1A,B), we investigated the 
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effect of GDF15 on a concentration response curve to KCl in wt mice. GDF15 impaired 
KCl responses at 30 mM (con: 1.7±0.2 mN, GDF15: 0.9±0.1 mN), 60mM (con: 3.8±0.3mN, 













































Figure 1: GDF15 impairs aortic contraction to PE in wt and GDF15 ko mouse. A) PE 
concentration response curve in wt mice aortic rings. B) PE concentration response curve in GDF15 
ko mice aortic rings. n=7 mice per condition. *P<0.05 control (con) vs GDF15 treatment. 
 
 
GDF15 inhibition of vascular contraction is endothelium-dependent and involves the NO 
pathway. 
To investigate the mechanism through which GDF15 impairs vascular contraction, PE 
induced vascular contraction was assessed in aortic rings after removal of the endothelium. 
In aortas with intact endothelium, pretreatment with GDF15 again resulted in impaired PE 
mediated contraction (Figure 2A). In contrast, denudation of aortic rings abrogated the 
inhibition of PE contraction by GDF15, indicating the requirement of endothelium for the 
GDF15 mediated inhibition of PE contractility.  
To further investigate which endothelium derived factors are required for the GDF15 
mediated inhibition of vascular contractility, (non-denuded) aortas were incubated with 
compounds that inhibit nitrous oxide release (L-NMMA) and prostaglandin synthesis 






GDF15 on vascular contractility (Figure 2B), whereas pretreatment with indomethacine did 
not affect the GDF15 mediated impaired vascular contractility (data not shown).  
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Figure 2: GDF15 inhibition of vascular contraction is endothelium-dependent and involves the NO 
pathway. A) Concentration-response curves to PE in intact or endothelium-denuded mice aortic rings 
obtained from wt mice. n=17 rings for intact aortas, n=14 rings for denudated aortas. B) Abrogation 
of GDF15 effect by inhibition of NO-synthase inhibitor by L-NMMA, n=5-6 for all groups. Data are 
expressed as means ± SEM. *P<0.05 vs control (con).  
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Figure 3: GDF15 inhibits endothelium-dependent induced relaxation of PE precontracted aortic 
rings in wt (A) and GDF15 ko mice (B). Data are expressed as means ± SEM. n=5-7 per condition. 
*P<0.05 control (con) versus GDF15 pretreatment. 
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GDF15 inhibits endothelium-dependent relaxation in wt and GDF15 ko mice. 
To investigate the effects of GDF15 on endothelium dependent relaxation of the aorta, we 
compared ACh induced vascular relaxation in wt and GDF15 ko mice. For this, rings were 
precontracted with PE and cumulative dose-response curves to ACh were constructed 
(Figure 3). Dose-response curves to ACh were similar for wt and GDF15 ko mice. 
Pretreatment of the aortas with GDF15 caused a strong impairment of the ACh induced 
relaxation in aortas of both wt and GDF15 ko mice. To investigate whether the effects of 
GDF15 on relaxation were distinct from those of TGF-β, we included rings that were 
pretreated with TGF-β. TGF-β did not affect the ACh mediated relaxation. 
 
The contribution of prostaglandins (PGs), nitric oxide (NO), and endothelium-derived 
hyperpolarizing factor (EDHF) to endothelium-dependent relaxation 
To investigate the relative contribution of the individual endothelium derived relaxing 
factors, dose-response curves to ACh were constructed in the presence of indomethacine 
and the combination of indomethacine and L-NMMA (Figure 4). The relative contribution 
was defined as the relative Areas Under the Curve (AUC). In wt mice, the total Area Under 
the Curve was 141±13.6 (%*log(M)). AUCs for PGs, NO and EDHF amounted 15±13, 
50±21 and 90±14, respectively, indicating that vascular relaxation in wt mice was mediated 
mainly through NO and EDHF (Figure 4A). 
In GDF15 ko mice, the total Area Under the Curve was 116±30 (%*log(M)). AUCs for 
PGs, NO and EDHF were 59±41, 14.5±33 and 31±45, respectively, indicating that vascular 
relaxation in GDF15 ko mice was mediated mainly through PGs and EDHF (Figure 4C). 
Therefore, the total ACh mediated relaxation was similar for wt and GDF 15 ko mice, 
however the relative contribution of the relaxing factors differs. 
Pretreatment of the aorta rings with GDF15 resulted in impaired relaxation as indicated by 
a decreased total Area Under the Curve in both wt (104±18) and GDF15 ko (62±27) 
(Figure 4B,D). In GDF15 pretreated wt mice, the impaired relaxation was mainly mediated 
by inhibition of the NO component (Figure 4B). In GDF15 ko mice the impaired relaxation 
after pretreatment with GDF15 appeared to be caused by inhibition of PGs (Figure 4D). 
However due to the larger variation in the data obtained the decrease in endothelial 
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Figure 4: Differences in contribution of endothelial components in endothelium-dependent 
relaxation of aortas of wt and GDF15 ko mice without and with pretreatment with GDF15. 
ACh-mediated relaxation of PE precontracted aortic rings from wt mice (A,B) and GDF15 ko mice 
(C,D). After indomethacine and L-NMMA treatment the contribution of prostaglandins (PGs), nitric 
oxide (NO), and endothelium-derived hyperpolarizing factor (EDHF) on endothelial function were 
calculated. Data are expressed as means ± SEM. n=5-7 per condition (*p<0.05 vs corresponding 
group without GDF15 pretreatment). 
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Vascular responses to sodium nitroprusside. 
To investigate potential differences in the sensitivity of smooth muscle cells to NO, we 
measured the effects of the NO donor sodium nitroprusside (SNP) on vascular relaxation. 
The relaxant response to SNP was similar in all groups (Table 2), indicating that the 
impaired relaxation after GDF15 pretreatment was not caused by differences in NO 
sensitivity of the vascular smooth muscle cells. 
 
Table 2: Maximal relaxation to SNP (% of PE contraction) 
 WT GDF15 ko 
Treatment n SNP n SNP 
control 6 98,10±0,86 7 98,28±1,78 
GDF15 7 89,76±4,5 7 100,92±7,43 
Data are expressed as a percentage of PE-mediated precontraction and were obtained using 0.1mM of 
SNP. No differences were found between groups (one-way ANOVA).  
 
Effects of ROS inhibition and caveolae disruption on aortic responses 
To investigate the mechanism through which GDF15 impairs vascular contraction and 
relaxation, we evaluated the involvement of reactive oxygen species and caveolae. For 
inhibition of reactive oxygen species, vascular segments were incubated with tempol and 
catalase (TC). For disruption of caveolae, aortas were pretreated with MCD. 
As in previous experiments, GDF15 inhibited PE mediated contraction, resulting in a 
significantly reduced AUC (Figure 5A, black bars). TC pretreatment did not affect PE 
mediated contraction, nor did it affect the GDF15 with TC mediated inhibition of PE 
induced contraction (Figure 5A, white bars). Pretreatment with MCD resulted in 
significantly lower PE mediated contraction. Importantly, pretreatment with MCD 
precluded the GDF15 mediated reduction in PE contraction (Figure 5A, grey bars). 
Similar effects of ROS inhibition and caveolae disruption were observed on ACh mediated 
relaxation. GDF15 inhibited ACh induced relaxation, resulting in a significantly decreased 
AUC (Figure 5B, black bars). Pretreatment with TC did not affect ACh mediated relaxation 
and GDF15 inhibited ACh mediated relaxation in the presence of TC (Figure 5B, white 
bars). MCD lowered ACh mediated relaxation, although this did not reach statistical 
significance (Figure 5B, grey bar). GDF15 did not further reduce ACh mediated relaxation 
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Figure 5: Disruption of caveolae, but not inhibition of ROS, results in a similar inhibition of 
vascular contraction and relaxation as GDF15. AUCs were calculated for PE dose response curves 
(A) or ACh relaxations (B) of aortic rings from wt mice. Relaxation was expressed as percentage of 
preconstriction. Data are expressed as means ± SEM. n=5 mice per condition. *p<0.05 vs control (con) 
 
 




The main findings of the present study is that GDF15 modulates endothelial function 
resulting in impaired vascular contraction and relaxation in murine aortic rings. The effects 
of GDF15 on the endothelium include increased basal NO release and impaired release of 
endothelial derived relaxation factors in response to ACh. Disruption of caveolae by MCD 
had similar inhibitory effects on vascular function as GDF15. Furthermore, MCD treatment 
abrogated the inhibitory effect of GDF15 both on contraction and relaxation, indicating that 
GDF15 may inhibit endothelial function through a caveolae dependent mechanism.  
 
Our data demonstrate that GDF15 mediated inhibition of PE induced aortic contraction is 
most likely caused by the induction of endothelial release of NO. First, removal of the 
endothelium resulted in abrogation of the inhibitory effects of GDF15 on aortic contraction. 
Furthermore, in intact aortic rings, the inhibitory effects of GDF15 was blocked by 
pretreatment with the NO-synthase blocker L-NMMA. Finally, contraction in responses to 
KCl was similarly inhibited as for PE, indicating that the inhibition of vascular contraction 
by GDF15 was not specific for the adrenergic receptor system. We therefore conclude that 
GDF15 inhibits aortic contraction and that this mechanism most likely involves 
enhancement of basal NO release by GDF15. 
 
In addition to its effects on contraction, an even more profound action of GDF15 was found 
with respect to relaxation. Pretreatment with GDF15 inhibited acetylcholine (ACh) induced 
relaxation of aortic rings that were precontracted with PE in both wt and GDF15 ko mice. 
As levels of relaxation were similar in control and GDF15 treated rings upon addition of the 
NO-donor sodium nitroprusside, GDF15 impairment of relaxation was not caused by 
possible effects on PE mediated preconstriction. Furthermore, sodium nitroprusside 
experiments indicate that the impaired relaxation to ACh was not caused by differences in 
the sensitivity of smooth muscle cells to NO. 
 
Identification of the components responsible for the GDF15 mediated impaired relaxation 
to ACh, demonstrated that GDF15 inhibited the NO component in aortic rings obtained 
from wt mice. In GDF15 ko mice, the inhibited relaxation appeared to be caused by a 








Taken together, our data demonstrates that GDF15 modulates endothelial function by 
increasing basal NO release, while inhibiting the release of relaxing factors after 
stimulation with ACh. These actions resulted in impaired contraction and impaired 
relaxation in aortic rings obtained from wt and GDF15 ko mice.  
The mechanism of action through which GDF15 exerts these effects remain elusive. As an 
obvious option, GDF15 may act on receptors of the TGF-β superfamily11. However, in 
contrast to GDF15, TGF-β did not affect PE mediated contraction or ACh mediated 
relaxation, precluding an effect of GDF15 through TGF-β type 1 and 2 receptors. 
 
Alternatively, given its opposite effects on unstimulated and stimulated endothelium, 
GDF15 may affect a general mechanism influencing endothelial cell signal transduction, 
including the generation of reactive oxygen species (ROS) signaling and caveolae 
dependent signaling. While ROS are known for the ability to react with and neutralize NO12, 
it is unlikely that modulation of this pathway is employed by GDF15, as tempol and 
catalase did not affect inhibition of vascular responses by GDF15. In contrast, GDF15 
seems to affect caveolar signaling as disruption of caveolae resulted in a similar inhibition 
of vascular responses as GDF15 and administration of GDF15 did not result in a further 
inhibition of vascular responses.  
 
Our current study demonstrates that GDF15 may impair PE mediated contraction through a 
mechanism that involves increased basal NO-release by the endothelium. Several studies 
have shown increased basal NO production in cells deficient for caveolin-1, a protein 
essential for caveolae formation13. Furthermore, a recent study demonstrated that the 
scaffolding domain of caveolin-1 acts as an endogenous negative regulator of e-NOS 
function where disruption of the scaffolding domain resulted in increased basal NO 
release14. Therefore, our data suggests that pretreatment with GDF15 may affect the 
interaction of caveolin-1 with eNOS, resulting in enhanced basal NO-production under 
non-stimulated conditions. 
In contrast to non-stimulated conditions, a previous study by our group demonstrated that 
caveolar disruption impaired ACh stimulated NO and EDHF release in aorta and other 
arteries in rat 13. Furthermore, the enzymes involved in prostaglandin release were found to 
be associated with caveolin-1, implicating a role for caveolae in prostaglandin release15. 
Therefore our data suggests that GDF15 may inhibit vascular relaxation by NO and other 
relaxing factors through a mechanism that involves modification of caveolar signaling of 
the endothelium.  
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The mechanism through which GDF15 modulates eNOS activity and caveolar function is 
unclear. However, for the related cytokine TGF-beta it was demonstrated that the TGF-beta 
receptor type 1 interacted with eNOS in the caveolae of human endothelial cells and had a 
regulatory function on basal eNOS enzymatic activity16. As the receptor(s) for GDF15 are 
still unknown, this mechanism can not yet be confirmed for GDF15. 
 
Our current study demonstrates that GDF15 has pronounced effects on endothelial function, 
resulting in impaired contraction and relaxation. Nevertheless, genetic deletion of GDF15 is 
not associated with major hemodynamic effects in GDF15 ko mice Concentration-response 
curves to PE and KCl were similar in wt and GDF15 ko mice, indicating that genetic 
deletion of GDF15 does not affect aortic responses to PE and KCl. Furthermore, the 
inhibitory effects of GDF15 on vascular contraction was not affected by genetic deletion of 
GDF15, indicating that the receptor signaling cascades for GDF15 remain active in the 
absence of GDF15. In addition, concentration response curves of ACh mediated relaxation 
were similar in wt and GDF15 ko animals, indicating that genetic deletion of GDF15 did 
not have a marked effect on total ACh mediated relaxation. However, inhibition of the 
individual components of endothelium derived relaxing factors demonstrated that wt mice 
employed primarily the NO and EDHF pathways, while GDF15 ko mice primarily used the 
prostaglandin and EDHF pathways in ACh mediated relaxation of aortic rings.  
 
The absence of a clear vascular phenotype of GDF15 ko mice despite the strong vascular 
effects of GDF15 may be explained by the observation that GDF15 expression is generally 
low in healthy animals and GDF15 expression is only induced after tissue damage17-20. We 
therefore performed a provisional experiment in type 2 diabetic db/db mice, an established 
model with endothelial dysfunction21-23. Genetic deletion of GDF15 in the db/db model 
prevented the impairment of ACh mediated aortic relaxation (unpublished data), indicating 
a role for GDF15 in endothelial dysfunction in diabetes. However, genetic deletion of 
GDF15 also had multiple effects outside the vasculature, including increased diabetic 
kidney damage. Therefore, we cannot exclude that indirect effects of genetic deletion of 
GDF15 resulted in the prevention of impaired ACh mediated relaxation in diabetes. 
Development of tissue-specific GDF15 ko mice and identification of the still unknown 
receptors for GDF15 will contribute to a better understanding of the role of GDF15 in the 
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Development of micro- or macroalbuminuria is associated with increased risk of        
cardio-renal complications, particularly in diabetes. For prevention of transition to micro- 
or macroalbuminuria more accurate prediction-markers on top of classical risk-markers are 
needed. We studied a new promising marker, Growth Differentiation Factor 15 (GDF15), to 
predict transition to increasing stage of albuminuria in type-2 diabetes (T2DM). In addition, 
we looked at the GDF15 potential in non-diabetic subjects with hypertension (HT). 
 
Methods 
Cases and controls were selected from the PREVEND-cohort, a large (n=8,592), 
prospective general population study on the natural course of albuminuria, with >10 years 
of follow-up and repeated albuminuria-measurements. We found 24 diabetic and 50 
hypertensive cases transitioning from normo to macro, and 9 diabetic and 25 hypertensive 
cases from micro to macro (average follow-up 2.8 yrs). Controls with stable albuminuria 
were pair-matched for age, gender, albuminuria-status and diabetes-duration. GDF15 was 
measured in samples prior to albuminuria-transition. 
 
Results 
Prior to transition, GDF15 was significantly higher in cases with T2DM than in controls 
(1288[885-1546] vs. 948[660-1016] pg/mL,P<0.001). The odds-ratio for transition in 
albuminuria increased significantly per SD of GDF15 (2.9 [95%CI 1.1-7.5],P=0.03). 
GDF15 also improved prediction of albuminuria-transition, with significant increases in   
C-statistic (from 0.87 to 0.92, P=0.03) and integrated-discrimination-improvement (0.148, 
P=0.001). In HT, GDF15 was also independently associated with transition in  
albuminuria-stage (2.0[1.1-3.5], P=0.02) and improved prediction significantly. 
 
Conclusions  
We identified GDF15 as a clinically valuable marker for predicting transition in 
albuminuria-stage in T2DM beyond conventional risk markers. These findings were 
confirmed in non-diabetic hypertensive subjects. 
 





The prevalence of chronic kidney disease (CKD) is increasing and has become a major 
public health challenge1. This increase in CKD is largely due to the rapidly expanding 
epidemic of type 2 diabetes mellitus (T2DM) leading to diabetic nephropathy and 
ultimately end-stage renal disease (ESRD)2;3. Transition to increasing stages of albuminuria 
(i.e. normo- to microalbuminuria and micro- to macroalbuminuria) is considered a hallmark 
of progression of renal disease in diabetes4. 
 
However, once transitioned from normo to microalbuminuria or to macroalbuminuria, 
regression of disease is very difficult to achieve. Indeed, recent trials in normo-, micro-, and 
macroalbuminuric diabetic subjects showed that early intervention (in normoalbuminuric 
stage) is more effective with the same intervention. Early markers that detect those that 
have an increased risk for developing micro- or macro- albuminuria could thus help us 
reduce the number of patients at renal risk through selective preventive treatments of such 
patients5;6. 
 
Many risk factors have been linked to transition from normo- to micro and micro- to 
macroalbuminuria, such as hyperglycemia, hypercholesterolemia and hypertension7;8. 
However, accurate risk stratification of subjects at risk remains challenging. Novel 
biomarkers may help to improve the identification of subjects at risk, as well as improve 
insight in the underlying pathophysiology of the development of micro- or 
macroalbuminuria. Whereas several promising novel biomarkers were described in 
literature, this had not led to improved risk stratification in T2DM9.  
 
The lack of well-designed prospective studies that first stored samples of individuals for 
novel risk marker analyses and then followed the course of albuminuria over time may 
explain the paucity of knowledge on the prognostic value of novel biomarkers to improve 
risk stratification. We performed a nested case-control study in the large general population 
cohort ‘Prevention of REnal and Vascular End-stage Disease’ (PREVEND) to investigate 
novel biomarkers that may precede and predict the transition in albuminuria  
 
Growth Differentiation Factor 15 (GDF15), a member of the TGF-β family, is a promising 
novel biomarker, which has been implicated as predictor for cardiovascular and all-cause 
mortality10. Interestingly it was also associated with renal outcome and a faster decline of 






whether these findings regarding renal outcome are also applicable to patients with type 2 
diabetes. In the current study, we investigated whether circulating GDF15 levels precede 
and predict the development of micro- or macroalbuminuria in type 2 diabetic patients. To 
test wheter this is specific to diabetes, we performed a replication study to assess the 
predictive value of GDF15 in non-diabetic hypertensive patients.  
 
Patients and methods 
The present study was performed as a nested case-control study in subjects participating in 
the ‘Prevention of REnal and Vascular End-stage Disease’ (PREVEND) study. This 
prospective community-based cohort study on the natural course of urinary albumin 
excretion with serial follow-up measurements was initiated in 1997. Details of the study 
protocol have been published elsewhere12. In short, all inhabitants of the city of Groningen 
aged 28–75 years were sent a questionnaire and a vial to collect a first-morning-void urine 
sample. Of these individuals, 40 856 responded (47.8%). From these individuals a cohort 
consisting of 8592 subjects was selected (the PREVEND cohort). In this ongoing study 
participant are invited to visit an outpatient clinic for detailed medical examination             
at ± 3-year intervals. At each screening round participants fill out questionnaires on 
demographics, medical history and drug use. Information on drug use is completed with 
data from community pharmacies, including information on class of antihypertensive 
medication (ACEi/ARB). At the study visits participants deliver two 24-hour urine 
collections, blood pressure is measured, anthropometrical measurements are performed, and 
fasting blood samples are taken.  
The PREVEND study was approved by the institutional ethics review board and was 
conducted in accordance with the guidelines of the Declaration of Helsinki. All participants 
provided written informed consent. 
 
Definitions 
Normoalbuminuria was defined as urinary albumin excretion (UAE) <30 mg/24h, 
microalbuminuria as UAE 30-299 mg/24h and macroalbuminuria as UAE >300 mg/24h. 
Albuminuria status was based on the average of 2 consecutive measurements in 24-hour 
urine collections. Transition in albuminuria was defined as a transition from normo- to 
micro- or from micro- to macroalbuminuria with at least 30% increase in urinary albumin 
excretion from baseline between two consecutive study visits. T2DM was defined as the 
use of oral anti-diabetic treatment (self-reported or by information retrieved from the 
regional pharmacy database), a fasting plasma glucose >7.0 mmol/L (126 mg/dL) or      




non-fasting plasma glucose >11.1 mmol/L (>200 mg/dL). HT was defined as the use of 
anti-hypertensive treatment or a systolic/diastolic blood pressure > 140/90 mmHg.  
 
Selection of cases and controls 
For the present study, we selected patients with type 2 diabetes mellitus (T2DM) and 
transition from normo- to microalbuminuria or from micro- to macroalbuminuria. As 
controls, we selected T2DM patients who had persistent normoalbuminuria or 
microalbuminuria throughout the same time interval as cases (Figure 1A). As a secondary 
cohort we selected similar cases and controls out of all non-diabetic patients with 
hypertension (Figure 1B). 
Controls were matched to the cases 1:1 based on diabetes/non-diabetes, age, gender, 
baseline normo- or microalbuminuria status, and if applicable duration of diabetes. For each 
subject that showed transition in albuminuria, a matched control was selected that most 
optimally resembled the case on these combined parameters. Plasma samples of these 
patients were used from the visit prior to the transition from normo- to microalbuminuria, 
or micro- to macroalbuminuria (baseline). The use of agents intervening in the            
Renin-Angiotensin-Aldosterone system (RAAS) (ACEi/ARB) was allowed, but the type of 
drug and their dose had to remain stable during the study period. 
Of the 8592 study participants, 318 had T2DM and 33 of these subjects had unambiguous 
transition in albuminuria and available samples of sufficient quality. Hypertension (without 
diabetes) was present in 1178 participants. Of these participants 75 subjects had 
unambiguous transition in albuminuria and available samples of sufficient quality. 
 
Measurements 
Plasma samples were stored at -800C and all samples underwent 1 freeze-thaw cycle. 
Measurements were performed blinded and in duplicate. GDF15 was measured with a 
novel pre-commercial assay based on the Eclia principle (Roche Diagnostics) with a LLD 
of  200 pg/mL and intra-individual CV of 6.7 to 9.2%.  
Urinary albumin excretion (UAE) is given as the mean of the two 24-hour urinary 
excretions. Blood pressure was measured twice, in the supine position, every min for 10 
min with an automatic device (Dinamap XLModel 9300; Johnson-Johnson Medical, 
Tampa, FL, USA). eGFR was estimated using the Modification of Diet in Renal Disease 
(MDRD) study equation, using gender, age, race and serum creatinine13. 
Urinary albumin concentration was determined by nephelometry (Siemens, Munich, 






standard methods. Serum creatinine was measured by dry chemistry (Eastman Kodak, 
Rochester, New York, USA), with intra-assay coefficient of variation of 0.9% and        
inter-assay coefficient of variation of 2.9%.  
 
Statistical Analysis 
Analyses were performed using STATA version 11.2 (StataCorp LP, Lakeway Drive, 
Texas, USA). A study with 50 patients will provide at least 80% power to detect an odds 
ratio of 1.5 assuming a type 1 error of 5% and no residual confounding after matching cases 
and controls (www.bioconductor.org). Variables with normal distribution are given as mean 
± standard deviation and variables with skewed distribution as median [inter quartile range 
(IQR)]. Variables with skewed distribution were log-transformed for analyses. Graphical 
methods were used to ascertain normalization of the distribution after transformation. 
Differences between the cases and controls were tested with paired-samples t-test for 
continuous variables and chi-squared test on paired proportions for categorical variables. 
Differences between non-paired groups were tested with independent samples t-test for 
continuous variables and chi-square test for categorical variables.  
 
To investigate the association between the levels of the marker and transition in 
albuminuria we used conditional logistic regression because of the paired study design. In 
multivariable analyses, we adjusted for the differences in baseline for differences in 
baseline urinary albumin excretion (UAE) and estimated glomerular filtration rate (eGFR) 
between cases and controls as these two markers are important risk factors for transition in 
albuminuria stage14;15. We tested for interaction between patients who made a transition 
from normo- to microalbuminuria and those who made a transition from micro- to 
macroalbuminuria by adding an interaction term for baseline albuminuria status and GDF15 
in the model. 
 
To assess whether the markers improved risk prediction and discrimination we determined 
the c-statistic and Integrated Discrimination Improvement (IDI). We calculated the            
c-statistic (discriminatory ability) based on the most important established risk factors 
(UAE, eGFR) and compared those to c-statistics after addition of GDF15 to the established 
model. Differences in c-statistic were tested with chi-square test.  
 
In addition to the c-statistic, we calculated the integrated discrimination improvement (IDI), 
another measure of discrimination16. The IDI is the difference in discrimination slopes 




between cases and controls before and after the addition of the biomarker(s) to the model. It 
assesses the improvement in average sensitivity without sacrificing average specificity. 
Calculation of the IDI is done by computing average predicted probabilities of the event in 
cases and controls in models with and without the biomarker(s) and subtracting the values 
from cases and controls from each other. The increase in difference between cases and 
controls after addition of the biomarker(s) is the integrated reclassification improvement. 
The IDI is often more sensitive than the rather conservative c-statistic because when several 
highly predictive markers are in the model, enormous odds ratios are required to 
meaningfully increase the c-statistic17. For all analyses two-sided P-values <0.05 were 







In total, 33 cases with type 2 diabetes mellitus (T2DM) and transition from normo- to 
microalbuminuria or from micro- to macroalbuminuria were identified. These cases were 
pair-matched to 33 controls with T2DM and stable albuminuria. The baseline 
characteristics are presented in Table 1.  
Mean age of the patients was 64.9 years, 176 (72%) patients were male, and the median 
urinary albumin excretion rate was 18 [9-44] g/24h. Cases had a significantly higher 
baseline UAE than controls, were more frequently treated with lipid lowering treatment and 
more often received ACEi/ARB treatment when compared to matched controls. All other 
parameters were similar. Median follow-up time was 2.7 [2.2-4.0] years. 
Change in albuminuria concentrations during the follow-up, according to the selection of 
cases and controls, is shown in Figure 1A. Patients with transition in albuminuria (cases) 
had a median increase in albuminuria of 31 mg/24h (164%) compared to 0 mg/24h (0%) in 
controls.  
 
GDF15 in Type 2 Diabetic Patients 
The mean concentration of GDF15 in cases and for controls, prior to transition in 
albuminuria, is presented in Figure 2A. In Figure 2B these concentrations are presented 
separately for transition from normo- to micro and micro- to macro. GDF15 concentrations 
were significantly higher in cases vs. controls (1288 [885-1546] vs. 948 [660-1016] pg/mL, 
P<0.001). The concentrations were lower in normoalbuminuric cases and controls than 
microalbuminuric cases and controls (910 [737-1162] vs. 1008 [763-1470], P=0.03).  
The odd ratio for transition in albuminuria was 3.58 [95%CI 1.51-8.47] (per standard 
deviation increment in GDF15) (Table 2) and 2.87 [95%CI 1.10-7.53] after adjustment for 
baseline albuminuria and eGFR. There was no statistical significant difference between the 
odds for transition from normo- to microalbuminuria and from micro- to macroalbuminuria 
with each SD increment in GDF15 (P for interaction = 0.55). GDF15 significantly 
improved the c-statistic on top of a baseline model consisting of UAE and eGFR (increase 
from 0.87 to 0.92, P=0.03). GDF15 also improved the Integrated Discrimination Index 
(IDI) (0.148, P=0.001), indicating that GDF15 improved the discrimination between cases 









Table 1: Baseline Characteristics for patients with T2DM and non-diabetic patients with HT. 
 Diabetes Hypertension 
Patient Characteristic Cases Controls Cases Controls 
Number - n  33 33 75 75 
Age - years 62.7 ± 9.2 62.8 ± 9.6 66.3 ± 9.8 65.6 ± 8.7 
Male gender - n (%) 25 (75.8) 25 (75.8) 53 (70.7) 53 (70.7) 
Race - n (%)     
  Caucasian 30 (90.9) 31 (93.9) 71 (94.7) 73 (97.3) 
  Other 3 (9.1) 2 (6.1) 4 (5.3) 2 (2.7) 
Smoking - n (%) 6 (18.1) 5 (15.1) 18 (24.0) 13 (17.3) 
BMI - kg/m2 30.0 ± 6.3 27.8 ± 4.2 28.5 ± 4.5 27.9 ± 4.5 
Systolic Blood Pressure - mmHg 137 ± 15 134 ± 20 139 ± 19 137 ± 18 
Diastolic Blood Pressure - mmHg 75 ± 9 75 ± 8 77 ± 8 78 ± 9 
History of Coronary Heart Disease$- n 
(%) 7 (21.3) 2 (6.1) † 11 (14.9) 9 (12.0) 
Follow-up time 2.7 [2.2-3.8] 2.8 [2.3-4.0] 2.8[2.3-4.0] 2.8 [2.1-3.7] 
     
Laboratory Parameters     
  Urinary albumin excretion - mg/24h 22 [17-34] 12 [6-40]* 22 [13-83] 11 [7 -37] ‡ 
  eGFR - mL/min/1.73m2 76 ± 18 80 ± 17 72 ± 21 69 ± 20 
  Total Cholesterol - mmol/L 5.0 ± 1.4 5.2 ± 1.4 5.3 ± 1.0 5.4 ± 1.1 
  Fasting Plasma Glucose - mmol/L 7.6 ± 1.9 7.2 ± 1.2 5.3 ± 0.8 5.1 ± 0.9 
     
Treatment - n (%)     
  Antihypertensive drugs 23 (69.7) 11 (33.3) 75 (100) 75 (100) 
  ACEi/ ARB 16 (48.5) 2 (6.1)* 39 (52.0) 39 (52.0) 
  Oral antidiabetics 24 (72.7) 24 (72.7) 0 (0) 0 (0) 
  Lipid lowering drugs 18 (54.6) 7 (21.2) † 27 (36.0) 20 (26.7) 
     
Baseline UAE status - n (%)     
  Normoalbuminuria 24 (72.7) 24 (72.7) 50 (66.7) 50 (66.7) 
  Microalbuminuria 9 (27.3) 9 (27.3) 25 (33.3) 25 (33.3) 
     
Median change in UAE - mg/24h   31 [22-151] 0 [-4 - 3]  ‡ 70 [29-310] 0 [-2 – 8] ‡ 
Median change in UAE - % 164 [106-340] 0 [-23 – 38] 314 [143-668] 5 [-18 – 46] 
     
Baseline Biomarker Levels     









*Cases vs. controls P < 0.05, † Cases vs. controls P<0.01, ‡ Cases vs. controls P<0.001. Plus-minus values are 
means ± SD and non-normally distributed variables are median [inter quartile range (IQR)]. $ Self-reported 
Coronary Heart Disease. T2DM: Type 2 Diabetes Mellitus; HT: Hypertension; BMI: body mass index (weight 
kg/length m2); eGFR: estimated glomerular filtration rate (modification of diet in renal disease-formula); ACEi: 
angiotensin-converting enzyme inhibitors; ARB: angiotensin-2 receptor blockers; UAE: urinary albumin excretion 
rate. To convert values for serum cholesterol from mmol/L into mg/dL multiply by 38.67, to convert values for 
fasting plasma glucose from mmol/L into mg/dL multiply by 18 and to convert values for serum creatinine from 

























































































































































Figure 1. Individual courses of urinary albumin excretion in progressors and non-progressors in 
albuminuria (cases and controls). Individual course of UAE during follow-up for cases (black) and 
controls (grey) in patients with diabetes (1A) or hypertension (1B) stratified for albuminuria-status at 
baseline (left: normoalbuminuria; right: microalbuminuria).  
 
 




GDF15 in non-diabetic Hypertensive patients 
The replication study was a second nested case-control study, which consisted of 75 (non-
diabetic) cases with hypertension (HT) and transition to increasing stages of albuminuria 
that were pair-matched to 75 controls with HT and stable albuminuria (Table 1). 
Characteristics of patients with HT were remarkably similar to patients with T2DM, as was 
the median follow-up time (2.8 [2.3-3.9] years in HT vs. 2.7 [2.2-4.0] years in T2DM). 
Cases with HT had a median increase in albuminuria of 70 mg/24h (314%) compared to  
0.2 mg/24h (5%) in controls. 
The GDF15 concentration in patients with HT was similar to the concentration in patients 
with T2DM (910 [738-1210] vs. 992 [799-1347] resp.; P=0.63). In cases with HT GDF15 
concentration was borderline significantly higher  than in controls (975 [739-1222] vs. 872 
[726-1172] pg/mL, P=0.09). The odds of transition to micro- or macroalbuminuria was 
significantly increased per SD increment in GDF15 (1.96 [95%CI 1.12-3.45]). Also in 
patients with HT no difference was observed in the odds for transition from normo- to 
microalbuminuria or micro- to macroalbuminuria with each increment in GDF15 (p for 
interaction = 0.90). Addition of GDF15 to the prediction model of transition in albuminuria, 
consisting of baseline UAE and eGFR, did not result in significant improvement of the      
c-statistic (from 0.88 to 0.89, P=0.8), but significantly improved IDI (0.059, P=0.04).  
 
Figure 2. GDF15 levels in progressors and non-progressors in albuminuria (cases and controls). 
GDF15 levels (pg/mL) (mean ± SD) in progressors and non-progressors in albuminuria for T2DM 
and hypertension; 2B: GDF15 levels (pg/mL) (mean ± SD) in progressors and non-progressors in 
albuminuria for T2DM and hypertension stratified for baseline albuminuria (normoalbuminuria or 
microalbuminuria); * P<0.05, ** P<0.001  
Control
Case
Control (Normo-Normo) Case (Normo-Micro)























































Table 2: Odds ratios for GDF15 and transition in albuminuria  per log-unit increase and per SD 
increase in the level of the biomarker for T2DM and non-diabetic patients with hypertension.  











Int. Odds ratio 95% Conf. Int. P-value 
GDF15 Crude 7.66 [1.94-30.14] 3.58 [1.51-8.47] 0.004 
GDF15 
Adjusted
* 5.39 [1.16-25.05] 2.87 [1.10-7.53] 0.03 
       
Hypertension       
Biomarker  Odds ratio 
95% Conf. 
Int. Odds ratio 95% Conf. Int. P-value 
GDF15 Crude 1.58 [0.92-2.73] 1.33 [0.95-1.88] 0.10 
GDF15 Adjusted 2.94 [1.20-7.20] 1.96 [1.12-3.45] 0.02 
       
* Adjusted for baseline albuminuria and estimated glomerular filtration rate (eGFR)  
Values were calculated with conditional logistic regression analyses 
 
Table 3: C-statistics and integrated discrimination improvements (IDI) for logistic regression 
models predicting transition in albuminuria  in patients with type 2 diabetes mellitus and non-
diabetic patients with hypertension. 
Type 2 Diabetes 
Mellitus C-statistic 95% Conf.Int P-value IDI 95% Conf.Int P-value 
       
Established Model* 0.87 [0.78-0.96] reference reference  Reference 
Established Model + 
GDF15 0.92 [0.86-0.99] 0.03 0.148 [0.056-0.240] 0.001 
       
Hypertension       
       
Established Model* 0.88 [0.82-0.94] reference reference  Reference 
Established Model + 
GDF15 0.89 [0.83-0.94] 0.8 0.045 [0.006-0.083] 0.02 
   
   
 
* Established model: prediction model based on urinary albumin excretion and estimated glomerular 
filtration rate. The biomarker was modeled as continuous (log-transformed) variable. P values are for 
comparison of the models with the baseline model.  





To our best of knowledge, this is the first study to indicate that GDF15 precedes and 
predicts the development of micro- or macroalbuminuria in patients with type 2 diabetes 
mellitus. GDF15 was not only independently associated with transition in albuminuria 
during a follow-up of ~3 years, it also improved discrimination between patients who did 
and did not develop micro- or macroalbuminuria, beyond conventional risk markers. These 
findings were extended and replicated in a cohort of  non-diabetic hypertensive patients. 
 
Previous studies mainly implicated GDF15 as predictor for cardiovascular events and all-
cause mortality in patients with previous myocardial infarction11;18;19. The only previous 
study focusing on GDF15 and renal outcome was performed by Lajer et al in patients with 
type I diabetes mellitus and macroalbuminuria. In this observational study, higher GDF15 
levels were associated with a faster decline of eGFR and development of end-stage renal 
disease11. Our study extends these latter findings to earlier stages of renal disease during 
which appropriate intervention is most beneficial. 
 
Despite a growing body of literature demonstrating that GDF15 is a valuable biomarker for 
cardiovascular disease, relatively little is known on the pathophysiological role of GDF15. 
Its expression is markedly increased in response to injury in various tissues, including heart 
and kidney, and is believed to be a protective factor by reducing apoptosis and influencing 
cellular proliferation20-22. Higher levels of GDF15 may thus indicate tissue damage. As 
endothelial cells appear to be a prominent source of GDF15, the circulating levels of 
GDF15 most likely represent generalized endothelial and microvascular damage23. The 
relation of GDF15 with microvasculature may explain the link with albuminuria, as 
albuminuria supposedly reflects established microvascular damage in the renal and 
peripheral vasculature24. Since our cases and controls were at the same albuminuria (either 
normo- or microalbuminuria) at time of GDF15 measurement, GDF15 seems to already be 
increased before microalbuminuria becomes detectable. Our finding that GDF15 also 
contributed in identifying subjects at risk for transition in albuminuria stage in a             
non-diabetic hypertensive cohort implies that GDF15 is not specifically related to diabetes. 
Future research will be necessary to clear up the exact pathophysiological role of GDF15 in 
diabetes or hypertension and to assess its relation with albuminuria.   
 
Traditional risk factors associated with transition in albuminuria are age, gender, 






diabetes, increased blood pressure, duration of hypertension, body mass index and 
smoking7;25. Despite identification of these important risk factors for transition in 
albuminuria, the ability to stratify subjects at risk is still limited. The current data, if 
confirmed, raise the possibility of identification of subjects at risk even when traditional 
risk factors do not indicate risk, facilitating early identification of those with an increased 
chance of developing micro- or macro- albuminuria. Because early intervention is more 
effective than late intervention, preventive treatment could thus reduce the risk of renal and 
cardiovascular events in patients with T2DM5;6. Our findings also applied to non-diabetic 
hypertensive patients, in whom albuminuria is strongly associated with renal and 
cardiovascular events8;26.   
 
We incorporated prediction analyses in the present study to determine GDF15 could add to 
risk prediction in individual subjects beyond traditional risk markers. Whereas the c-static 
is most commonly used, the c-statistic is not very sensitive in detecting small but 
meaningful contributions of biomarkers in correctly classifying individuals. Hardly any 
improvement of the c-statistic can be reached when the model already includes one or 
several important risk markers17. Yet, we found improvement in c-statistic in our study in 
T2DM. Because of the insensitivity of the c-statistic, other measures of risk classification 
such as the IDI have recently been proposed16;28. In our analyses, we also found significant 
improvement in IDI for GDF15, both in patients with T2DM and non-diabetic subjects with 
hypertension.  
 
The availability of patient samples from the large general population cohort PREVEND 
was a unique feature of this study. Because this study followed the natural course of 
albuminuria during by performing repeated measurements of albuminuria for more than 10 
years, we were able to measure GDF15 in samples prior to the transition in albuminuria, 
whereas many study have a cross-sectional design and test biomarkers in patients with 
established increased albuminuria.   
 
Other strengths include the well-defined phenotype of the population, with albuminuria 
status based on two consecutive 24-hour urine collections, the rigorous definitions for 
transition in albuminuria, and the availability of samples that had never been thawed. 
Because of these strict criteria and the limited number of patients with diabetes in this 
general population cohort we were only able to obtain 33 valid cases.  




A limitation of this study was the modest difference in baseline albuminuria. This small 
baseline difference in albuminuria was inherent to the design of the study, as the level of 
albuminuria in itself is related to transition to increase stages of albuminuria and we 
matched by albuminuria-stage rather than by albuminuria level. Adjustment for baseline 
albuminuria showed that the association of GDF15 with albuminuria transition was 
independent of baseline albuminuria.  
 
A second limitation is the fact that the nested case-control design of the study may 
overestimate the true predictive capacity of the models because of the relative high event 
rate in case-control studies29. Absolute values of the c-statistic should therefore be 
interpreted with caution. The improvement of the c-statistic and the level of significance, 
however are unaffected by case-control design of studies. Lastly, whereas these results are 
promising and could be confirmed in non-diabetic hypertensive patients, replication of the 
current results in other studies, preferably large prospective cohort studies, is warranted 
before final conclusions can be reached.  
 
In conclusion, we identified GDF15 as marker for prediction of transition in albuminuria in 
type 2 diabetic subjects. GDF15 moreover had significant additive value on top 
conventional risk markers in the prediction of albuminuria-transition. These finding were 
confirmed in non-diabetic hypertensive subjects. If these findings prove to be replicable in 
other studies, GDF15 might be a valuable marker for individual risk stratification, 
facilitating start or intensification of treatment in high risk patients in order to prevent or 
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Type 2 diabetes mellitus (T2DM) is the most common type of diabetes and the prevalence 
of T2DM is increasing rapidly due to population growth, aging, urbanization, and 
increasing prevalence of obesity and physical inactivity. The incidence of type 1 diabetes 
mellitus (T1DM) is also increasing although the underlying mechanisms are less well 
understood. Diabetic nephropathy is a common complication of diabetes and cause of 
chronic renal failure, resulting in an increased number of patients requiring end-stage renal 
failure management, particularly dialysis1. Therefore, new therapies to prevent or halt the 
progression of diabetic nephropathy are urgently needed2. 
 
Prevention of fibrosis has been identified as a possible target for delaying the progression 
of diabetic nephropathy. One of the most prominent and most frequently studied cytokine 
involved in these processes is Transforming Growth Factor beta (TGF-β). TGF-β is part of 
an extensive family of signaling molecules including the three different isoforms of TGF-β, 
activins, inhibins, growth differentiation factors (GDFs), and bone morphogenetic proteins 
(BMPs)3.   
 
Despite the overwhelming body of literature on the involvement of TGF-β in the 
development of diabetic nephropathy, we hypothesized that other growth factors may be 
involved in the development of diabetic nephropathy. Furthermore, the involvement of 
these factors may have been obscured by the fact that most experimental studies 
investigating the development of diabetic nephropathy were conducted several weeks after 
the induction of experimental diabetes. We therefore set out to identify new factors 
involved in the induction of diabetic nephropathy in the first week of experimental diabetes 
using an expression micro-array experiment. In Chapter 2 we identified several genes 
which were associated with the induction of renal fibrosis in diabetes. Our micro-array 
analysis was the first to show that Growth Differentiation Factor 15 (GDF15) was 
upregulated in the kidney immediately after induction of experimental diabetes. Moreover, 
we confirmed GDF15 gene expression by RT-PCR and western blot. The upregulation of 
GDF15 was particularly present in the glomerulus and preceded changes in TGF-β 
expression. These results led us to hypothesize that GDF15 is a factor involved in the 
development of diabetic nephropathy.  
 
Consequently, we aimed at establishing the role of GDF15 in development of diabetic 
nephropathy in an in vitro model. As GDF15 expression was highly induced in the 




glomerulus and because mesangial cells are the prime cell type involved in excess 
glomerular extracellular matrix production, we investigated the functional effects and 
signaling pathways of GDF15 in cultured mesangial cells (Chapter 3). GDF15 did not 
affect fibrosis and apoptosis but stimulated proliferation of human mesangial cells (THMC) 
through activation of the MAPK members JNK and p38 and involved the BMPR2 receptor. 
In contrast, unlike TGF-β, the signaling evoked by GDF15 in THMC did not employ the 
classical Smad pathway. 
 
Although Chapter 3 demonstrated the receptor and signaling cascades of GDF15 in a renal 
cell type, it did not fully clarify the role for GDF15 in diabetic nephropathy. To further 
investigate the role of GDF15 in diabetes, we evaluated the development of diabetic 
nephropathy in GDF15 knockout mice and wild type mice in models of type 1 and type 2 
diabetes (Chapter 4). Genetic deletion of GDF15 resulted in augmented tubular and 
interstitial damage in both models of diabetes, despite a similar diabetic state in GDF15 
knockout and wild type mice. Increased tubular damage in knockout animals was 
associated with increased glucosuria and polyuria in both models. While diabetic knockout 
mice showed increased interstitial damage, glomerular damage was similarly elevated in 
diabetic knockout and wild type mice. In the type 1 model, GDF15 knockout mice 
demonstrated increased expression of inflammatory markers. In the type 2 model, elevated 
levels of plasma creatinine indicated impaired kidney function in knockout mice. Therefore, 
this chapter demonstrated that GDF15 protected the kidney from diabetic damage and 
maintained renal tubular function in both type 1 and type 2 models of diabetes. 
 
Cardiovascular disease (CVD) and development of diabetic nephropathy are closely 
connected. Impairment of the endothelium, the cells lining the blood vessels, results in 
vascular dysfunction in diverse vascular beds including the kidney. In addition, endothelial 
dysfunction causes increased protein leakage over the filtration barrier of the kidney, 
resulting in albuminuria. Both vascular dysfunction and albuminuria contribute to the 
progression of diabetic nephropathy. 
As GDF15 is emerging as a biomarker for CVD, we investigated the effects of GDF15 on 
vascular and endothelial function. In Chapter 5, we demonstrated that GDF15 played an 
important role in the inhibition of vascular contraction and relaxation in both wild type and 
GDF15 knockout mice. Phenylephrine induced contractions and Acetylcholine (ACh) 
mediated relaxations were similar in wild type and GDF15 knockout mice. Pretreatment 






basal nitrous-oxide (NO) release. Pretreatment with GDF15 also inhibited ACh induced 
relaxation in both wild type and knockout groups by reducing the stimulated NO release. 
Disruption of caveolae resulted in a similar inhibition of vascular responses as GDF15 and 
administration of GDF15 with the caveolae disrupting agent methyl-β-cyclodextrin (MCD) 
did not result in a further inhibition of vascular responses. Therefore, GDF15 impaired 
endothelial function by modulating endothelial NO-synthase activity, possibly through a 
mechanism that involved modification of caveolar signaling of the endothelium. 
 
To further explore the relationship between GDF15 and renal endothelial dysfunction, we 
aimed at establishing the relationship between GDF15 and progression of albuminuria in 
humans (Chapter 6). For this, we carefully selected cases and controls. Cases were defined 
by transition from normo- to micro-, and micro- to macro-albuminuria. Controls with stable 
albuminuria were pair-matched for age, gender, albuminuria-status and diabetes-duration. 
Two different populations were studied: T2DM patients and patients with hypertension. 
Plasma GDF15 levels were measured in both populations at baseline, i.e. prior to the 
transition in the extent of albuminuria. Baseline GDF15 levels prior to transition were 
higher in cases than in controls. Moreover, GDF15 was independently associated with 
progression in albuminuria in T2DM and improved the prediction of progression of 
albuminuria with a higher c-statistic and Integrated Discrimination Improvement (IDI). 
Furthermore, these finding were extended to non-diabetic subjects with hypertension. 
Therese results demonstrate that baseline GDF15 level may represent a valuable prognostic 
marker for the progression of albuminuria and renal endothelial dysfunction.  
 
In summary, the studies presented in this thesis demonstrated a profound role for GDF15 in 
the development of diabetic nephropathy. GDF15 expression was strongly induced in the 
glomerulus after induction of diabetes in rats and mice. Further, our study in GDF15 
knockout and wild type mice showed that GDF15 preserved tubular function and prevented 
interstitial damage in both type 1 and type 2 diabetes. However, GDF15 did not protect the 
glomerulus from sclerosis nor did it prevent albuminuria. Furthermore, pretreatment of 
vessels (aortas) with GDF15 affected endothelial function resulting in impaired vascular 
contraction and relaxation. Finally, plasma levels of GDF15 correlated with progression of 
albuminuria in patients with T2DM. The notion that BMPR2 seems to be involved as a 
main receptor for GDF15, may facilitate development of novel therapeutic approaches to 
limit renal damage in diabetic patients. 
 




Discussion and future perspectives 
In our studies, GDF15 was found to protect the tubulus and renal interstitium from 
development of diabetic damage. The protective effects of GDF15 have previously been 
demonstrated in the heart and cultured cardiomyocytes after induction of myocardial 
infarction4;5 and ischemia/ reperfusion6. In addition, the protective effects of GDF15 have 
been suggested in several other organs and tissues in response to diverse noxious stimuli, 
including surgical, toxic, ischemic, and hyperoxic damage to lung and kidney7, surgical and 
chemical injury and heat shock to liver8 and ischemia of the bile duct9. 
 
The mechanisms through which GDF15 protects these tissues and organs are diverse. 
Inhibition of apoptosis by GDF15 has been suggested in endothelium, heart, lung and 
kidney4;6;10-12. In addition, GDF15 affects cellular proliferation in lung and kidney10;13, 
suggesting that GDF15 may be involved in regeneration of specific cell types after injury. 
In the kidney, GDF15 mediated regeneration of epithelial cells in mouse kidney collecting 
duct in response to metabolic acidosis13. Finally, GDF15 may inhibit inflammation as 
GDF15 was found to modulate leukocyte integrin activation on the endothelium in the 
heart14. In our studies in models of diabetic nephropathy, we confirmed the effects of 
GDF15 on proliferation and inflammation, although we did not find effects of GDF15 on 
apoptosis. 
 
Despite the protective properties of GDF15 in several organs and tissues, several studies 
reported a correlation between plasma GDF15 levels and mortality and morbidity in 
CVD15-20 and in diabetes21-23. Furthermore, our study in T2DM patients demonstrated that 
increased levels of GDF15 predicted the progression of albuminuria in diabetes and 
hypertension (Chapter 6). 
 
These apparent opposing effects of GDF15 may be explained by the findings described in 
this thesis.  
First, in Chapter 2 and 3 we demonstrated that the glomerulus is a source of GDF15 
immediately after induction of diabetes in rats and mice. Furthermore, Chapter 6 
demonstrated that plasma GDF15 levels predicted the progression of glomerular diabetic 
damage in patients with T2DM. Therefore, plasma GDF15 levels appear to reflect early 
glomerular damage in diabetes. Further, in Chapter 4 we demonstrated that the interstitium 
and tubules were the main targets for GDF15 in the diabetic kidney. As genetic deletion of 






targets of GDF15 are distinct. Therefore plasma GDF15 levels may reflect the extent of 
diabetic glomerular damage (which is not affected by GDF15), while GDF15 provides 
protection to downstream tissues such as the tubulus and renal interstitium. 
 
Secondly, in Chapter 5 we demonstrated that GDF15 had profound effects on vascular 
function as GDF15 treatment of isolated aortic rings resulted in inhibited vascular 
contraction and relaxation by modulating the function of the endothelium. The impaired 
relaxation mediated by GDF15 resembled endothelial dysfunction observed in several 
models of CVD, an established determinant of susceptibility to end-organ damage24-29. 
Therefore these results suggest that while GDF15 provides protection to injured organs and 
tissues, long term elevation of GDF15 levels may result in endothelial dysfunction 
contributing to the development of CVD and kidney disease. 
 
In conclusion, the data presented in this thesis demonstrates a profound role for GDF15 in 
the development of diabetic nephropathy. GDF15 protects the tubulus and renal interstitium 
in diabetes and is a prognostic marker for the progression of albuminuria.  
 
In future experiments, we aim at development of kidney specific GDF15 knockout mice to 
further elucidate the role of renal GDF15 production in diabetes. The role of the BMPR2 as 
GDF15 receptor in mediating GDF15 effects will be investigated in other renal tissues, 
including the tubulus. Furthermore, the identification of the GDF15 receptor provides new 
tools for intervention into the GDF15 signaling system, allowing to the development of new 
therapeutic strategies to treat diabetic nephropathy. 
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Ouderdomsdiabetes of type 2 diabetes mellitus (T2DM) is de meest voorkomende vorm 
van diabetes en het aantal patiënten met T2DM neemt snel toe als gevolg van 
bevolkingsgroei, vergrijzing, verstedelijking en door toename van obesitas en lichamelijke 
inactiviteit. Het aantal gevallen van juveniele of type 1 diabetes mellitus (T1DM) neemt 
ook toe, hoewel de onderliggende mechanismen minder goed bekend zijn. Een veel 
voorkomende complicatie van diabetes is schade aan de nieren, een aandoening die bekend 
staat als diabetische nefropathie. Diabetische nefropathie is een belangrijke oorzaak voor 
het ontstaan van chronisch nierfalen, resulterend in een toename in het aantal patiënten met 
eindstadium nierfalen die afhankelijk is van nier dialyse. Gezien de verwachte toename in 
het aantal diabetes patienten, zijn er dringend nieuwe therapieën nodig om diabetische 
nefropathie te voorkomen, of de progressie ervan te stoppen. 
 
Diabetische nefropathie wordt onder andere gekenmerkt door verhoogde productie van 
bindweefsel in de nier (fibrose) en preventie van fibrose is een mogelijk doelwit voor het 
vertragen van de progressie van diabetische nefropathie. Een van de meest prominente en 
meest bestudeerde eiwitten die betrokken zijn bij het fibrose proces is de cytokine 
Transforming Growth Factor beta (TGF-β). TGF-β is een onderdeel van een uitgebreide 
familie van signaalmoleculen, waartoe drie verschillende vormen van TGF-β, activins, 
inhibins, growth differentiation factors (GDFs), en bone morphogenic proteins (BMP) 
behoren. Ondanks de overweldigende hoeveelheid literatuur over de betrokkenheid van 
TGF-β in het ontstaan van nierfibrose, veronderstelden wij dat ook andere groeifactoren 
betrokken zijn bij het ontstaan van nierfibrose ten gevolge van diabetes. De betrokkenheid 
van deze factoren zijn mogelijk onopgemerkt gebleven doordat de meeste studies naar de 
ontwikkeling van diabetische nefropathie in proefdieren pas relatief laat na het induceren 
van diabetes werden uitgevoerd.  
 
Onze eerste studie was daarom gericht op het identificeren van nieuwe factoren die 
betrokken zijn bij het ontstaan van nierfibrose in de eerste week van de experimentele 
diabetes met behulp van een expressie micro-array experiment. In Hoofdstuk 2 
identificeerden wij genen die geassocieerd waren met de inductie van nierfibrose in 
diabetische ratten. Onze micro-array analyse toonde als eerste aan dat de genexpressie van 
Growth Differentiation Factor 15 (GDF15) sterk verhoogd was in de nier onmiddellijk na 
inductie van experimentele diabetes. De verhoogde expressie van GDF15 was met name 
aanwezig in de glomerulus en ging vooraf aan veranderingen in TGF-β expressie. Deze 




resultaten leidden ons tot de hypothese dat GDF15 een factor is die betrokken is bij de 
ontwikkeling van nierfibrose en diabetische nefropathie. 
 
Om onze hypothese te toetsen, werd het effect van GDF15 op fibrose onderzocht met 
behulp van in-vitro modellen. Omdat GDF15 met name tot expressie kwam in de 
glomerulus, hebben wij de effecten van GDF15 onderzocht op het type cellen die betrokken 
zijn bij fibrose van de glomerulus, de zogenaamde mesangiale cellen (Hoofdstuk 3). GDF15 
had geen invloed op fibrose en apoptose, maar stimuleerde proliferatie van gekweekte 
mesangiale cellen door middel van activatie van de BMPR2 receptor en de MAPK 
signaalcascade. GDF-15 activeerde niet de klassieke TGF-β signaalcascades. 
 
Om de rol van GDF15 in diabetes verder te onderzoeken, hebben we vervolgens gebruik 
gemaakt van muizen waarin het GDF15 gen verwijderd was, zogenaamde GDF15 knockout 
muizen. In Hoofdstuk 4 werd de ontwikkeling van diabetische nefropathie vergeleken 
tussen GDF15 knockout muizen en wild-type muizen in modellen van type 1 en type 2 
diabetes. Genetische deletie van GDF15 resulteerde in verhoogde nier schade met name aan 
de tubuli en het interstitium in beide diabetische modellen. Bovendien hadden GDF15 
knockout dieren meer glucose verlies in de urine en verhoogde urineproductie. Schade aan 
de glomerulus was echter vergelijkbaar in GDF15 en wild type muizen. Daarmee is in dit 
hoofdstuk aangetoond dat GDF15 de nieren beschermd tegen diabetische schade aan 
tubulus en interstitium en dat GDF15 belangrijk is voor het instant houden van tubulus 
functie in zowel type 1 en type 2 modellen van diabetes.  
 
Hart- en vaatziekten en de ontwikkeling van diabetische nefropathie zijn nauw met elkaar 
verbonden. Aantasting van het endotheel, de epitheelcellen van de bloedvaten, resulteert in 
een vasculaire dysfunctie in diverse vaatsystemen waaronder die van de nieren. 
Endotheliale dysfunctie veroorzaakt daarnaast een verhoogde lekkage van eiwit over het 
filtratiemembraan van de nier, wat resulteert in albuminurie. Zowel vasculaire dysfunctie 
als albuminurie dragen bij aan de progressie van diabetische nefropathie. Omdat GDF15 in 
opkomst is als een biomarker voor hart-en vaatziekten, hebben we de effecten van GDF15 
onderzocht op vasculaire en endotheliale functie. Hoofdstuk 5 toont aan dat GDF15 een 
belangrijke rol speelt in de vermindering van vasculaire contractie en relaxatie in zowel 
wild-type en GDF15 knock-out muizen. Fenylefrine geïnduceerde contractie en 
acetylcholine (ACh) gemedieerde relaxatie was gelijk in wild type en GDF15 knock-out 




knockout groepen door een verhoogde basale stikstofmonoxide (NO) productie. GDF15 
verminderde daarentegen ACh geïnduceerde relaxatie in zowel wildtype en de knock-out 
groepen door het verminderen van de gestimuleerde afgifte van NO. Disruptie van caveolae 
resulteerde in een soortgelijke remming van vasculaire functie als voorbehandeling met 
GDF15 en toediening van GDF15 met MCD resulteerde niet in een verdere remming van 
de vaatfunctie. GDF15 verslechtert dus de endotheelfunctie door het moduleren van 
endotheliale NO-synthase middels een mechanisme van veranderde caveolaire 
signaaltransductie. 
 
Om de relatie tussen GDF15 en renale endotheliale dysfunctie verder te onderzoeken, 
hebben we ons gericht op de relatie tussen GDF15 spiegels in het bloed en de progressie 
van eiwitlek in de urine (albuminurie) bij mensen (Hoofdstuk 6). GDF15 spiegels werden 
hiertoe vergelijken tussen patiënten met progressieve albuminurie (‘cases’) en patiënten 
met stabiele albuminurie (‘controles’). De eigenschappen van de patiënten in de controle 
groep waren gelijk aan die van de ‘cases’ groep voor leeftijd, geslacht, albuminuriestatus en 
diabetesduur. Twee verschillende populaties werden onderzocht: T2DM patiënten en 
patiënten met hypertensie. Plasma GDF15 niveaus werden voorafgaand gemeten in beide 
populaties, dat wil zeggen vóór de progressie in albuminurie. Baseline GDF15 waardes van 
vóór de progressie waren hoger in de ‘cases’ groep dan in de controlegroep. GDF15 was 
onafhankelijk geassocieerd met progressie in albuminurie in T2DM en verbeterde de 
voorspelling van de progressie van albuminurie met c-statistiek en geïntegreerde 
discriminatie verbetering (IDI). Deze resultaten tonen aan dat het baseline GDF15 niveau 
mogelijk een belangrijke prognostische marker is voor de progressie van albuminurie en 















Sammenvattend, de data gepresenteerd in dit proefschrift demonstreren een grote rol voor 
GDF15 in de ontwikkeling van diabetische nefropathie. GDF15 expressie was sterk 
geïnduceerd in de glomerulus na inductie van diabetes bij ratten en muizen. Verder toonde 
onze studie in GDF15 knockout en wild type muizen aan dat GDF15 tubulaire functie in 
stand houdt en interstitiële schade voorkomt in zowel type 1 en type 2 diabetes. Echter, 
GDF15 beschermde de glomerulus niet tegen sclerose en beschermde niet tegen 
albuminurie. Bovendien tastte voorbehandeling van aorta’s met GDF15 de endotheelfunctie 
aan, met als gevolg een verstoorde vasculaire contractie en relaxatie. Ten slotte zijn 
plasmaspiegels van GDF15 gecorreleerd aan de progressie van albuminurie bij patiënten 
met T2DM. De vinding dat BMPR2 lijkt te zijn betrokken als één van de belangrijkste 
receptoren voor GDF15, kan de ontwikkeling van nieuwe therapeutische benaderingen voor 
het beperken van nierschade bij diabetespatiënten bespoedigen.   


































Záver a možná implementácia pre prax 
Diabetes mellitus 2 typu (T2DM) sa v porovnaní s prvým typom vyskytuje častejšie a jeho 
prevalencia sa alarmujúco zvyšuje v dôsledku rastu počtu obyvateľstva, starnutia populácie, 
urbanizácie, rastúceho výskytu obezity a nedostatku telesnej aktivity.  
 
Jednou z najzávažnejších komplikácií diabetu a hlavnou príčinou chronického zlyhania 
funkcie obličiek je diabetická nefropatia. Vedie k zvyšujúcemu sa počtu pacientov, 
u ktorých je potrebná liečba pokročilého štádia poruchy funkcie obličiek, až ich zlyhania, 
pričom často vedie až k dialýze. Preto je nevyhnutne potrebný rozvoj inovačných 
terapeutických prístupov, zameraných na prevenciu, či zastavenie progresie diabetickej 
nefropatie. 
 
Jedným z cieľom oddialenia progresie diabetickej nefropatie je stanovenie rozsahu fibrózy. 
Transformujúci rastový faktor beta (Transforming Growth Factor beta-TGF-β) patrí medzi 
najvýznamnejšie a najviac študované cytokíny zapojené do fibrotického procesu. TGF-β je 
súčasťou rozsiahlej rodiny signálnych molekúl, kde patria aj rôzne jeho izoformy, ako 
aktivíny, inhibíny, rastové diferenciačné faktory (Growth Differentiation Factors-GDFs), a 
kostné morfogenetické proteíny (Bone Morphogenetic Protein-BMP). 
Na základe veľkého množstva literatúry opisujúcej účasť TGF-β vo vývoji diabetickej 
nefropatie predpokladáme, že na jej rozvoji sa  môžu podieľať aj ďalšie rastové faktory 
z tejto rodiny. 
 
Väčšina štúdií, zameraných na vývoj diabetickej nefropatie, prebieha až niekoľko týždňov 
po vyvolaní diabetu. Preto sme sa s pomocou DNA microarray rozhodli vyhľadať nové 
faktory podieľajúce sa na vzniku diabetickej nefropatie už v prvom týždni po vyvolaní 
epxerimentálneho diabetu. V kapitole 2 sme identifikovali niekoľko génov, ktoré boli 
spojené s indukciou renálnej fibrózy u diabetických potkanov. Ukázali sme po prvý krát, že 
rastový diferenciačný faktor 15 (Growth Differentiation Factor 15-GDF15) je 
bezprostredne po vyvolaní experimentálneho diabetu 1. typu v obličkách zvýšený. Naviac 
sme jeho zvýšenú expresiu potvrdili aj pomocou metód RT PCR a Western blotu. Zvýšená 
expresia GDF15 bola obzvlášť viditelná v glomerulách. Tieto výsledky viedli k 
predpokladu, že práve GDF15 je faktor, ktorý sa podieľa na rozvoji diabetickej nefropatie. 
 
Na základe tohoto zistenia sme sa zamerali na skúmanie úlohy GDF15 vo vývoji 
diabetickej nefropatie v in vitro modeli. Pretože expresia GDF15 je zvýšená v glomerulách 




a primárny typ buniek podieľajúcich sa na vzniku glomerulárneho extracelulárneho matrixu 
sú hlavne mezangiálne bunky, skúmali sme účinok a signálne dráhy GDF15 
v kultivovaných mezangiálnych bunkách (kapitola 3). I keď GDF15 v uvedenom in vitro 
modeli neovplyvnil fibrózu ani apoptózu, stimuloval proliferáciu ľudských mezangiálnych 
buniek (THMC), a to cez aktiváciu MAPK členov JNK a p38, prostredníctvom BMPR2 
receptorov. Na rozdiel od TGF-β, intracelulárne signály vyvolané GDF15 v THMC 
nepôsobia prostredníctvom klasickej Smad kaskády. 
 
I keď kapitola 3 poukazuje na existenciu receptorov a signálnych kaskád GDF15 
v mezangiálnych bunkách obličiek, jeho úloha v diabetickej nefropatii zostáva neodhalená. 
Pre objasnenie úlohy GDF15 pri diabete sme sledovali vývoj diabetickej nefropatie u 
knockout myší (KO) bez GDF15 a „divokých“ (wild type) myší ako v modeloch prvého, 
tak aj druhého typu diabetu (kapitola 4). Genetické odstránenie GDF15 vyústilo do 
zvýšeného poškodenia v tubuloch a interstíciu v oboch modeloch diabetu, a to aj napriek 
podobnému štádiu diabetu u GDF15 knockout myšiach a wild type myšiach. Poškodenie 
tubulov bolo sprevádzané zvýšenou glykozúriou i polyúriou v oboch modeloch. Kým 
diabetické knockout myši vykazovali zvýšené poškodenie interstícia, vplyv na 
glomerulárnu funkciu u diabetických knockout myší a divokých myší bol nezmenený. 
V modeli s diabetom prvého typu GDF15 knockout myši preukázali zvýšenú expresiu 
zápalových bio markerov. V modeli diabetu typu 2 sme evidovali zvýšenú hladinu 
kreatinínu v plazme. V tejto kapitole sme teda ukázali, že GDF15 chráni obličky pri 
diabetickom poškodení a vplýva na udržaní renálnej tubulárnej funkcie v oboch typoch 
diabetu. 
 
Kardiovaskulárne ochorenia (KVO) a rozvoj diabetickej nefropatie sú úzko spojené. 
Poškodenie funkcie endotelu vedie k cievnej dysfunkcii v rôznych typoch ciev. Endotelová 
dysfunkcia spôsobuje zvýšený únik proteínov cez filtračné membrány obličiek, čo vedie k 
albuminúrii. Cievna dysfunkcia ako aj albuminúria prispievajú k progresii diabetickej 
nefropatie. 
 
Pretože GDF15 sa v súčasnosti používa ako biomarker pri KVO, skúmali sme účinky 
GDF15 na cievnu a endotelovú funkciu. V kapitole 5 sme ukázali, že GDF15 zohráva 
dôležitú úlohu v inhibícii cievnej kontrakcie a relaxácie v oboch skupinách divokých aj 
GDF15 knockout myší. Fenylefrínom vyvolané kontrakcie a acetylcholínom (ACh) 




Predinkubácia s GDF15 inhibovala kontrakcie u oboch typov myší tým, že zvyšovala výdaj 
bazálneho oxidu dusného (NO). Taktiež inhibovala acetylcholínom vyvolanú relaxáciu u 
oboch skupín myší, a to znížením stimulácie uvoľňovania NO. Narušenie kaveolárnym 
blokátorom viedlo k podobnej inhibícii cievnych reakcií ako predinkubácia s GDF15 a 
kombinácia GDF15 s týmto blokátorom neviedla k ďalšiemu zníženiu cievnych reakcií. 
Zdá sa teda, že GDF15 poškodzuje endoteliálnu funkciu moduláciou endoteliálnej         
NO-syntázy prostredníctvom zmeny kaveolárnej signalizácie v endoteli. 
 
V nasledujúcej kapitole (kapitola 6) sme sa zamerali na vzťah medzi GDF15 
a endotelovým poškodením v obličkách, ktorý vedie k progresii albuminúrie u ľudí. Pre 
túto štúdiu sme použili starostlivo vybrané skupiny pacientov s píznakmii poškodenia 
a kontrolnej skupiny, pričom poškodenia boli definované zmenami v albuminúrii-
prechodom vedúcim od normo- k mikro- a od mikro- k makro-albuminúrii. Pacienti 
v kontrolnej skupine s nezmenenou albuminúriou boli presne spárovaní podľa veku, 
pohlavia, hodnoty albuminúrie a priebehu trvania diabetu. Pozorovali sme dve rôzne 
populácie: skupinu subjektov s T2DM a skupinu subjektov s hypertenziou. Plazmatické 
hladiny GDF15 boli stanovené u oboch skupín pacientov na začiatku, tj pred prechodom do 
rozsahu zvýšenej albuminúrie. Základné hladiny GDF15 pred prechodom do albuminúrie 
boli vyššie v prípadoch poškodenia, než u kontrol. Okrem toho bola hladina GDF15 
nezávisle spojená s progresiou albuminúrie u skupiny pacientov s T2DM a zlepšila 
predikciu progresie albuminúrie s vyššou hodnotou c-štatistiky a zlepšenou hodnotou 
integrovanej diskriminácie (IDI). Meranie hladiny GDF15 v sére bolo rozšírené na skupinu 
subjektov s hypertenziou bez diabetu. Naše výsledky ukazujú, že hladina GDF15 v sére 
môže predstavovať cenný prognostický ukazovateľ pri progresii albuminúrie a renálnej 
endotelovej dysfunkcie u pacientov s ochorením T2DM. 
 
Naše údaje uvedené v danej práci poukazujú na dôležitú úlohu GDF15 v rozvoji diabetickej 
nefropatie. Lokalizácia GDF15 u diabetických potkanoch a myšiach bola identifikovaná v 
glomeruloch. Ďaľšie štúdie s GDF15 knockout myšami a divokými myšami preukázali, že 
GDF15 zachováva tubulárnu funkciu a zabraňuje intersticiálnemu poškodeniu počas 
diabetu typu 1 i 2. Avšak GDF15 nechráni glomeruly pred sklerotizovaním a ani nezlepšuje 
hladinu albumínu v moči. Predinkubácia aorty s GDF15 vplýva na endotelovú funkciu, 
pretože zhoršuje cievnu kontrakciu a relaxáciu. Plazmatické hladiny GDF15 korelujú s 
progresiou albuminúrie u pacientov s T2DM. Poznatok, že BMPR2 je hlavný receptor 




GDF15 aktivácie, môže identifikovať smer pri liečbe u T2DM a uľahčiť vývoj nových 
terapeutických postupov na obmedzenie poškodenia obličiek u diabetikov. 
 
Záverečná diskusia 
V našich štúdiách sme zistili, že GDF15 chráni tubuly obličiek a interstícium pri vývoji 
diabetického poškodenia. V predchádzajúcich experimentoch na srdci a na kultivovaných 
kardyomyocytov po vyvolaní infarktu myokardu a ischémie/reperfúzie boli preukázané 
ochranné účinky GDF15 a boli taktiež potvrdené v niekoľkých ďalších štúdiách na rôznych 
orgánoch a tkanivách po pôsobení škodlivých podnetov, vrátane chirurgických, toxických, 
ischemických a hypertoxických poškodení pľúc a obličiek, po chirurgických a chemických 
zraneniach či po tepelnom šoku pečene a ischémii žlčovodu. 
 
Mechanizmy, ktorými GDF15 chráni tieto tkanivá a orgány sú rôznorodé. Inhibícia 
apoptózy buniek plyvom GDF15 bola zistená v endoteli, srdci, pľúcach a obličkách. Okrem 
toho GDF15 ovplyvňuje aj bunkovú proliferáciu v pľúcach a obličkách, čo naznačuje, že 
GDF15 môže byť zapojené do regenerácie špecifických typov buniek po poškodení. Pri 
reakcii na metabolickú acidózu GDF15 sprostredkováva regeneráciu epiteliálnych buniek 
v zberných kanálikoch v obličkách myší. GDF15 moduluje aktiváciu leukocytov 
v srdcovom endoteli, čím bráni zápalu. V našich experimentoch v modeloch diabetickej 
nefropatie sme potvrdili účinky GDF15 na proliferáciu a zápal, ale nenašli sme vplyv 
GDF15 na apoptózu. 
 
Napriek ochranným vlastnostiam GDF15 v rôznych orgánoch a tkanivách, niekoľko 
vedeckých skupín objavilo koreláciu medzi hladinou GDF15 v plazme a morbiditou i 
mortalitou pri KVO aj diabete. Navyše naša štúdia ukázala, že zvýšené hladiny GDF15 
v sére dokážu predpovedať progresiu albuminúrie u pacientov s T2DM (kapitola 6).  
 
Zjavné protichodné účinky GDF15 v sére a v obličkách možno vysvetliť zisteniami 
opísanými v tejto práci. Po prvé, v kapitole 2 a 3 sme preukázali, že zdrojom GDF15 
bezprostredne po indukcii diabetu u potkanov a myší je práve glomerulus. V kapitole 6 zase 
ukazujeme, že plazmatické hladiny GDF15 predpovedali priebeh glomerulárneho 
poškodenia u pacientov s T2DM. Zvýšené plazmatické hladiny GDF15 preto podľa 
všetkého odrážajú počiatočné glomerulárne poškodenie pri diabete. V kapitole 4 
dokazujeme, že interstícium a tubuly sú hlavné ciele pre ochranné pôsobenie GDF15 v 




glomerulárne poškodenie, preto naše údaje naznačujú, že zdroje a ciele GDF15 sú odlišné. 
Plazmatické hladiny GDF15 môžu odrážať rozsah diabetického glomerulárneho poškodenia 
(čo nie je ovplyvnené GDF15), zatiaľ čo GDF15 poskytuje ochranu tkanivám, ako sú 
tubuly obličiek a interstícium. 
Po druhé, v kapitole 5 sme dokázali, že predinkubácia s GDF15 mala účinok na cievny 
endotel aorty, následkom čoho bola cievna kontrakcia a relaxácia inhibovaná, čo viedlo 
k zmenám vo funkcii cievneho endotelu aorty. Zhoršená relaxácia sprostredkovaná 
akútnym vplyvom GDF15 je podobná endotelovej dysfunkcii pozorovanej v niekoľkých 
modeloch KVO. Výsledky v našich pokusoch naznačujú, že zatiaľ čo GDF15 poskytuje 
ochranu poškodeným orgánom a tkanivám, dlhodobé zvýšenie hladiny GDF15 môže viesť 
k endotelovej dysfunkcii prispievajúcej k rozvoju KVO a ochoreniu obličiek. 
 
Na záver môžeme zhodnotiť, že údaje uvedené v tejto práci poukazujú prvý krát na úlohu 
GDF15 v rozvoji diabetickej nefropatie. GDF15 chráni u diabetikov tubuly a interstícium 
obličiek a je prognostickým ukazovateľom progresie albuminúrie. 
 
V nasledujúcich experimentoch sa môžeme zamerať na vývoj GDF15 knockout myší 
špecificky iba v obličkách a na presné objasnenie úlohy GDF15 v obličkách pri diabete. 
Úloha BMPR2 ako receptora pre aktiváciu GDF15 by mala byť skúmaná v iných tkanivách 
obličiek, vrátane tubulov. Identifikácia GDF15 receptora poskytuje totiž nový nástroj na 
ovplyvnenie jeho signalizačného systému, ktorý umožňuje vývoj moderných postupov v 
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